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PROLOGUE 
The work described in this thesis was initiated as part of a NWO funded project, within 
the BION/Biofysica theme 'intracellular signal transduction, entitled:'Signal transduction 
of TGFß and retinoic acid in phenotypic transformation of normal rat kidney cells. 
Biochemical and biophysical aspects of density-dependent inhibition of growth'. This 
thesis consists of two parts. A: 'The effect of bradykinin on phenotypic transformation of 
NRK cells', and B: 'Transcriptional regulation of the human PDGFa receptor gene'. 
Based on these titles, there is no apparent correlation between the two parts. However, all 
the work described in this thesis has been originally designed to investigate the signal 
transduction routes of TGFß. 
In part A, the original focus was on the molecular mechanisms involved in the TGFß-
induced phenotypic transformation of NRK cells. The inhibitory effect of bradykinin was 
used as a tool to gain more insight in this process. Although this approach has lead to a 
better understanding of the mechanisms involved in the inhibitory action of bradykinin, no 
specific information was obtained about TGFß signal transduction. Therefore, an 
additional approach has been undertaken as described in part B. 
In part B, the PDGFa receptor-mediated inhibitory effect of TGFß on several cell lines 
was used as a model system to investigate TGFß signal transduction. This work has 
resulted in a much better insight in the regulation of PDGFa receptor gene expression, but 
so far no direct studies have been performed with respect to TGFß signal transduction. 
Thus, the work described in this thesis does not meet its original goal as reflected in 
the project title. However, it has resulted in two pieces of research, which relation can 
only be appreciated from this prologue. 
N^O 

PARTA 
Effect of bradykinin on phenotypic transformation of 
NRK cells 

CHAPTER 1 
Introduction 
Neoplastic transformation of cells is accompanied by large alterations in cellular 
behaviour. In vitro, transformed cells display a reduced requirement for externally added 
growth factors, they have acquired an indefinite life span, and have a reduced ability to 
differentiate. In addition, transformed cells have an altered morphology compared to their 
normal counterparts, are not limited by density-dependent growth inhibition, and have 
acquired the ability to grow under anchorage-independent conditions (Folkman and 
Moscona, 1978; Ozanne et al., 1982). This last characteristic is considered to be the best 
in vitro correlate with the capacity of transformed cells to induce tumors in nude mice 
(Freedman and Shin, 1974; Colbura et al., 1978; Barret et al., 1979) and therefore, 
anchorage-independent growth may reflect a fundamental characteristic of tumor cells. 
Neoplastic transformation is generally a result of genetic mutations. However, certain non-
transformed cells can acquire a transformed phenotype in response to externally added 
growth factors. These phenotypically transformed cells display the same morphology, loss 
of density-dependent growth inhibition and anchorage-independent growth as neoplastically 
transformed cells. Normal rat kidney (NRK) cells are a widely used model system to 
investigate the role of growth factors in phenotypic transformation. 
Phenotypic transformation of NRK cells 
NRK cells typically grow as immortalized, non-transformed cells which require the 
addition of growth factors to their culture medium for proliferation. However, these cells 
undergo phenotypic transformation in response to transforming growth factor ß (TGFß) in 
the additional presence of either epidermal growth factor (EGF) or transforming growth 
factor a (TGFa) (Roberts et al., 1981; Anzano et al., 1982; 1983) and thereby they 
acquire characteristics similar to neoplastically transformed cells, including morphological 
alterations, loss of density-arrest and anchorage-independent growth. In contrast to 
neoplastic transformation, the phenotypic transformation of NRK cells is reversible. Upon 
removal of TGFß the cells continue to grow with a normal, non-transformed phenotype. 
The mechanisms involved in the TGFß-induced phenotypic transformation of NRK cells 
and the concomitant anchorage-independent growth and loss of density-arrest are not 
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completely understood. However, several observations have indicated that modulation of 
EGF receptor numbers at the cell surface seems to play an essential role in this process. 
The involvement of EGF/TGFa and the EGF receptor in the TGFß-induced anchorage-
independent growth of NRK cells has already evolved from the earliest studies on the 
characterization of the transforming growth factors. The so-called sarcoma growth factor, 
isolated from conditioned medium of murine sarcoma virus-transformed cells, stimulated 
cell division in normal fibroblasts and interacted with the EGF receptor (Todaro et al., 
1976; 1977; De Larco and Todaro, 1978). In addition, it was able to induce soft-agar 
growth of NRK cells. Subsequent studies have shown that the sarcoma growth factor 
consist of two componenents: TGFa, which competes with EGF for receptor binding, and 
TGFß, which strongly synergizes with EGF to induce anchorage-independent growth of 
NRK cells (Roberts et al., 1982; Anzano et al, 1982; 1983). However, the involvement 
of the EGF receptor in this process became evident when it was demonstrated that TGFß 
upregulates EGF receptor numbers in confluent NRK cells (Assoian et ai, 1984; Assoian, 
1985). 
A similar mechanism has been described for retinoic acid (RA). Like TGFß, RA is a 
potent inducer of phenotypic transformation in NRK cells, in combination with EGF, as 
characterized by its capacity to induce anchorage-independent growth and loss of density-
arrest. This effect of RA has also been correlated with an increase of EGF receptor 
numbers on the cell surface (Jetten, 1983; Jetten and Goldfarb, 1983; Roberts et al; 
1984). Together with the observations of Rizzino et al. (1988; 1990), which show that 
EGF receptor numbers on the cell surface decrease with increasing NRK cell densities, 
these data have lead to a model that describes the phenotypic transformation of NRK cells 
as a function of EGF receptor numbers. In short: 'In subconfluent cultures, NRK cells 
have sufficient EGF receptors on their cell surface to proliferate in response to EGF. 
However, at a critical cell density this EGF receptor number has dropped to a level at 
which the cells become unresponsive to EGF for proliferation and are density-arrested in 
their G[/G0- phase. When additional TGFß or RA is presented to the cells, the number of 
EGF receptors increases again above a treshold level and as a result the cells reinitiate 
proliferation in response to EGF'. 
A point of consideration in the EGF receptor model is that this model does not 
completely cover all the aspects of phenotypic transformation of NRK cells. As shown by 
van Zoelen et al. (1988; 1993) and in chapter 3 of this thesis, platelet-derived growth 
factor (PDGF) and lysophosphatidic acid (LPA) are not completely dependent on the 
presence of EGF for their transforming effects on NRK cells. In addition, PDGF and LPA 
are very well capable to induce a mitogenic response in serum-starved, quiescent NRK 
cells. This in contrast to RA and TGFß, which do not elicit a mitogenic response in 
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quiescent cells, but are only capable to induce phenotypic transformation (in combination 
with EGF). Another observation that supports the notion that PDGF transforms NRK cells 
through a fundamentally different mechanism than TGFß and RA, is provided by the 
kinetics of the proliferative response. Compared to PDGF, TGFß and RA display delayed 
kinetics in the induction of loss of density-arrest (Van Zoelen et al., 1992), which reflects 
the time necessary to induce EGF receptors. Thus, PDGF provides a direct proliferative 
signal to the cells. Together these observations have lead to a slightly modified version of 
the EGF receptor model (Van Zoelen, 1991), which is summarized in figure 1.1. 
figure 1.1 Model for growth factor-induced loss of 
density-dependent inhibition of growth of NRK cells 
(Van Zoelen, 1991). NRK cells cultured in the 
presence of EGF become density inhibited at high cell 
densities because the EGF-induced growth-stimulating 
signals (indicated by the single arrow from the EGF 
receptor) are insufficient for induction of cell 
proliferation. Cells can be restimulated to proliferate 
by the activity of a growth factor such as PDGF 
acting in parallel (A), such that the growth-stimulating 
signals of the two factors combined are sufficient to 
induce proliferation. Alternatively (B), factors such as 
TGFß and RA can be added, which enhance the 
number of EGF receptors and thereby the level of 
growth-stimulating signals induced by EGF (double 
arrow). 
Besides the proliferative response as a result of EGF receptor upregulation, this model 
also includes the possibility of another, direct growth stimulatory pathway parallel to that 
of EGF. Together these stimuli may also be sufficient to overcome density-dependent 
growth inhibition and thus initiate phenotypic transformation. 
There are also some restrictions that apply to the EGF receptor model in general. 
Based on the observations of Van Zoelen et al. (1988), which demonstrate that the growth 
factor requirements for both loss of density-arrest and the induction of anchorage-
independent growth are quite similar, it has been assumed that the molecular basis for 
both these phenomena is similar. However, nothing is known about regulation of EGF 
receptor expression under anchorage-independent conditions. In addition, other 
mechanisms than EGF receptor modulation have been proposed tó be involved in the 
phenotypic transformation of NRK cells. Ignotz and Massagué (1986) have postulated that 
EGF 
EGF 
PDGF 
\ 
\ 
д 
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stimulation of extracellular matrix components by TGFß is responsible for the anchorage-
independent growth of NRK cells. Also the occurrence of a specific factor in the plasma 
membrane of NRK cells, capable of triggering density-arrest has been reported to play a 
role (Nagasaki et al., 1994). Furthermore, anchorage-independent growth has been 
associated with an enhanced intracellular pH (Schwartz et al., 1989; 1990), a phenomena 
that may also occur in the TGFß-induced phenotypic transformation of NRK cells (Van 
Zoelen and Tertoolen, 1991). Recently, it has been demonstrated that cyclins are also 
important determinants of density-arrest and anchorage-independent growth in several cell 
lines, incuding NRK cells (Guadagno et ai, 1993; Deffie et al., 1995). However, not one 
of these mechanisms has been investigated extensively. It is therefore difficult to 
appreciate their contribution to the phenotypic transformation of NRK cells, and to 
determine whether they act in concert, or are a result of EGF receptor modulation. 
Intracellular signaling pathways involved in phenotypic transformation 
The role of the different intracellular signaling routes activated by the above mentioned 
factors in the phenotypic transformation of NRK cells has not been established yet. TGFß, 
RA, PDGF/EGF and LPA are representatives of growth factors which are linked to 
completely different receptor and signal transduction systems. 
TGFß and RA 
TGFß and RA share many characteristics in their ability to transform NRK cells, in 
particular their dependence on EGF to establish anchorage-independent growth and loss of 
density-arrest (van Zoelen et al., 1986; 1988). However, their intracellular signal 
transduction mechanisms are completely different. 
TGFß belongs to a large family of related growth factors, which also includes, among 
others, members of the bone morphogenetic proteins, activin, inhibin and Miillerian 
inhibitory substance (reviewed by Massagué, 1992; Attisano et ai, 1994). TGFß displays 
a wide variety of effects (reviewed by Barnard et al., 1990; Roberts and Sporn, 1991), 
but its inhibitory and stimulatory effects on cell proliferation are the most extensively 
studied (Moses et al., 1990). Although many membrane-bound proteins have been 
identified that bind TGFß, it appears that only the so-called TGFß receptors I and II are 
directly involved in TGFß signaling (Massagué, 1992; Lin and Lodish, 1993; Segarmi, 
1993). Both the type I and II receptors are transmembrane serine/threonine kinases, which 
form a heteromeric complex upon TGFß binding. A general model for TGFß receptor 
signaling depicts that TGFß first binds to the type II receptor, which in turn recruits the 
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type I receptor by means of bound TGFß The type I receptor becomes subsequently 
phosphorylated on serines and threonines by the the kinase activity of the type II receptor 
and this allows the type I receptor to propagate the signal to downstream substrates 
(Wrana et al , 1994) However, there are no downstream substrates for the TGFß receptor 
identified yet 
RA also displays a pleiotropy of effects, but is best characterized in its differentiating 
effects on cells (reviewed by De Luca, 1991) In contrast to TGFß, RA does not bind to a 
transmembrane receptor, but to a nuclear RA receptor Two families of these nuclear RA 
receptors exist retinole acid receptors (RARs) and retinole X receptors (RXRs), each 
consisting of an a, ß and y receptor type (reviewed by Leid et al, 1992) These RARs 
and RXRs are transcription factors and after RA binding they heterodimenze and bind to 
RA-responsive DNA elements within target genes and affect transcription of these genes 
(Leid et al, 1992, Stunnenberg, 1993) 
Although their signal transduction routes differ completely, both TGFß and RA have 
been shown to increase EGF receptor gene expression through enhanced transcriptional 
activation (Thompson et al, 1988, Thompson and Rosner, 1989) The mechanism by 
which this enhanced transcription is accomplished is not understood It has recently been 
demonstrated that TGFß increases EGF receptor transcription through a loss of protein 
binding to a negatively regulatory element (Hou et al , 1994) However, there is currently 
no information whether RA affects the same regulatory element or binds directly through 
its receptors to the EGF receptor gene There is also no additional information about 
signal transduction mechanisms more upstream from the TGFß- and RA induced 
transcription of the EGF receptor gene These observations clearly illustrate the gap of 
information between activation of TGFß and RA receptors and the increase of EGF 
receptor gene transcription 
The induction of another growth factor or growth factor receptor is being considered as 
a typical characteristic of the TGFß-induced transformation of cells In AKR-2B 
fibroblasts, TGFß induces the production of a growth factor (PDGF-B) to elicit a 
proliferative response in these cells (Leof et al , 1986) 
PDGF and EGF 
In contrast to RA and TGFß, EGF and PDGF are mitogenic to serum-starved, quiescent 
NRK cells (Rizzino et al , 1986, van Zoelen et al, 1988) In addition, they appear to 
elicit a parallel growth stimulatory response in density-arrested NRK cells, which together 
is sufficient to induce phenotypic transformation of these cells (van Zoelen, 1991) Thus it 
appears that EGF and PDGF also share some common mechanisms in the phenotypic 
transformation of NRK cells This similarity is also reflected in their mode of signal 
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transduction. Both EGF and PDGF bind to receptors which belong to the large family of 
transmembrane tyrosine kinase receptors (Ullrich and Schlessinger, 1990; Fanti et al, 
1993). Upon ligand binding these receptors dimerize and become phosphorylated on 
specific tyrosine residues due to the receptors' own kinase activity. This 
autophosphorylation results in the recruitment of several signal transduction molecules, 
which bind by virtue of their SH2-domain to the phosphorylated tyrosine residues. These 
signal transduction molecules take care of the receptors downstream signaling, which 
finally results in activation of the genes necessary for cell proliferation. 
LPA 
It has not been until recently that it was recognized that LPA, the simplest natural 
occurring phospholipid, is a potent mitogen for quiescent fibroblasts (Van Corven et al., 
1989). In addition, in chapter 3 of this thesis it will be shown that LPA is also a potent 
inducer of phenotypic transformation in NRK cells, as characterized by its ability to 
induce loss of density-dependent growth inhibition. 
Stimulation of fibroblasts with LPA results in activation of signal transduction pathways 
typically correlated to activation of G protein-coupled receptors. This includes: activation 
of phospholipase С and the subsequent hydrolysis of phosphoinositides, leading to Ca2+-
mobilization and activation of protein kinase С (Van Corven et al., 1989; Jalink et al., 
1990); a GTP-dependent release of arachidonic acid, presumably as a result of 
phospholipase A2 activation (Van Corven et al., 1989); activation of phospholipase D 
(Van der Bend et al., 1992a); inhibition of adenylate cyclase via an activation of a 
pertussis toxin-sensitive G, protein (Van Corven et al., 1989). In addition, a putative LPA 
receptor has been characterized which has at least the molecular mass of a G protein-
coupled receptor (Van der Bend et ai, 1992). However, the exact contribution of these 
signal transduction pathways to the effects of LPA is not completely understood, but 
recent observations have stressed the importance of G, proteins and Ras in the mitogenic 
signaling route of LPA (reviewed by Moolenaar, 1995). 
The following chapters of part A will deal with the role of EGF receptor levels and signal 
transduction pathways (in particular those elicited by G protein-coupled receptors) in the 
process of phenotypic transformation of NRK cells. Firstly, in chapter 2 additional 
evidence will be provided that modulation of EGF receptor levels is indeed the major 
determinant for RA- and TGFß-induced phenotypic transformation of NRK cells. This 
evidence is based on the correlation between the growth inhibitory effects of bradykinin 
and its effect on cell-surface EGF receptor and EGF receptor mRNA levels in NRK cells. 
Secondly, in chapter 3 the molecular mechanisms involved in the inhibitory effect of 
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bradykinin are studied in more detail. The intracellular responses elicited by bradykinin 
are compared with those elicited by LPA and prostaglandin F2a. All three compounds 
mediate their effects through G protein-coupled receptors, but have completely different, 
and even opposite effects on the phenotypic transformation of NRK cells. 
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CHAPTER 2 
Bradykinin-induced growth inhibition of normal rat kidney (NRK) cells 
is paralleled by a decrease in epidermal growth factor receptor 
expression 
ABSTRACT 
Normal rat kidney fibroblasts, grown to density arrest in the presence of epidermal growth 
factor (EGF), can be induced to undergo phenotypic transformation upon treatment with 
transforming growth factor β or retinole acid Here we show that bradykinin blocks this 
growth stimulus-induced loss of density-dependent growth arrest by a specific, receptor-
mediated mechanism The effects of bradykinin are specific, and are not mimicked by 
other phospho-inositide mobilizing agents such as prostaglandin F 2 a Northern analysis and 
receptor binding studies demonstrate that bradykinin also inhibits the retinole acid-induced 
increase in EGF receptor levels in these cells These studies provide additional evidence 
that EGF receptor levels modulate EGF-induced expression of the transformed phenotype 
in these cells 
Published in Biochemical Journal 298, 335-340, 1994, by Everardus J J Van Zoelen, Peter Η J Peters, 
Gijs В Afink, Siebe Van Genesen, Albert D G De Roos, Walter van Rotterdam & Alexander Ρ R 
Theuvenet 
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INTRODUCTION 
Normal rat kidney (NRK) fibroblasts have been widely used as a non-transformed 
indicator cell line for studying the role of polypeptide growth factors in phenotypic 
transformation (Van Zoelen, 1991). When cultured in the presence of epidermal growth 
factor (EGF) as the only growth stimulating polypeptide, these cells have a normal 
phenotype and undergo density-dependent growth inhibition. When cultured in the 
additional presence of transforming growth factor 0 (TGF/J), retinoic acid (RA) or 
platelet-derived growth factor (PDGF), however, cells acquire a transformed phenotype 
characterized by loss of density-dependent growth inhibition (Van Zoelen et ai, 1988). 
These cells therefore form an attractive model system for studying the control mechanisms 
involved in density-dependent growth regulation, since they can first be grown to density 
arrest, from which they can be released upon treatment with specific additional growth 
factors (Van Zoelen et al., 1992). 
Exponentially growing NRK cells in sparse cultures have low EGF receptor levels 
already, but EGF binding is reduced even further at high cell densities (Rizzino et al., 
1990). Neither TGF/3 nor RA by itself has a growth stimulatory effect on NRK cells (Van 
Zoelen et al., 1988), but both are able to increase the number of EGF receptors these 
cells express (Roberts et al., 1984; Assoian et al, 1984; Assoian, 1985) by transcriptional 
activation of the receptor gene (Thompson et al, 1988; Thompson and Rosner, 1989). 
These observations have led to the model that EGF receptor levels control density-
dependent growth arrest of NRK cells cultured in the presence of EGF (Van Zoelen, 
1991). Upon increasing cell density, EGF receptor levels decrease to such a level that 
EGF-induced growth stimulating signals are insufficient for induction of cell proliferation. 
Factors such as TGF/3 or RA enhance these growth stimulating signals induced by EGF by 
increasing EGF receptor levels. 
In this study we have investigated the effects of the nonapeptide bradykinin on 
phenotypic transformation of NRK cells. Bradykinin is a regulatory peptide with a variety 
of physiological and pharmacological activities, ranging from vasodilation and control of 
neurotransmission to regulation of cell proliferation (Roberts, 1989). Here we show that 
bradykinin inhibits the loss of density-dependent growth arrest of NRK cells induced by 
TGF/3 or RA during the first twenty hours of incubation, a property which is not shared 
by other phosphoinositide mobilizing agents. The observed growth inhibition induced by 
bradykinin is paralleled by a repression of the upregulation in EGF receptor expression, 
strongly suggesting that EGF-induced proliferation of NRK cells is a direct function of 
EGF receptor density. These data are discussed in the light of the current hypotheses on 
the molecular mechanism involved in density-dependent growth control. 
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RESULTS 
Effect of bradykinin on loss of density-dependent growth inhibition 
When confluent, serum-deprived cultures of NRK cells are treated with EGF and insulin, 
cells are stimulated to undergo one additional cell cycle, after which they become 
quiescent in the G/Gß-phase as a result of density-dependent growth inhibition (Van 
Zoelen et al , 1988) In the continuous presence of EGF and insulin, these density-
arrested cells can be restimulated to proliferate in a synchronous manner by treatment with 
additional growth factors, such as TGF/3, RA, PDGF or basic fibroblast growth factor 
(Van Zoelen et al , 1992) In contrast to the latter two factors, TGF/3 and RA as such 
have no growth stimulating activity on NRK cells, and can only exert their transforming 
activity in the additional presence of EGF (Van Zoelen et al , 1988) 
Figure 2 ΙΑ shows the effect of bradykinin on the loss of density inhibition of NRK 
cells induced by TGF/3, RA and the tumor promotor tetradecanoyl phorbol acetate (TPA) 
Cells were density-arrested in the presence of EGF and insulin, and cumulative thymidine 
incorporation was subsequently measured during the first 20 hours following addition of 
the modulating factors indicated It is shown that although bradykinin by itself has no 
significant effect on the proliferation of these density-arrested cells, it almost completely 
abolishes the growth stimulating effect of TGF/3 and RA As a comparison it is shown that 
Figure 2 1: Effect of bradykinin on growth factor-
induced loss of density inhibition of NRK cells 
A Density arrested cells were incubated with 2 ng/ml 
TGF/3 50 ng/ml RA (retinole acid), 50 ng/ml ΤΡΑ 
(tetradecanoyl phorbol acetate) or without stimulus 
(CONT), in the additional presence ( + ) or absence ( ) 
of 1 μΜ bradykinin (BK) Incorporation of [3H] 
thymidine (TdR) was determined between 4 and 20 
hours after growth factor addition Indicated standard 
errors of the mean are based on at least triplicate 
experiments 
В Time course of pH] thymidine (TdR) incorporation 
(2 hour pulses) into density arrested NRK cells after 
the following treatments (Δ Δ) no addition 
(A - A) 1 μΜ bradykinin, (O O) 2 ng/ml 
TGF/3, ( · · ) 2 ng/ml TGF/3 + 1 μΜ bradykinin, 
(D D) 50 ng/ml RA, ( • •) 50 ng/ml RA 
+ 1 μΜ bradykinin 
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TPA is only a poor inducer of phenotypic transformation of NRK cells under these 
conditions, but that the effect induced is also sensitive to the inhibitory action of 
bradykinin. 
Figure 2. IB shows in a time course experiment that the growth inhibitory effect of 
bradykinin depends on the time of incubation. Previous studies have indicated that 10 
hours after addition of TGF/3 or RA to density-arrested NRK cells, the first cells from 
these synchronized populations enter the S-phase (Van Zoelen et ai, 1992). By studying 
2-hour pulses of [3H]-thydimidine incorporation, the present data show that in the case of 
TGF/3 and RA a maximum rate of thymidine incorporation is reached within 20 hours of 
growth factor addition, in agreement with previous data (Van Zoelen et al., 1992). In the 
additional presence of bradykinin, however, these curves are shifted in time to reach a 
maximum around 24 hours of incubation. Within the first 20 hours of growth factor 
treatment, bradykinin therefore appears to have a strong inhibitory effect on loss of 
density-dependent growth arrest induced by TGF/3 or RA. At later time points, however, 
bradykinin is shown to have growth stimulatory effects by itself, and to enhance 
proliferation induced by TGF/3 and RA. 
Bradykinin effect on cell proliferation is receptor mediated 
Bradykinin is known to exert its action by activation of a set of G-protein coupled 
receptors, designated the B[ and B2 receptor types (Roberts, 1989). Dose-response curves 
showed that half-maximum inhibition of RA-induced loss of density inhibition of NRK 
cells was obtained at a concentration of 30 nM bradykinin (data not shown), which is 
indicative of a process mediated by a high affinity receptor. Figure 2.2 shows that the 
inhibition of TGF/3 and RA-induced loss of density inhibition by 0.1 μΜ bradykinin is 
counteracted by the B2-receptor antagonist [D-Arg°, Hyp3, ThP ", D-Phe7]-bradykinin in a 
Figure 2.2: Reversal of bradykmin-induced 
growth inhibition of NRK cells by bradykinin 
receptor antagonist [5H]-lhymidine 
incorporation into density-arrested NRK cells 
was measured following incubation with 2 
ng/ml TGF/3, 50 ng/ml RA or no addition 
(CONT), in the additional presence (+) or 
absence (-) of 0.1 μΜ bradykinin (BK), and the 
indicated concentrations in μΜ of the 
antagonist [D-Arg°, Hyp5, Thi5 8, D-Phe7]-
bradykinin (ANT) Indicated standard errors of 
the mean are based on at least triplicate 
experiments. CONT TSFß RA 
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dose dependent fashion. The bradykinin effect was also antagonized, although to a lesser 
extent, by [Des-Arg9, Leu8]-bradykinin (data not shown), which is known to have B
r 
receptor antagonist effects (Patel and Schrey, 1992). Although the present data do not give 
direct information on the type of bradykinin receptor involved, they show that the 
observed biological effects of bradykinin are receptor mediated. 
Bradykinin effect is not related to degradation of inositol-containing phospholipids 
Upon receptor activation bradykinin is known to induce degradation of inositol-containing 
phospholipids through activation of a phospholipase C, and to induce release of fatty acids 
including arachidonic acid by activation of a phospholipase A2 (Roberts, 1989). It has 
been shown before that bradykinin is able to mobilize Ca2+ from intracellular sources in 
NRK cells (Marks et al., 1988). Figure 2.ЗА shows that under the conditions tested 
bradykinin is a relatively poor inducer of inositol polyphosphate formation, when 
compared to prostaglandin F 2 a and fetal calf serum. As shown in figure 2.3B, however, 
prostaglandin F 2 o is unable to mimic the growth inhibitory effect of bradykinin on NRK 
cells, and generally by itself induces slight mitogenic effects. Also with respect to release 
of [3H]-arachidonic acid, prostaglandin F 2 a was found to be far more potent than 
bradykinin in NRK cells (G.B. Afink, D.C.J.G. van Alewijk and E.J.J, van Zoelen, 
unpublished observation). Also other agents such as the protein kinase С activator TPA 
and the protein kinase С inhibitor sphingosine did not mimic the growth inhibitory effect 
of bradykinin on NRK cells (data not shown). Taken together these data show that the 
inhibitory effect of bradykinin on loss of density-dependent growth inhibition is specific, 
and is not a general property of phosphoinositide mobilizing agents. 
Figure 2.3: Comparison of bradykinin 
(BK) and prostaglandin F,„ (PGF2a;) in 
inducing degradation of ìnositol-
containing phospholipids (A) and growth 
inhibition (B) of NRK cells Indicated 
stimuli were added to density-arrested 
NRK cells at the following 
concentrations. CONT, no addition, BK, 
10 ¡M (A) or 1 μΜ (В); PGF2OÍ, 1 μΜ, 
FCS, 9% fetal calf serum; TGF/3, 
2 ng/ml; RA, 50 ng/ml Incorporation of 
[3H)-thymidine was determined between 
4 and 20 hours after addition of the 
growth stimuli Indicated standard errors 
of the mean arc based on at least triplicate 
experiments. 
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Effects of bradykinin on EGF receptor density 
It has been established in a number of cell lines including NRK cells, that treatment with 
RA results in an immediate increase in the number of EGF receptors per cell (Jetten, 
1982; Roberts et al, 1984). In the case of TGF0 treatment, EGF receptor density in NRK 
cells first decreases, and then increases after more than four hours of incubation 
(Assoian,1985). Figure 2.4 shows that bradykinin blocks the RA-induced increase in EGF 
binding sites during the first four hours of incubation. Subsequently, bradykinin synergizes 
with RA in increasing EGF receptor levels, resulting in enhanced EGF binding after 
incubation for more than six hours. During the time period investigated, bradykinin does 
by itself not affect EGF receptor densities in NRK cells, which contrasts with observations 
by Earp et al. (1988) in WB cells, that hormones stimulating phosphoinositide hydrolysis 
may enhance levels of EGF binding. 
The insert of figure 2.4 shows Scatchard plots for binding of EGF to density-arrested 
NRK cells, before and after treatment with RA. Both plots have been fitted to a single 
receptor affinity model, although the curves show a slight tendency toward curvilinearity, 
in agreement with data of Assoian (1985). The present Scatchard plots show that before 
RA treatment density-arrested NRK cells contain approximately 1100 EGF receptors with 
a dissociation constant of 0.5 nM, while after 20 hours of incubation with RA cells 
contain approximately 9500 EGF receptors with a dissociation constant of 0.6 nM. These 
data underline the low number of EGF receptors in density-arrested NRK cells and the 
significant effect of RA on these EGF receptor levels. 
Figure 2.4: Effect of bradykinin on RA-induced EGF 
receptor levels in density-arrested NRK cells. Time 
course of ,24I-EGF (4 ng/ml) binding after addition of 50 
ng/ml RA (О О), 50 ng/ml RA + 1 μΜ 
bradykinin ( · · ) , 1 μΜ bradykinin ( • — • ) or 
no addition (U-—D). The dashed horizontal line 
represents the level of non-specific binding obtained by 
additional treatment with a hundred-fold excess of 
unlabclled EGF. The insert shows a Scatchard plot for 
specific binding (B
sp) of 1 ng/ml l25I-EGF and variable 
concentrations of unlabelled EGF, without (D D) 
and with ( • • ) pretreatment for 20 hours with 
50 ng/ml RA. Free ligand concentrations (F) have been 
expressed in nM. Indicated standard errors of (he mean 
are based on at least triplicate experiments. 
0 2 4 β θ 16 
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Figure 2.5 shows the effect of bradykinin on EGF receptor mRNA levels in a 
Northern analysis. Rat EGF receptor mRNA chromatographs at a size of 9.6 kb, with an 
occasional additional transcript at 5 kb (Oberg and Carpenter, 1991). The data presented 
here show that the steady-state mRNA levels for the EGF receptor rapidly increase with 
time upon RA treatment, but that within the period of four hours tested this effect is 
completely abrogated by bradykinin. In TGF/3-treated cells, an increase in EGF receptor 
mRNA levels was only visible after four hours of incubation, while PDGF, which in 
combination with EGF also induces phenotypic transformation of NRK cells, had no effect 
on EGF receptor mRNA levels (data not shown). The data of figure 2.5 also show that in 
EGF-R W 
GAPDH 9 Щ * 
Figure 2.5: Northern blot of EGF receptor (EGF-R) 
mRNA levels in density-arrested NRK cells following 
time incubations (0,2,4 hours) with 50 ng/ml RA in 
the absence (-) and additional presence ( + ) of 1 μΜ 
bradykinin (BK). Expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is shown as a 
loading control; mRNA sizes EGF-R 9.6 kb, GAPDH 
1.4 kb. 
0 2 2 4 4 h . 
+ + + + RA 
- + - + BK 
NRK cells density-arrested in the presence of EGF, little expression of the EGF receptor 
gene is detectable under the present experimental conditions. This observation agrees with 
the EGF binding data of figure 2.4, and is in line with the concept that EGF receptor 
levels decrease with increasing cell density (Rizzino et al., 1990). Interestingly, however, 
it has been shown in a variety of studies that EGF is able to enhance expression of its own 
receptor gene by a combination of both transcriptional and post-transcriptional controls 
(Clark et al., 1985; Earp et ai, 1988; Thompson and Rosner, 1989; Fernandez-Pol et al., 
1989; Hudson et ai, 1989). The present data show that in NRK cells which have 
undergone density-dependent growth inhibition EGF is unable to induce EGF receptor 
expression to a detectable level, which may be an important aspect of the molecular 
mechanisms involved in density-dependent growth control. In conclusion, the present data 
show that, in parallel with a four hours shift in RA- and TGF/3-induced release from 
density arrest (see figure 2. IB), bradykinin also blocks the RA-induced increase in EGF 
receptor levels during the same period of time. 
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DISCUSSION 
In the present study we have shown that bradykinin selectively inhibits the expression of a 
transformed phenotype in NRK cells. We have used this observation to demonstrate that a 
close correlation exists between EGF receptor levels in these cells, and the ability of 
growth modulating agents such as TGF/3 and RA to release these cells from density-
dependent growth arrest. Earlier studies have shown that EGF receptor levels decrease 
with increasing cell density (Holley et al, 1977; Rizzino et al, 1988; 1990), and that 
agents such as TGF/3 and RA enhance the number of EGF receptors in NRK cells 
(Roberts et al, 1984; Assoian et al., 1984; Assoian, 1985; Thompson et al, 1988; 
Thompson and Rosner, 1989). Taken together with the present results on the effect of 
bradykinin on EGF receptor expression and density-dependent growth control, these data 
strongly suggest that EGF receptor density is one of the major controlling parameters in 
density-dependent growth inhibition and phenotypic transformation of NRK cells. It is 
well established that EGF receptor expression can be controlled at both the transcriptional 
and post-transcriptional level (Hadcock and Malbon, 1991). Further experiments are 
required to investigate if under the present experimental conditions bradykinin inhibits 
RA-induced transcriptional activation of the EGF receptor gene, or decreases EGF 
receptor mRNA stability. 
Bradykinin has been associated with both growth stimulation (Owen and Villereal, 
1983; Roberts and Gullick, 1989; Roberts, 1989 and references therein) and growth 
inhibition (Newman et al, 1989; Patel and Schrey, 1992) on a variety of cells. On still 
other cell lines, no direct growth effect of bradykinin has been observed in spite of the 
presence of specific receptors and bradykinin mediated second messengers (Van Corven et 
al., 1989; Ruggiero et al, 1989). Here we have shown that bradykinin induces both short 
term growth inhibition and long term growth stimulation of NRK cells. The short term 
growth inhibitory effects are paralleled by repression of TGF/3- and RA-induced 
enhancement of EGF receptor levels. These inhibitory effects are specific for density-
arrested NRK cells, since no such effects were observed on growth-stimulated NRK cells 
which were first made quiescent by serum deprivation. In the case of prostaglandin ¥2a, 
only long term growth stimulatory effects were observed similar to bradykinin, but no 
growth inhibitory effects. Bradykinin exerts its action through a set of high and low 
affinity receptors, which results in degradation of choline and inositol-containing 
phospholipids and release of arachidonic acid (Van Blitterswijk et al, 1991, 1991a; Kast 
et al., 1991), as well as in enhancement of tyrosine phosphorylation (Leeb-Lundberg and 
Song, 1991). Degradation of inositol-containing phopholipids and release of arachidonic 
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acid are also induced in NRK cells by prostaglandin F2a, endothelin (Kusuhara et al., 
1992) and lysophosphatidic acid (data not shown; see also Van Corven et al., 1989), even 
to larger extent than observed for bradykinin. However, only bradykinin is a growth 
inhibitory factor for NRK cells, also when added in combination with one of the other 
above factors. These observations suggest that bradykinin must induce a so far unknown 
second messenger relevant for growth inhibition, which is not induced by other 
phosphoinositide mobilizing agents. Bradykinin-induced effects on cell proliferation 
generally result from the induction of prostaglandin derivatives (Patel and Schrey, 1992). 
Preliminary results indeed show that the observed growth inhibitory effects of bradykinin 
can be largely blocked by inhibitors of cyclo-oxygenase activity such as indomethacin 
(G.B. Afink, D.C.G.J. van Alewijk and E.J.J, van Zoelen; unpublished). It is presently 
unclear, however, which growth inhibitory prostaglandin is specifically induced by 
bradykinin in NRK cells. The observed inhibitory effects could not be mimicked by 
addition of well-characterized prostaglandins such as F^, Ej, A2 or D2 to NRK cells (data 
not shown). 
NRK cells form an attractive model for studying the molecular mechanisms involved in 
density-dependent growth control since depending on the growth factors added, cells 
display either a normal or a transformed phenotype (Van Zoelen, 1991). When cells are 
cultured in the presence of insulin and EGF they become arrested at a saturating density, 
from which they can be released upon treatment with additional growth factors including 
TGF/3 and RA (Van Zoelen, 1991). Still relatively little is known about the molecular 
mechanisms involved in density-dependent growth inhibition, and the loss of this density 
control upon tumorigenic transformation. The following processes, however, have been 
proposed as playing a possible role. It has been shown that normal cells can become 
quiescent at high densities because of production of autocrine growth inhibitory factors 
(Holley et al., 1978; Harel et al., 1985). In the case of NRK cells, however, no evidence 
for production of such factors by density-arrested cells was found (Van Zoelen, 1991). In 
the case of the epithelial NRK cell line 52E an abrupt increase in the membrane potential 
has been observed as the cells reach a saturating density (Binggeli and Weinstein, 1985). 
In line with this observation we found that NRK-49F fibroblasts released from density 
arrest by TGF/3 rapidly depolarize, underlining the importance of the membrane potential 
in controlling density-dependent growth inhibition (A.P.R. Theuvenet, P.H.J. Peters and 
E.J.J, van Zoelen; unpublished observation). In addition, gap junction-mediated 
intercellular communication has been considered to control growth arrest by direct 
intercellular contacts (Loewenstein, 1979), but in the case of NRK cells no significant 
intercellular communication was detected in density-arrested cells (Van Zoelen and 
Tertoolen, 1991). Wieser et al. (1990) have published evidence that a membrane 
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glycoprotein known as contactinhibin, is involved in contact-dependent growth inhibition, 
but as yet no effects of this factor have been described in NRK cells. 
The present and previous studies (Holley et al., 1977; Rizzino et al., 1988, 1990) have 
shown that modulation of growth factor receptor densities may provide an additional 
mechanism for controlling cell proliferation. This may be paralleled by a density-
dependent modulation of protein-tyrosine phosphatase activity; together with a modulation 
of growth factor receptor levels this may control growth factor-induced phospho-tyrosine 
levels in the cell (Pallen and Tong, 1991). In support of this idea we have recently 
observed that the phosphatase inhibitor vanadate mimics TGF/3 in preventing EGF-
stimulated NRK cells from becoming density-arrested (Rijksen et al., 1993; 1993a). It is 
likely that all of the above mechanisms in fact play a distinct role in the regulation of 
density-dependent growth control. Based on the observation of Rizzino et al. (1990) that 
in NRK cells EGF receptor levels decrease with increasing cell density, and the present 
observations on the effect of bradykinin on EGF receptor expression, it seems that for 
NRK cells modulation of receptor densities is the most appropriate mechanism for 
describing density-dependent growth regulation. This is also underlined by the observation 
that mutant NRK-49F cells with only a three-fold reduction in EGF receptor levels, are 
fully unresponsive to the growth stimulating activity of EGF (Hamanaka et al., 1990). It 
is well realized, however, that the other above described mechanisms may play a more 
dominant role in other cell types. For example, in the case of human glial cells, it has 
been shown that density-dependent growth inhibition is associated with even an increase in 
EGF receptor levels (Westermark, 1977). 
MATERIALS AND METHODS 
Growth stimulation assays 
Normal rat kidney (NRK) fibroblasts, clone 49F, were plated at a density of 15,000 cells/cm2, and grown to 
confluence in serum-containing medium for four days, and subsequently cultured m serum-free medium tor 
three days, as described (Van Zoelen et al , 1988). These cells are referred to as scrum-deprived, quiescent 
cells. These cells were then density-arrested by incubation in 5 ng/ml EGF and 5 μg/mI insulin for an 
additional 48 hours (Van Zoelen et al., 1988) Density-arrested cells were restimulated to proliferate by 
treatment with additional growth factors, and incorporation of [3H]-thymidine (0 5 μθ/ml added; 
Amersham) was measured either cumulatively between 4 and 20 hours of growth factor addition, or as a 
pulse during consecutive 2-hour periods (Van Zoelen et al., 1992). 
EGF binding studies 
Density-arrested NRK cells (10 cm2 wells) were incubated for 24 hours m fresh scrum-free medium without 
insulin and EGF Subsequently factors to be tested were added during the indicated time period, after which 
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the medium was changed for 0 S ml binding buffer (Dulbecco's modified Eagle's medium, containing 0 1 % 
bovine serum albumin and 50 mM BES, pH 6 8) Subsequently 1-4 ng/ml 12SI-EGF (105 cpm/ng) and 
various concentrations of unlabelled EGF were added After incubation for 1 hour at room temperature cells 
were washed with phosphate buffered saline containing 0 1 % bovine serum albumin, and extracted with a 
1 % Tnton X-100 solution Receptor-hgand binding data were analysed using the linear subtraction method 
(Van Zoelen, 1989) 
Lipid degradation studies 
Confluent NRK cultures (10 cm2 wells) were incubated for 24 hours with 4 μ€ι [3H]-inositol (Amersham) in 
serum-contaimng medium After subsequent incubation for 24 hours in serum-free medium, cells were 
grown to density arrest by incubation for 48 hours in the presence of 5 /tg/ml insulin and 5 ng/ml EGF 
Subsequently agents to be tested were added together with 10 mM LiCl, and after 30 min the medium was 
changed for 1 ml 10% tnchloro-acetic acid. Inositol phosphates were determined by elution from an AG 1X8 
anion exchange column (BioRad) with 0 8 M ammoniumformate/0 1 M formic acid (pH 4 5), as described 
in detail by Tilly et al (1987) 
Northern analysis 
Poly-A* RNA was isolated from density-arrested and restimulated NRK cells, as described previously (Van 
Zoelen et al , 1992) Samples (20 /ig) were denatured, electrophoresed on agarose gels and transferred to 
nitrocellulose blots as described (Van den Eijnden-Van Raaij et al, 1989), and hybridized with a mixture of 
a 0 77 kb and a 1 84 kb EcoRI cDNA fragment of the human EGF receptor 
Materials 
125I-EGF was a generous gift from Dr Τ Benraad (Department of Endocrinology, University of Nijmegen) 
TGF/3, was isolated from human platelets as described (Van den Eijnden Van Raaij el al , 1988) RA, ΤΡΑ 
and prostaglandin F2a were from Sigma, bradykinin from Boehnnger and bradykinin-related compounds 
from Peninsula Laboratories 
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CHAPTER 3 
Lysophosphatidic acid and bradykinin have opposite effects on 
phenotypic transformation of normal rat kidney cells 
ABSTRACT 
The bioactive lipid lysophosphatidic acid is besides a strong mitogen for quiescent 
fibroblasts, a potent inducer of phenotypic transformation of normal rat kidney cells The 
lysophosphatidic acid-induced loss of density-arrest is strongly inhibited by bradykinin 
Although their effects on normal rat kidney cell proliferation are opposite, bradykinin 
mimics many of the intracellular effects induced upon lysophosphatidic acid receptor 
activation, including phosphoinositide turnover, Ca24-mobilization and arachidonic acid 
release Bradykinin does not counteract the lysophosphatidic acid-induced reduction of 
cAMP levels in normal rat kidney cells However, bradykinin inhibits the lysophosphatidic 
acid and other growth factor-induced phenotypic transformation through the induction of a 
so far uncharactenzed prostaglandin G/H synthase product The growth inhibitory effect 
of bradykinin is limited to density-arrested cells, while upon prolonged treatment 
bradykinin itself is capable to induce the loss of density-dependent growth control It is 
concluded that bradykinin is a bifunctional regulator of normal rat kidney cell proliferation 
and that its inhibitory effects are mediated via the induction of a prostaglandin derivative 
Published in Journal of Cellular Biochemistry 56, 480-489, 1994, by Gijs В Afink, Dirk С G J Van 
Alewijk, Albert D G De Roos & Everardus J J Van Zoelen 
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INTRODUCTION 
Density-dependent growth inhibition or contact-inhibition is an important mechanism by 
which normal non-transformed cells become limited in their growth However, upon 
tumongenic transformation this density-dependent growth control is lost and cells become 
able to proliferate without restrictions Density-dependent growth control is one of the 
most prominent differences between the growth characteristics of transformed and non-
transformed cells The precise molecular mechanisms that underly this growth inhibition at 
increasing cell densities are not completely understood (reviewed in Van Zoelen, 1991) 
Several polypeptide growth factors are capable to induce the loss of density-dependent 
growth mibition and thus phenotypically transform cells The cell line NRK-49F, derived 
from normal rat kidney fibroblasts, provides an excellent model system to study the role 
of growth factors in this transformation process NRK cells become density-arrested when 
cultured in the sole presence of epidermal growth factor (EGF) However, the cells are 
reversibly transformed and lose their density-dependent growth inhibition if additional 
transforming growth factor ß (TGFß), retinole acid (RA) or platelet-derived growth factor 
(PDGF) is present (Van Zoelen et al, 1988) At the molecular level this TGFß- and RA-
ìnduced loss of density-dependent growth inhibition in NRK cells can be explained by the 
regulation of EGF receptor numbers EGF receptor densities on the surface of NRK cells 
decrease with increasing cell densities (Rizzino et al , 1988, 1990) At the stage of 
density-dependent growth arrest these EGF receptor numbers have been decreased to a 
level at which EGF is no longer able to provide a mitogenic signal to the cells However, 
addition of TGFß or RA, which by themselves are not mitogenic for these cells, results in 
an increase of EGF receptor numbers in NRK cells (Roberts et al , 1984, Assoian et al, 
1984, Assoian, 1985, Van Zoelen et al , 1994) As a result the cells become respondent to 
EGF again and resume growing with a transformed phenotype 
The lipid lysophosphatidic acid (LPA) is a potent mitogen for a number of different 
fibroblasts (Van Corven et al , 1989) A putative LPA receptor has been described, which 
is most likely G-protein coupled (Van der Bend et al , 1992, Van Corven et al , 1993, 
Howe and Marshall, 1993) The intracellular second messenger systems affected upon 
LPA activation include phosphatidyl inositol (Pl)-hydrolysis, Ca2+-mobilization, PLA2-
activation and a decrease in cAMP levels (Van Corven et al , 1989, Jalink et al , 1990) 
Recently Van Corven et al (1993) have also reported that the proto-oncogene tflX^ is 
rapidly activated upon LPA stimulation In these studies the nonapeptide bradykinin has 
been shown to mimic a large variety of the intracellular messengers induced by LPA 
However, in contrast to LPA, bradykinin has no growth stimulatory effect on the 
investigated fibroblasts Moreover we have recently shown that bradykinin is a strong 
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inhibitor of the RA- and TGFß-induced increase in EGF receptor number and the 
concomitant loss of density-dependent growth inhibition of NRK cells (Van Zoelen et al., 
1994). 
To gain more insight in the working mechanisms of LPA and bradykinin we studied the 
effects of these growth regulatory agents on the phenotypic transformation of NRK cells. 
LPA showed to be both a strong mitogen and a very potent inducer of phenotypic 
transformation in these cells. Bradykinin on the contrary inhibits not only the TGFß- and 
RA-induced phenotypic transformation but also the induction of this process by LPA. This 
inhibitory effect of bradykinin is specific for density-arrested cells. Quiescent, serum-
starved NRK cells are not affected by bradykinin. The specific LPA-induced reduction in 
cAMP levels is not the target for the inhibitory effect of bradykinin, because bradykinin is 
not able to prevent this decrease in cAMP. However, the inhibition of growth factor-
induced phenotypic tranformation by bradykinin is mediated through an arachidonic acid 
(AA) metabolite and more specifically via the induction of a prostaglandin G/H (PGH) 
synthase product. 
RESULTS 
Effect of LPA and bradykinin on the loss of density-dependent growth arrest 
We have previously shown that bradykinin acts as a potent inhibitor of RA- and TGFß-
induced phenotypic transformation of NRK cells (Van Zoelen et al., 1994). The inhibitory 
action of bradykinin has been correlated with a specific inhibition of EGF receptor mRNA 
formation. LPA has been described as a very potent mitogen for serum-starved quiescent 
Figure 3.1. Effect of bradykinin on growth factor-
induced loss of density-arrest. 
Density-arrested NRK cells were incubated with 2 ng/ml 
TGFß, 5 ng/ml PDGF-BB, 50 ng/ml RA, 100 μΜ LPA 
or without stimulus (CONT) in the absence (-) or 
presence (+) of an additional 1 μΜ bradykinin [3H]-
TdR incorporation was determined between 4 and 19 
hours after the additions. Values represent the mean + 
s.e.m. of triplicate determinations. 
fibroblasts (Van Corven et al., 1989, 1992). Figure 3.1 shows the effect of LPA on the 
[3H]-TdR incorporation in density-arrested NRK cells, compared with the transforming 
effects of TGFß, RA and PDGF-BB. LPA induces the loss of density-dependent growth 
arrest to the same extent as RA. The transforming capacities of LPA were confirmed by 
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induction of anchorage-independent growth (data not shown) Also shown in this figure is 
the inhibitory effect of bradykinin on this growth factor-induced loss of density-arrest 
Bradykinin does not only inhibit the RA- and TGFß-induced loss of density-arrest, but it 
abolishes also the transforming capacities of LPA and to a lesser extent those of PDGF-
BB These results might suggest that bradykinin is a general inhibitor of NRK cell growth, 
but this is not the case The inhibitory action of bradykinin is specific for density-arrested 
cells as shown in figure 3 2 This figure compares the effects of LPA and bradykinin on 
the [3H]-TdR incorporation in both serum-starved, quiescent cells (figure 3 2A) and 
density-arrested cells (figure 3 2B) LPA displays besides its transforming effect on 
density-arrested cells also a strong mitogenic response on quiescent NRK cells More 
importantly however is the observation that bradykinin does not inhibit this mitogenic 
action of LPA on quiescent cells, while it completely inhibits the transforming effect of 
LPA on density-arrested cells 
Figure 3 2. The inhibitory effect of bradykinin 
on NRK cells is specific for density arrested 
cells 
Serum starved quiescent (A) or density 
arrested (B) NRK cells were incubated with the 
indicated substances Final concentrations 100 
μΜ I PA 1 μΜ bradykinin 1 μΜ PGF2,„ and 
5 ng/ml EGF or no addition (CONT) pH] 
TdR incorporation was determined between 3 
and 22 hours (A) or between 2 and 16 hours 
(B) after addition of the growth factors Values 
represent the mean ± s e m of triplicate 
determinations 
It is concluded that bradykinin is a potent inhibitor of growth factor-induced phenotypic 
transformation, but this inhibition is specifically limited to the conditions of density-arrest 
Furthermore LPA shows to be both a potent mitogen and a transforming growth factor for 
NRK cells 
The opposite effects of bradykinin and LPA are not correlated to the induction of inositol 
phosphates, arachidonic acid, Ca2*-release or changes in cAMP levels 
In Rat-1 and IIF cells bradykinin mimics several intracellular responses evoked by LPA, 
including Pi-hydrolysis, Ca2+-mobihzation and AA-release (Van Corven et al, 1989, 
Jalink et al , 1990) However the biological effects of LPA and bradykinin on density 
arrested NRK cells are completely opposite This observation can be used to characterize 
the intracellular mechanisms involved in the process of phenotypic transformation To 
.® ® 
« f 
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investigate the role of these second messenger systems in the cell proliferation of density-
arrested NRK cells, the effect of prostaglandin F2„ (PGF^) on NRK cell growth was 
studied, which is also shown in figure 3 2 PGF2a is like LPA and bradykimn a G-protein 
coupled agonist PGF2„ however does not display a remarkable effect on either quiescent 
or density-arrested cell proliferation It also does not inhibit the LPA-induced cell growth, 
but it rather synergises with LPA to stimulate NRK cell growth 
CONT LPA BK P G F t a LPA LPA 
»BK »PGF2H 
5 
Ί — t t 
LPA PGF2g BK 
Figure 3.3. Induction of inositol phosphates, arachidonic 
acid or Ca!+-mobilization by LPA, bradykimn and PGF,„ in 
NRK cells 
A Density-arrested, [3H] inositol labeled NRK cells were 
incubated for 30 minutes with the indicated agonists and the 
cumulative total inositol phosphate mobilization was 
determined Final concentrations LPA 100 μΜ, bradykimn 
(BK) 10 μΜ, PGF2„ 10 μΜ or no addition (CONT) Values 
represent the mean ± s e m of duplicate determinations 
from a representative experiment 
В Typical Ca2+-responses to sequential addition of LPA (10 
μΜ), PGF2„ (1 μΜ) and bradykimn (BK, 1 μΜ) to density 
arrested NRK cells Ca2+ levels are represented as Fura2 
fluorescence intensities 
С [3H] arachidonic acid labeled, density arrested NRK cells 
were incubated with the indicated agonists The pH) 
arachidonic acid release into the medium was measured after 
1 hour incubation at 37 'C Final concentrations are the 
same as under A, with the addition of 1 /ig/ml mellitin 
(MEL) Values represent the mean ± s e m of duplicate 
determinations from a representative experiment 
CONT LPA ΘΚ PGF2a MEL 
The stimulation of Pi-hydrolysis, Ca2+-mobilization and AA-release by LPA, 
bradykimn and PGF2a does not correlate with their effects on cell growth as shown in 
figure 3 3 Figure 3 ЗА displays the data of the cumulative Pi-hydrolysis in density-
arrested NRK cells after treatment with these agonists LPA and bradykimn generate a 
similar, rather weak Pi-response when compared to PGF2„ Although PGF2„ elicits a much 
stronger PI response than LPA and bradykimn, the resulting Ca2+ transients are the same 
as shown in figure 3 3B Typical is the very strong Pi-response when LPA and PGF2a are 
added together This synergistic action was also observed in the [3H]-TdR incorporation 
assays (figure 3 2) Figure 3 3C gives a comparable picture for the LPA-, bradykimn- and 
PGF2a-stimulated AA release PGF2a is also the most potent inducer of AA-release 
compared to LPA and bradykimn PGF2„ generates the same amount of AA-release as the 
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phospholipase A2 activator mellitin. Again, bradykinin and LPA give a equal response in 
AA-release. The same experiments on serum-starved, quiescent NRK cells show similar 
results (data not shown). Although PGF2„ generates the strongest PI and AA response, it 
does not show a pronounced effect on NRK cell proliferation compared to LPA and 
bradykinin. LPA and bradykinin however display a similar response in both AA-release 
and Pi-hydrolysis, but they have completely opposite effects on NRK cell growth. Taken 
together these data strongly suggest that there is no correlation between the potency of 
bradykinin and LPA to generate Pi-hydrolysis, Ca2+-mobilization or AA-release and their 
effect on density-arrested NRK cell growth. 
Another second messenger pathway that might be involved in the growth regulatory 
actions of LPA and bradykinin is cAMP. Increases in intracellular cAMP levels can 
inhibit fibroblast proliferation (Hollenberg and Cuatrecasas, 1973; Heldin et al., 1989, 
Burgering et al., 1989). As shown in figure 3.4A, proliferation of NRK cells is also 
inhibited when intracellular cAMP levels are elevated. The adenylate cyclase agonist 
forskolin inhibits the growth factor-induced loss of density-arrest of NRK cells in a 
concentration dependent manner. Decreases in cAMP levels have been reported as an 
RA + lorstolkiOiM) 
Figure 3.4. A Effect of forskolin on loss of density-arrest 
Density-arrested NRK cells were treated with 50 ng/ml RA in the absence or additional presence of 
indicated concentrations of forskolin CONT represents untreated cells ['H]-TdR incorporation was 
determined between 4 and 19 hours after the additions Values represent the mean + s e.m of 
triplicate determinations from a representative experiment 
В Effect of LPA and bradykinin on cAMP levels in NRK cells 
Time course of cAMP levels in density-arrested NRK cells after treatment with 0 1 μΜ forskolin 
(G • ) , 15 mm. 0 1 μΜ forskolin followed by the addition of 100 μΜ LPA (arrow, •-- •) or 
no addition (O O) The bargraphs on the right show the cAMP levels after a 30 mm treatment 
with 1 μΜ bradykinin (BK) or a 15 min treatment with 0 1 μΜ forskolin followed by a subsequent 15 
mm incubation in the additional presence of 1 μΜ bradykinin (FK+BK) or 100 μΜ LPA and 1 μΜ 
bradykinin (LPA + FK + BK) All data are from the same experiment. Values represent the mean + 
s e m. of duplicate determinations from a representative experiment 
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important early signaling event for LPA (Van Corven et al, 1989; Kumagai et al, 1993). 
The data in figure 3.4B clearly demonstrate that also in NRK cells LPA dramatically 
decreases forskolin-stimulated cAMP levels. However bradykinin does not show any effect 
on either basal, elevated or decreased cAMP levels. Thus it seems unlikely that cAMP 
plays a role in the inhibitory effect of bradykinin on NRK cells. The rapid decrease in 
elevated cAMP levels is specific for LPA, but not required for phenotypic transformation. 
The other investigated transforming growth factors RA, TGFß and PDGF-BB do not 
affect с AMP levels in NRK cells (data not shown). 
The combined data on intracellular messengers suggest that Pi-hydrolysis, Ca2+-
mobilization, AA-release and changes in cAMP levels per se, do not mediate the 
inhibitory effect of bradykinin. Pi-hydrolysis, Ca2+-mobilization and AA-release are also 
not sufficient for the transforming effect of LPA. The only specific LPA effect is the 
decrease in forskolin-stimulated cAMP levels, but this effect is not the target for the 
inhibitory action of bradykinin. 
The inhibitory effect of bradykinin is mediated through a PGH synthase product 
In previous reports on bradykinin mediated inhibition of cell growth, this effect could 
always be abolished by indomethacin, an inhibitor of PGH synthase (Straus and Pang, 
1984; Patel and Schrey, 1992; McAllister et al., 1993). It is known that several products 
of the metabolic conversion of AA by PGH synthase can be potent inhibitors of cell 
growth (reviewed in Fukushima, 1992). In our system indomethacin also completely 
abolished the inhibitory effect of bradykinin on growth factor-induced loss of density-
arrest (figure 3.5), as did other PGH synthase inhibitors such as flurbiprofen and 
ibuprofen (data not shown). It is also shown in figure 3.5 that inhibitors of lipoxygenase 
(nordihydroguaiaretic acid) or epoxygenase (2-methyl-l,2-di-3-pyridyl-l-propanone), two 
Figure 3.5. Inhibitory effect of bradykinin is abolished by 
indomethacin. 
Density-arrested NRK cells were incubated with the indicated 
growth factors at the following concentrations: 50 ng/ml RA, 
1 μΜ bradykinin (BK) or no addition (CONT). In the 
indicated lanes the cells were incubated with 1 μΜ 
indomethacin (INDO), 1 μΜ nordihydroguaiaretic acid 
(NDGA) or 1 μΜ 2-mefhyl-l,2-di-pyridyl-l-propanone 
(MDPP) before the addition of RA and bradykinin. r3H]-TdR 
incorporation was determined between 4 and 19 hours after 
the addition of the growth factors. Values represent the mean 
+ s.e.m. of triplicate determinations. 
IIIIIII 
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other AA converting enzymes, had no effect on the bradykinin inhibition of phenotypic 
transformation. These results give a strong indication that one or more PGH synthase 
products mediate the inhibitory effect of bradykinin. 
To test whether the observed effect was mediated by one of the well characterized 
PGHsynthase products several AA metabolites were added to RA-induced density-inhibited 
NRK cells, including the prostaglandins A2, D2, E,, Ej, F2„, I2 and the thromboxane A2 
agonist U46619. However, no inhibition of phenotypic transformation by any of these 
compounds was observed (data not shown). Preliminary data with conditioned medium 
from bradykinin-stimulated, density-arrested NRK cells however indicate that a growth 
inhibitory compound is released from the cells (DHTP Lahaye and EJJ Van Zoelen, 
unpublished observation). These observations suggest that bradykinin induces the 
formation of a so far uncharacterized PGH synthase product which is responsible for the 
inhibition of phenotypic transformation. 
Bradykinin is a potential transforming growth factor for NRK cells 
An important observation in the phenotypic transformation assays was that the inhibitory 
effect of bradykinin was fading after prolonged incubation times. To investigate this 
phenomenon in more detail, time courses of ['H]-TdR incorporation into NRK cells were 
made under different growth conditions. In figure 3.6A the time course of [3H]-TdR 
incorporation after the addition of LPA to density-arrested cells with or without additional 
bradykinin is shown. LPA displays a typical stimulation of [3H]-TdR incorporation with a 
maximum incorporation rate between 19-21 hours after the addition. These kinetics are 
similar to those reported for TGFß, but are delayed when compared to the PDGF-
stimulated [3H]-TdR incorporation in density-arrested NRK cells (Van Zoelen et al., 
1992). These delayed kinetics may reflect that the LPA-induced loss of density-arrest is a 
indirect mechanism, like that of TGFß. However, LPA does not require EGF for its 
transforming activity (data not shown). Van Corven et al. (1992) have also shown that the 
kinetics for LPA-induced mitogenesis in quiescent Rat-1 fibroblasts are slower than for 
EGF-induced mitogenesis. Thus it might be possible that the relative slow kinetics of LPA 
rather reflect a slow working mechanism than a indirect mechanism. 
In the additional presence of bradykinin the LPA-induced loss of density-arrest is 
inhibited, but not permanently. Bradykinin causes a delay of the LPA-stimulated growth 
curve of approximately 8 hours. Importantly, bradykinin alone displays a growth 
stimulatory effect with the same kinetics as LPA plus bradykinin, although the maximum 
incorporation rate is somewhat lower. This slow growth stimulatory effect of bradykinin 
explains the fading of the inhibitory effect in the [3H]-TdR incorporation assays. When 
RA-, TGFß-, LPA- or PDGF-BB-stimulated density-arrested cells in these cumulative 
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Figure 3.6. Kinetics of the growth stimulatory and inhibitory 
effect of bradykimn 
A Time course of the [Ή] TdR incorporation (2-hour 
pulses) into density-arrested NRK cells after the addition of 
100 μΜ LPA (Δ Δ ) , 100 μΜ LPA and 1 μΜ 
bradykimn (A A), 1 μΜ bradykimn ( · - · ) or 
without stimulus ( O — O ) 
В Time course of the [3H]-TdR incorporation (2 hour 
pulses) into serum-starved, quiescent NRK cells after the 
addition of 5 ng/ml EGF ( • •) 5 ng/ml EGF and 
1 μΜ bradykimn (D - Π ) , 1 μΜ bradykimn ( · · ) , 
or no stimulus (O - O ) Values represent the mean ± 
s e m of triplicate determinations 
11 15 19 23 27 31 35 3fl « 47 51 
assays were incubated for more than 19 hours in the presence of bradykimn, the growth 
stimulatory effect of bradykimn became visible and compensates its inhibitory effect 
The fact that bradykimn is able to induce the loss of density-dependent growth 
inhibition makes it a potential transforming growth factor The question remains whether 
this bradykinin-induced loss of density-arrest is EGF dependent, similar to the 
transforming activities of RA and TGFß (Van Zoelen et al , 1988) To address this 
problem the kinetics of bradykimn-stimulated [3H]-TdR incorporation in serum-starved, 
quiescent NRK cells were investigated in the presence and absence of EGF (figure 3 6B) 
Addition of EGF to quiescent NRK cells induces a single round of DNA synthesis, after 
which the cells become density-arrested However, in the additional presence of 
bradykimn the cells continue for another round of DNA synthesis, which is indicative for 
the loss of density-dependent growth inhibition (Van Zoelen, 1991) It is clear from the 
data in figure 3 6B that bradykimn needs the presence of EGF for its transforming effect 
When added alone, bradykimn is not able to induce [^ HJ-TdR incorporation These data 
are very similar to those obtained with TFGß and RA as described in detail previously 
(Van Zoelen et al, 1988) 
In conclusion, bradykimn displays a biphasic effect on density-arrested NRK cell 
growth Initially bradykimn transiently inhibits the growth factor-induced loss of density-
arrest However, in the additional presence of EGF, extended incubation periods with 
bradykimn cause the phenotypic transformation of these cells 
34 CHAPTER 3 
DISCUSSION 
The bioactive lipid LPA has obtained much attention in recent years for its role in 
fibroblast proliferation (Van Corven et al, 1989, 1992) and regulation of cytoskeletal 
elements (Ridley and Hall, 1992, Edwards et al, 1993, Jalink et al , 1993) However, the 
intracellular signals that convey the LPA actions still remain obscure In the present study 
the intracellular effects of LPA were compared with those of bradykinin Bradykinin is a 
small peptide with a wide range of reported biological effects including neurotransmission, 
pain perception, smooth muscle contraction and cell proliferation (Roberts, 1989) 
Bradykinin mimics many of the LPA-induced intracellular responses, including PI-
hydrolysis, Ca2+-mobihzation and AA-release as described in this paper and previously by 
others (Van Corven et al , 1989, Jalink et al , 1990) However their effect on density-
arrested NRK cell proliferation is completely opposite LPA induces the loss of density-
arrest in NRK cells, while this process is strongly inhibited by bradykinin The differential 
growth effects of LPA and bradykinin could not be correlated to différentes in PI-
hydrolysis, Ca2+-mobilization or AA-release The specific effect of LPA on forskohn-
stimulated cAMP levels was not counteracted by bradykinin, indicating that the growth 
inhibitory effect of bradykinin is not mediated by cAMP Although the inhibitory action of 
bradykinin is not correlated with the level of AA per se, it appears to be mediated through 
the formation of a specific AA metabolite by PGH synthase Other studies on the 
inhibitory effect of bradykimn on fibroblast proliferation have also indicated the 
involvement of a PGH synthase product in this process (Straus and Pang, 1984, Patel and 
Schrey, 1992, McAllister et al , 1993) The exact nature of the PGH synthase product has 
not been characterized yet, but externally added prostaglandins tested so far did not mimic 
the bradykinin inhibition of NRK cells This is in contrast to the observations of Patel and 
Schrey (1992), and McAllister et al (1993) In both studies bradykinin could be replaced 
by externally added prostaglandin Ьг to elicit an inhibitory effect on fibroblast cell growth 
This indicates that in NRK cells another prostaglandin is involved in the inhibitory action 
of bradykinin Current studies are underway to identify this prostaglandin 
An intriguing observation is the specificity of the bradykinin inhibition for density 
arrested cells McAllister et al (1993a) have also reported a cell density-dependent 
inhibitory effect of bradykinin on human gingival fibroblasts but not as strict as in NRK 
cells These authors correlate the bradykinin responsiveness to the increase in bradykinin 
receptor numbers at increasing cell densities It remains to be investigated whether the 
bradykinin receptor number increases upon density arrest in NRK cells, but bradykinin-
ìnduced Pi-hydrolysis and AA-release are similar in both quiescent and density-arrested 
cells Another option is an induction of a different bradykinin receptor subtype when NRK 
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cells become density-arrested. In general, bradykinin receptors are defined in two 
subtypes. The type 2 subtype is widely expressed in many cell types and seems to be 
responsible for the bradykinin-induced Pi-response and stimulation of cell growth 
(Roberts, 1989; Roberts and Gullick, 1989). The type 1 subtype is in general not 
expressed, but its involvement in bradykinin mediated inhibition of human breast 
fibroblasts has been reported (Patel and Schrey, 1992). The exact contribution of either 
subtype in the inhibition of NRK cells has not been established yet (Van Zoelen et al., 
1994). Regulation of the phosphorylation state of the bradykinin receptor (Jong et al., 
1993) or regulation of processes downstream of the receptor upon density-arrest can also 
be reponsible for the specificity of the bradykinin inhibition. However at present not much 
is known about these processes and possible modes of regulation. 
Upon prolonged incubation bradykinin induces the loss of density-dependent growth 
arrest of NRK cells. The mechanism by which bradykinin phenotypically transforms NRK 
cells is similar to that of RA and TGFß, although the kinetics are much slower (Van 
Zoelen et al., 1988). The EGF dependence of this transforming effect of bradykinin 
suggests that bradykinin, like RA and TGFß, upregulates EGF receptor numbers to release 
the cells from density-arrest. 125I-EGF binding is indeed increased upon bradykinin 
treatment of density-arrested NRK cells (unpublished observation). Stimulation of PI-
turnover might be responsible for this effect on EGF receptor levels and the concomitant 
loss of density-arrest. The correlation between agents linked to the phosphoinositide 
signaling system and upregulation of EGF receptors has been reported previously by Earp 
et al. (1988). The observation that PGF2„ is also able to induce loss of density-arrest, in a 
EGF dependent manner, with the same kinetics as bradykinin (data not shown) further 
support this hypothesis. LPA also increases '"I-EGF binding in density-arrested cells 
(unpublished observation). However, the phenotypic transformation of NRK cells is not 
dependent on EGF. This suggests that the transforming effect of LPA is mediated through 
another, as-yet-unidentified pathway. 
METHODS 
Phenotypic Iransformation assay 
NRK-49F cells, were grown to confluency in 24-well tissue culture dishes m Dulbecco's modified Eagle 
medium (Gibco), supplemented with 10% newborn calf serum (Hyclone). Confluent cells were made 
quiescent by a subsequent three days incubation in serum-free medium, as described previously (Van Zoelen 
et αϊ , 1988) These cells were grown to density-arrest by an additional 48 hours incubation in the presence 
of 5 ng/ml EGF (Collaborative Research) and 5 μ§/ιη1 insulin (Sigma) After treatment with additional 
growth factors, the capacity of these growth factors to induce phenotypic transformation was determined by 
the measurement of ['H]-thymidine (TdR) incorporation (0 5 μθ/ml, Amersham), either in a cumulative 
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manner between 4 19 hours after agonist addition, or in consecutive 2-hours pulse intervals 
Inositol phosphate determination 
Confluent NRK cultures in 6 well tissue culture dishes were labeled for 24 hours with 4 /¿Ci/ml [3H]-inositol 
(Amersham) in serum-containing medium After a subsequent 24 hours incubation in scrum-free medium, 
cells were grown to density-arrest by a 48 hours treatment with 5 ng/ml EGF and 5 ng/ml insulin The cells 
were stimulated with agonists for 30 minutes in the additional presence of 10 mM LiCl The reactions were 
terminated by changing the medium for 10% trichloro-acetic acid (TCA) Inositol phosphates were 
determined by el ut ion from a AG 1X8 anion exchange column (BioRad) with 0 8 M ammonium formate/0 1 
M formic acid (pH 4 5), as described in detail by Tilly et al (1987) 
cAMP measurements 
Density-arrested NRK cells in 6-well tissue culture dishes were prcincubated for 10 minutes with 0 5 mM 3 
isobutyl-1-methylxanthine (Sigma), followed by the addition of agonists After the appropriate incubation 
times the cells were rinsed with ice-cold phosphate-buffered saline and the reactions were slopped by 
treatment with 1 ml 10% icecold TCA The TCA was removed by a fivefold extraction with diethylcther and 
the samples were lyophilysed cAMP content was determined using the Amersham pHl-cAMP kit, according 
to the instructions of the manufacturer 
[Ή] arachidonic acid release 
Density-arrested NRK cells in 6-well tissue culture dishes were labeled with 1 μΟι/πύ [3H]-arachidonic acid 
(180-240 Ci/mmol, NEN) for 15 hours After the labeling the medium was replaced by 1 5 ml HEPES 
buffered Dulbecco's modified Eagle medium with additonal 0 1 % fatty acid free bovine serum albumin 
(Sigma) This medium was changed several times to remove unincorporated label Agonists were added and 
after 1 hour 0 5 ml of the culture medium was withdrawn and total radioactivity released into the medium 
was determined by liquid scintillation analysis 
Measurements of intracellular Ca2* 
Cells were grown on gelatin-coated glass coverslips instead of tissue culture plastic as described above 
Density-arrested NRK cells were loaded for 90 minutes with 5 ^g/ml Fura-2AM (Molecular Probes) and 
0 01% pluronic acid in Hepes/bicarbonate-buffered serum free medium at room temperature Subsequently 
the cells were washed and incubated in Hepes/bicarbonate buffered saline (in mM 25 NaCl, 5 KCl, 2 
CaCl2, 10 glucose, 15 Hepes, 17 6 NaHCOj) at 25 °C Intracellular calcium measurements were performed 
using a spectrofluorometer (SPF 500 Aminco), at an excitation wavelength of 340 nm (4 nm bandwidth) and 
an emission wavelength of 480 nm (8 nm bandwidth) Data were sampled and stored at a rate of 0 1 Hz 
using a data processor Growth factors were added directly to the incubation medium At the end of the 
experiment, lonomycin (5 μΜ) and Mn 2 t (1 mM) were added to obtain an estimate of maximum and 
background calcium values 
Materials 
TGFß was purified from human platelets according to the protocol of Van den Eijnden-Van Raaij et al 
(1988) Recombinant PDGF-BB was a generous gift from Dr C-Η Heldin (Uppsala, Sweden) LPA was 
purchased from both Sigma and Serdary RA, indomethacin nordihydroguaiarelic acid, 2 methyl-1,2 di 
pyridyl-1-propanone and PGF,„ were from Sigma, bradykinm was from Boehnnger 
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CHAPTER 4 
Discussion & references 
Phenotypic transformation of NRK cells is a widely used model system to investigate the 
molecular mechanisms involved in the process of cellular transformation. In the previous 
two chapters, some aspects of these molecular mechanisms have been described. In 
chapter 2, the growth inhibitory effect of bradykinin was used to demonstrate the strong 
correlation between EGF receptor levels and the phenotypic transformation of NRK cells. 
These data provided additional support for the model that describes the phenotypic 
transformation of NRK cells as a function of EGF receptor numbers (Van Zoelen, 1991). 
The molecular mechanism by which bradykinin elicits its inhibitory effect is described in 
more detail in chapter 3. From the experimental data it appeared that a PGH synthase 
product is responsible for the bradykinin-induced growth inhibition. Although these studies 
clearly demonstrate the central role for the EGF receptor in the transformation process, 
some important questions remain unanswered. 
Firstly, are the described observations applicable to all aspects of phenotypic 
transformation ? The present data are derived from studies on the loss of density-
dependent growth arrest, which is only one aspect of phenotypic transformation. Whether 
bradykinin also inhibits for instance anchorage-independent growth of NRK cells is not 
possible to determine. The inhibitory effect lasts too short to study its effect on NRK 
growth in semi-solid medium, and only the long-term transforming effects are visible in 
these kind of experiments. Therefore, it is more appropriate to apply the model of EGF 
receptor modulation currently only to the control of density-dependent growth arrest. In 
this respect it may also be important to question whether growth-arrest in the presence of 
EGF can be considered as density-dependent growth inhibition. NRK cells have a very 
low level of EGF receptors and a further decrease of EGF receptor numbers at increasing 
cell densities will indeed stop the cells from proliferation in response to EGF. However, 
will NRK cells also become density-arrested at the same cell density in the presence of 
other growth factors ? From studies with PDGF it appears that NRK cells in the presence 
of either PDGF-AB or PDGF-BB reach higher cell densities before density-arrest than in 
the presence of EGF or PDGF-AA (Van Zoelen et α/., 1993). 
Secondly, how does bradykinin inhibit EGF receptor levels ? In chapter 2, it has been 
shown that the inhibitory effect of bradykinin is paralleled by an inhibition of EGF 
receptor mRNA formation. From the data in chapter 3, it appears that bradykinin inhibits 
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the loss of density-arrest, and thus the formation of EGF receptor mRNA formation, 
through the formation of a PGH synthase product. In addition, subsequent studies have 
indicated that prostaglandin J2 may be the intermediate responsible for this inhibitory 
effect (Lahaye et al., 1994). Prostaglandins, including prostaglandin J2, are potent 
inhibitors of cell proliferation (reviewed by Fukushima, 1992). It has been postulated that 
this anti-proliferative effect is mediated through an induction of heat-shock proteins (Ohno 
et al., 1988; Santoro et al., 1989), thereby arresting the cells in their Grphase. Whether 
the decrease of EGF receptor mRNA formation and the resulting inhibition of phenotypic 
transformation is indeed a consequence of prostaglandin-induced cell cycle arrest still 
needs to be investigated. In addition, prostaglandins may regulate Ras-GAP (Han et al., 
1991), and thus affect Ras activity. Ras has been shown to be involved in the 
transformation of many cell types (Satoh and Kaziro, 1992; Downward, 1992). Therefore, 
when activation of the EGF receptor gene would be located downstream of Ras in the 
process of phenotypic transformation, prostaglandins can block both these processes 
through modulation of Ras-GAP. However, both these models are rather speculative and 
additional experimental data is necessary to propose a good working mechanism for the 
inhibitory action of bradykinin. 
A third question that remains is what differences in signal transduction are responsible 
for the observed differences between LPA, bradykinin and prostaglandin F2o in the 
phenotypic transformation of NRK cells ? As already indicated in chapter 3, these 
differences in effects are apperently not due to differences in Pi-turnover, Ca2"-
mobilization, cAMP levels or AA-release. A likely explanation for the growth stimulatory 
effects of LPA on NRK cells is that the LPA receptor couples to a G, protein, in contrast 
to the bradykinin and prostaglandin F2„ receptors. However, not the resulting decrease in 
cAMP levels (Van Corven et al., 1989; chapter 3), but the G, protein-mediated activation 
of Ras (Van Corven et al., 1993), triggered by the G„y subunits (Koch et al., 1994), is 
believed to be responsible for the LPA-induced growth stimulation of fibroblasts and may 
also be the mechanisms by which LPA induces phenotypic transformation of NRK cells. 
The signal transduction route that leads to the typical inhibitory effect of bradykinin is, 
however, more difficult to imagine, based on the data presented in chapter 3. There is 
currently no information about unique intracellular events that are generated upon 
bradykinin receptor activation, but not by other G protein-coupled receptors. Therefore it 
would be a blind guess to speculate about possible signaling cascades involved in this 
process. Additional research is currently being performed to gain more information about 
the complete mechanism by which bradykinin elicits its inhibitory effect on NRK cells. 
The resulting information may also provide more insight in the molecular mechanisms 
involved in the process of phenotypic transformation in general. 
CHAPTER 4 41 
REFERENCES 
Anzano MA, Roberts AB, Meyers CA, Komoriya A, Lamb LC, Smith JM, Sporn MB (1982) 
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells Cancer 
Res 42:4776-4778 
Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE (1983) Sarcoma growth factor from 
conditioned medium of virally transformed cells is composed of both type a and type ß transforming 
growth factors Proc Natl Acad Sci USA 80:6264-6268 
Assoian RK (1985) Biphasic effects of type fl transforming growth factor on epidermal growth factor 
receptors in NRK fibroblasts Functional consequences for epidermal growth factor-stimulated mitosis J 
Biol Chem 260:9613-9617 
Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB (1984) Transforming growth factor-B 
controls receptor levels for epidermal growth factor in NRK cells Cell 36:35-41 
Affisano L, Wrana JL, López-Casillas F, Massgué J (1994) TGF-ß receptors and actions Biochim 
Biophys Acta 1222:71-80 
Barnard JA, Lyons RM, Moses HL (1990) The cell biology of transforming growth factor β Biochim 
Biophys Acta 1032:79-87 
Barret JC, Crawford BD, Mixter LO, Schechtman LM, Ts'o POP, Pollack R (1979) Correlation of in 
vitro growth properties and tumongenicity of synan hamster cell lines Cancer Res 39:1504-1510 
Binggeli R, Weinstein RC (1985) Deficits in elevating membrane potential of rat fibrosarcoma cells after 
cell contact Cancer Res 45:235-241 
Burgering BMT, Snijders AJ, Maassen JA, Van der Eb AJ, Bos JL (1989) Possible involvement of 
normal p21 Η-ras in the insulin/insulinhke growth factor 1 signal transduction pathway Mol Cell Biol 
9:4312-4322 
Clark AJL, Ishii S, Richert N, Merlino GT, Pastan I (1985) Epidermal growth factor regulates the 
expression of its own receptor Proc Natl Acad Sci USA 82:8374-8378 
Colburn NH, Vorder Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, Shimida Τ (1978) 
Correlation of anchorage-independent growth with tumongenicity of chemically transformed mouse 
epidermal cells Cancer Res 38:624-634 
Deffie A, Hao M, Montes de Oca Luna R, Hulboy DL, Lozano G (1995) Cyclin E restores p53 activity 
in contact-inhibited cells Mol Cell Biol 15:3926-3933 
De Larco JE, Todaro GJ (1978) Growth factors from murine sarcoma virus-transformed cells Proc Natl 
Acad Sci USA 75:4001-4005 
De Luca LM (1991) Retinoids and their receptors in differentiation, embryogenesis, and neoplasia FASEB 
J 5:2924-2933 
Downward J (1992) Regulatory mechanisms for ras proteins Bioessays 14:177-184 
Earp HS, Hepler JR, Petch LA, Miller A, Berry AR, Harris J, Raymond VW, McCune BK, Lee LW, 
Grisham JW, Harden TK (1988) Epidermal growth factor (EGF) and hormones stimulate 
phosphoinositide hydrolysis and increase EGF receptor protein synthesis and mRNA levels in rat liver 
epithelial cells J Biol Chem 263:13868-13874 
Edwards JG, Campbell G, Carr M, Edwards CC (1993) Shapes of cells spreading on fibronectin 
Measurement of the stellationof B1IK21 cells induced by raising cyclic AMP, and of its reversal by 
serum and lysophosphatidic acid J Cell Sci 104:399-407 
Fanti WJ, Johnson DE, Williams LT (1993) Signalling by receptor tyrosine .kinases Annu Rev Biochem 
62:453-481 
42 CHAPTER 4 
Fernandez-Pol JA, Klos DJ, Hamilton PD (1989) Modulation of transforming growth factor alpha-
dependent expression of epidermal growth factor receptor gene by transforming growth factor beta, 
triiodothyronine, and retinole acid J Cell Biochem 41:159-170 
Folkman J, Moscona A (1978) Role of cell shape in growth control Nature 273:345-349 
Freedman VH, Shin S (1974) Cellular lumongenicity in nude mice Correlation with cell growth in semi­
solid medium Cell:355-359 
Fukushima M (1992) Biological activities and mechanisms of action of PGJ, and related compounds an 
update Prostagl Leukotri Essen Fatty Acids 47:1-12 
Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK (1993) A link between Cyclin A expression and 
adhesion-dependent cell cycle progression Science 262:1572-1575 
Hadcock JR, Malbon CC (1991) Regulation of receptor expression by agonists transcriptional and post-
transcnptional controls Trends Neurosci 14:242-247 
Hamanaka R, Ono M, Kuratomi Y, Mizoguchi H, Hira, R, Kohno K, Kuwano M (1990) Epidermal 
growth factor (EGF)-nonresponsive variants of normal rat kidney cell line Response to EGF and 
transforming growth factor-/3 Exp Cell Res 186:83-89 
Han J-W, McCormick F, Macara IG (1991) Regulation of Ras-GAP and the neurofibromatosis-1 gene 
product by eicosanoids Science 252:576-579 
Harel L, Blat C, Chatelai, G (1985) Regulation of cell proliferation inhibitory and stimulatory factors 
diffused by 3T3 cultured cells J Cell Physiol 123:139-143 
Heldin N-E, Paulsson Y, Forsberg K, Heldin C-Η, Westermark В (1989) Induction of cyclic AMP 
synthesis is followed by a reduction in the expression of c-myc messenger RNA and inhibition of 3H-
thymidine incorporation in human fibroblasts J Cell Physiol 138:17-23 
Hollenberg MD, Cuatrecasas Ρ (1973) Epidermal growth factor receptors in human fibroblasts and 
modulation of action by cholera toxin Proc Natl Acad USA 70: 2964-2968 
Holley RW, Armour R, Baldwin JH (1978) Density-dependent regulation of growth of BSC-1 cells in tell 
culture growth inhibitors formed by the cells Proc Natl Acad Sci USA 75:1864-1866 
Holley RW, Armour R, Baldwin JH, Brown KD, Yeh YC (1977) Density-dependent regulation of 
growth of BSC-1 cells in cell culture control of growth by serum factors Proc Natl Acad Sci USA 
74:5046-5050 
Hou X, Johnson AC, Rosncr MR (1994) Induction of epidermal growth factor receptor gene transcription 
by transforming growth factor ßl Association with loss of protein binding to a negative regulatory 
element Cell Growth Differ 5:801-809 
Howe LR, Marshall CJ (1993) Lysophosphatidic acid stimulates mitogen-activated protein kinase activation 
via a G-protein coupled pathway requiring p21RAS and p74RAr ' J Biol Chem 268:20717-20720 
Hudson LG, Santon JB, Gill GN (1989) Regulation of epidermal growth factor receptor gene expression 
Molec Endocrinol 3:400-408 
Ignotz RA, Massagué J (1986) Transforming growth factor ß stimulates the expression of fibronectin and 
collagen and their incorporation into the extracellular matrix J Biol Chem 261:4337-4345 
Jalink K, Eicholt7 T, Van Corven EJ, Moolenaar WH (1993) Lysophosphatidic acid induces neuronal 
shape changes via a novel, receptor-mediated signaling pathway Similarity to thrombin action Cell 
Growth Differ 4:247-255 
Jalink K, Van Corven EJ, Moolenaar WH (1990) Lysophosphatidic acid, but not phosphatide acid, is a 
potent Ca2+-mobihzing stimulus for fibroblasts J Biol Chem 265:12232-12239 
Jetten AM (1982) Effects of retinole acid on the binding and mitogenic activity of epidermal growth factor 
J Cell Physiol 110:235-240 
CHAPTER 4 43 
Jetten AM (1983) Action of retinoids on the anchorage-independent growth of normal rat kidney fibroblasts 
induced by 12-0-letradecanoylphorbol-13-acetateor sarcoma growth factor Cancer Res 43:68-72 
Jetten AM, Goldfarb RH (1983) Action of epidermal growth factor and retinoids on anchorage-dependent 
and -independent growth of nontransformed rat kidney cells Cancer Res 43:2094-2099 
Jong Υ.Π, Dalemar LR, Wilhelm В, Baenziger NL (1993) Human bradykinin B2 receptors isolated by 
receptor specific monoclonal antibodies are tyrosine phosphorylated Proc Natl Acad Sci USA 
90:10994-10998 
Kast R, Furstenberger G, Marks F (1991) Activation of a keratinocyle phosphohpase A2 by bradykinin 
and 4|3-phorbol 12-mynstate 13-acetate Evidence for a receptor-GTP binding protein versus a protein-
kmase-C mediated mechanism Eur J Biochem 202:941-950 
Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ (1994) Direct evidence that G.-coupled receptor 
stimulation of mitogen-activated protein kinase is mediated by G 9 7 activation of р2Г" Proc Natl Acad 
Sci USA 91:12706-12710 
Kumagai N, Morii Ν, Fujisawa К, Nemoto Y, Narumiya S (1993) ADP-nbosylation of rho p21 inhibits 
lysophosphatidic acid induced protein tyrosine phosphorylation and phosphatidyhnositol 3 kinase 
activation in cultured Swiss 3T3 cells J Biol Chem 268:24535-24538 
Kusuhara M, Yamaguchi K, Kuranami M, Suzaki A, Ishikawa S, Moon H, Adachi I, Hon S, Handa 
S (1992) Stimulation of anchorage-independent cell growth by endothclm in NRK 49F cells Cancer 
Res 52:3011-3014 
Lahaye DHTP, Afink GB, Bleijs DA, Van Alewijk DCGJ, Van Zoelen EJJ (1994) Effect of bradykinin 
on loss of density-dependent growth inhibition of normal rat kidney cells Cell Mol Biol 40:717-721 
Lecb-Lundberg LMF, Song XH (1991) Bradykinin and bombesin rapidly stimulate tyrosine 
phosphorylation of a 120-kDa group of proteins in Swiss 3T3 cells J Biol Chem 266:7746-7749 
Leid M, Kastner Ρ, Chambón Ρ (1992) Multiplicity generates diversity in the retinole acid signalling 
pathways Trends Biochem Sci 17:427-433 
Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto PE, Moses HL (1986) Induction of c-sis 
mRNA and activity similar to platelet-derived growth factor by transforming growth factor ß a 
proposed model for indirect mitogenesis involving autocrine activity Proc Natl Acad Sci USA 83:2453-
2457 
Lin HY, Lodish HF (1993) Receptors for the TGF-ß superfamily multiple polypeptides and 
serine/threonine kinases Trends Cell Biol 3:14-19 
Loe wenst ein WR (1979) Functional intercellular communication and the control of growth Biochim 
Biophys Acta 560:1-65 
Marks PW, Kruskal BA, Maxfield FR (1988) Simultaneous addition of EGF prolongs the increase in 
cytosolic free calcium seen in response to bradykinin in NRK 49F cells J Cell Physiol 136:519-525 
Massagué J (1992) Receptors for the TGF-ß family Cell 69:1067-1070 
McAllister BS, Leeb-Lundberg F, Olson MS (1993) Bradykinin inhibition of EGF- and PDGF induced 
DNA sysnthesis in human fibroblasts Am J Physiol 265:C477-C484 
McAllister BS, Leeb-Lundberg LMF, Ja vors MA, Olson MS (1993a) Bradykinin receptors and signal 
transduction pathways in human fibroblasts integral role for extracellular calcium Arch Biochem 
Biophys 304:294-301 
Moolenaar WH (1995) Lysophosphatidic acid, a multifunctional phospholipid messenger J Biol Chem 
270:12949-12952 
Moses HL, Yang EY, Pietenpol JA (1990) TGF-ß stimulation and inhibition of cell proliferation new 
mechanistic insights Cell 63:245-247 
44 CHAPTER 4 
Nagasaki Τ, Liao G, Gundersen GG (1994) Isolated plasma membranes induce the loss of oriented 
detyrosinated microtubules and other contact inhibition-like responses in migrating NRK cells J Cell Sci 
107:3413-3423 
Newman EL, Hyldahl L, Larsson O, Engstrom W, Rees AR (1989) Bradykinin blocks the action of 
EGF, but not PDGF, on fibroblast division FEBS Lett 251:225-229 
Oberg КС, Carpenter G (1991) Dexamethasone and retinole acid regulate the expression of epidermal 
growth factor receptor mRNA by distinct mechanisms J Cell Physiol 149:244-251 
Owen NE, Villereal ML (1983) Lys-bradykinin stimulates Na+ influx and DNA synthesis in cultured human 
fibroblasts Cell 32:979-985 
Ohno K, Fukushima M, Fujiwara M, Narumiya S (1988) Induction of 68,000-dalton heat shock proteins 
by cyclopentenone prostaglandins J Biol Chem 263:19764-19770 
Ozanne B, Wheeler T, Kaplan PL (1982) Cells transformed by RNA and DNA tumor viruses produce 
transforming growth factors Federation Proc 41:3004-3007 
Pallen CJ, Tong PH (1991) Elevation of membrane tyrosine phosphatase activity in density dependent 
growth-arrested fibroblasts Proc Natl Acad Sci USA 88:6996-7000 
Patel KV, Schrey MP (1992) Inhibition of DNA synthesis and growth in human breast stromal cells by 
bradykinin evidence for independent roles of B, and B, receptors in the respective control of cell growth 
and phospholipid hydrolysis Cancer Res 52:334-340 
Ridley AJ, Hall A (1992) The small GTP-bmding protein rho regulates the assembly of focal adhesions and 
actin stress fibers in response to growth factors Cell 70:389-399 
Rijksen G, Voller MCW, Van Zoelen EJJ (1993) Orthovanadate both mimics and antagonizes the 
transforming growth factor β action on normal rat kidney cells J Cell Physiol, 154:393-401 
Rijksen G, Voller MCW, Van Zoelen EJJ (1993a) The role of protein tyrosine phosphatases in density 
dependent growth control of normal rat kidney cells FEBS Lett 322:83-87 
Rizzino A, KazakofT P, Nebelsick J (1990) Density-induced down regulation of epidermal growth factor 
receptors In Vitro Cell Dev Biol 26:537-542 
Rizzino A, KazakofT P, Ruff E, Kuszynski C, Nebelsick J (1988) Regulatory effects of cell density on 
the binding of transforming growth factor ß epidermal growth factor, platelet derived growth factor, and 
fibroblast growth factor Cancer Res 48:4266-4271 
Rizzino A, Ruff E, Rizzino Η (1986) Induction and modulation of anchorage-independent growth by 
platelet-derived growth factor, fibroblasts growth factor, and transforming growth factor-ß Cancer Res 
46:2816-2820 
Roberts AB, Anzano MA, Lamb LC, Smith JM, Frolik CA, Marquardt H, Todaro GJ, Sporn MB 
(1982) Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF 
Nature 295:417-419 
Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1981) New class of transforming growth 
factors potentiated by epidermal growth factor isolation from non neoplastic tissues Proc Natl Acad Sci 
USA 78:5339-5343 
Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1984) Antagonistic actions of retinole acid 
and dexamethasone on anchorage-independent growth and epidermal growth factor binding of normal rat 
kidney cells Cancer Res 44:1635-1641 
Roberts AB, Sporn MB (1991) The transforming growth factor-ßs In Peptide Growth Factors and Their 
Receptors I Spom MB, Roberts AB (eds) Springer Verlag, New York, NY, pp 419-472 
Roberts RA (1989) Bradykinin receptors characterization, distribution and mechanisms of signal 
transduction Prog Growth Factor Res 1:237-252 
CHAPTER 4 45 
Roberts RA, Gullick WJ (1989) Bradykinin receptor number and sensitivity to ligand stimulation of 
mitogenesis is increased by expression of a mutant ras oncogene J Cell Sci 94:527-535 
Ruggiero M, Srivastava SK, Fleming TP, Ron D, Eva A (1989) NIH3T3 fibroblasts transformed by the 
dbl oncogene show an altered expression of bradykinin receptors effect on inositol turnover Oncogene 
4:767-771 
Santoro MG, Garaci E, Amici С (1989) Prostaglandins with antiproliferative activity induce the synthesis 
of a heat shock protein in human cells Proc Natl Acad Sci USA 86:8407-8411 
Satoh T, Kaziro Y (1992) Ras in signal transduction Semin Cancer Biol 3:169-177 
Schwartz MA, Both G, Lechene С (1989) Effect of cell spreading on cytoplasmic pH in normal and 
transformed fibroblasts Proc Natl Acad Sci USA 86:4525-4529 
Schwartz MA, Rupp ЕЕ, Frangioni JV, Lechene CP (1990) Cytoplasmic pH and anchorage-independent 
growth induced by v-Ki-ras, \-src or polyoma middle Τ Oncogene 5:55 
Segarini PR (1993) TGF-ß receptors a complicated system of multiple binding proteins Biochim Biophys 
Acta 1155:269-275 
Straus DS, Pang KJ (1984) Effects of bradykinin on DNA synthesis in resting NIL8 hamster cells and 
human fibroblasts Exp Cell Res 151:87-95 
Stunnenberg HG (1993) Mechanisms of transactivation by retinole acid receptors Bioessays 15:309-315 
Thompson KL, Assoian R, Rosner MR (1988) Transforming growth factor-0 increases transcription of 
the genes encoding the epidermal growth factor receptor and fibronectin in normal rat kidney fibroblasts 
J Biol Chem 263:19519-19524 
Thompson KL, Rosner MR (1989) Regulation of epidermal growth factor receptor gene expression by 
retinole acid and epidermal growth factor J Biol Chem 264:3230-3234 
Tilly ВС, Van Paridon PA, Verlaan I, Wirtz KWA, De Laat SW, Moolenaar WH (1987) Inositol 
phosphate metabolism in bradykimn-stimulated human A431 carcinoma cells Biochem J 244:126-135 
Todaro GJ, De Larco JE, Cohen S (1976) Transformation by murine and feline sarcoma viruses 
specifically blocks binding of epidermal growth factor to cells Nature 264:26-31 
Todaro GJ, De Larco JE, Nissley SP, Rechler MM (1977) MSA and EGF receptors on sarcoma virus 
transformed cells and human fibrosarcoma cells in culture Nature 267:526-528 
Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity Cell 
61:203-212 
Van Blitterswijk WJ, Hilkmann H, De Widt J, Van der Bend RL (1991) Phospholipid metabolism in 
bradykinin stimulated human fibroblasts I Biphasic formation of diacylglycerol from 
phosphatidyhnosilol and phosphatidylcholine, controlled by protein kinase С J Biol Chem 266:10337-
10343 
Van Blitterswijk RL, Hilkmann H, De Widt J, Van der Bend RL (1991a) Phospholipid metabolism in 
bradykimn-stimulated human fibroblasts II Phosphatidylcholine breakdown by phosphohpases С and D, 
involvement of protein kinase С J Biol Chem 266:10344-10350 
Van Corven EJ, Groenink A, Jalink K, Eicholtz T, Moolenaar WH (1989) Lysophosphatidate induced 
cell proliferation identification and dissection of signaling pathways mediated by G proteins Cell 59:45-
54 
Van Corven EJ, Hordijk PL, Medema RH, Bos JL, Moolenaar WH (1993) Pertussis toxin sensitive 
activation of p21R A S by G protein coupled receptor agonists in fibroblasts Proc Natl Acad Sci USA 
90:1257-1261 
Van Corven EJ, Van Rijswijk A, Jalink K, Van der Bend RL, Van Blitterswijk WJ, Moolenaar WH 
(1992) Mitogenic action of lysophosphatidic acid and phosphatide acid on fibroblasts Biochem J 
281:163-169 
46 CHAPTER 4 
Van den Eijnden-Van Raaij AJM, Koomneef I, Van Oostwaard TM J, Feijen A, Kruijer W, De Laat 
SW, Van Zoelen EJJ (1989) Purification of a growth factor related to platelet derived growth factor 
and a type β transforming growth factor secreted by mouse neuroblastoma cells Biochem J 257:375-382 
Van den Eijnden-Van Raaij AJM, Koorneef I, Van Zoelen EJJ (1988) A new method for high yield 
purification of type beta transforming growth factor from human platelets Biochem Biophys Res 
Commun 157:16-23 
Van der Bend RL, Brunner J, Jalink K, Van Corven EJ, Moolenaar WH, Van Blitterswijk WJ (1992) 
Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid 
EMBO J 11:2495-2501 
Van der Bend RL, De Widt J, Van Corven EJ, Moolenaar WH, Van Blitterswijk WJ (1992a) 
Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts 
Biochim Biophys Acta 1125:110-112 
Van Zoelen EJJ (1989) Receptor-hgand interaction a new method for determining binding parameters 
without a priori assumptions on non-specific binding Biochem J 262:549-556 
Van Zoelen EJJ (1991) Phenotypic transformation of normal rat kidney cells A model for studying cellular 
alterations in oncogenesis In CRC Reviews in oncogenesis 2, pp311-333 
Van Zoelen EJJ, Peters PHJ, Afink GB, Van Genesen S, De Roos ADG, Van Rotterdam W, 
Theuvenet APR (1994) Bradykinin-induced growth inhibition of normal rat kidney cells is paralleled by 
a decrease in epidermal growth factor receptor expression Biochem J 298:335-340 
Van Zoelen EJJ, Tertoolen LGJ (1991) Transforming growth factor-/? enhances the extent of intercellular 
communication between normal rat kidney cells J Biol С hem 266:12075-12081 
Van Zoelen EJJ, Van Oostwaard TMJ, De Laat SW (1986) Transforming growth factor β and retinole 
acid modulate phenotypic transformation of normal rat kidney cells induced by epidermal growth factor 
and platelet-derived growth factor J Biol Chem 261:5003-5009 
Van Zoelen EJJ, Van Oostwaard TMJ, De Laat SW (1988) The role of polypeptide growth factors in 
phenotypic transformation of normal rat kidney cells J Biol Chem 263:64-68 
Van Zoelen EJJ, Van Rotterdam W, Van de Wetering RAC, Heldin C-Η (1993) Differentil effects of 
PDGF isoforms on proliferation of normal rat kidney cells Growth Factors 9:329-339 
Van Zoelen EJJ, Van Rotterdam W, Ward-Van Oostwaard TMJ, Feijen A (1992) Phenotypic 
transformation of normal rat kidney cells by transforming growth factor ß is not paralleled by enhanced 
production of a platelet-derived growth factor Eur J Biochem 209:89-94 
Westcrmark В (1977) Local starvation for epidermal growth factor cannot explain density dependent 
inhibition of normal human glial cells Proc Natl Acad Sci USA 74:1619-1621 
Wieser RJ, Schutz S, Tschank G, Thomas H, Dienes HP, Oesch F (1990) Isolation and charatcrization 
of a 60-70 kD plasma membrane glycoprotein involved in the contact-dependent inhibition of growth J 
Cell Biol 111:2681-2692 
Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J (1994) Mechanism of activation of the TGH-ß 
receptor Nature 370 341-347 
PART В 
Transcriptional regulation of the human PDGFaR gene 

CHAPTER 5 
Introduction 
Platelet-Derived Growth Factor 
As its name already indicates, platelet-derived growth factor (PDGF) was originally 
characterized as the platelet-derived source for fibroblast and smooth muscle cell 
proliferation (Kohier and Lipton, 1974; Ross et al, 1974). Subsequent studies have shown 
that the production of PDGF is not only restricted to platelets, but that a wide variety of 
both normal and tumor cells is able to produce PDGF (reviewed in: Raines et al., 1991; 
Westermark, 1993). In addition to its mitogenic activity, PDGF is able to elicit many 
different biological effects, ranging from vasoconstriction to Chemotaxis (Ross et al., 
1990; Raines et al., 1991). As a result of this widely distributed expression and pleiotropy 
of effects, PDGF has been postulated to play a role in many biological processes. This 
includes embryogenesis, growth and development, atherosclerosis, wound-healing and 
neoplasia (Ross et al., 1986, 1990; Bowen-Pope et al., 1991; Raines et al., 1991; Raines 
and Ross, 1993). 
PDGF is a dimer, composed of two different, but highly homologous PDGF chains, 
denoted A and B. The A and В chains can either form homo- or hetero-dimers by 
disulfide bonds, which results in three PDGF isoforms: AA, AB and BB. These isoforms 
can bind to two different PDGF receptors, denoted a (PDGFaR) and ß (PDGFßR). The 
PDGF receptors belong to the family of protein tyrosine kinase receptors, which, among 
others, also contains the receptors for epidermal growth factor (EGF), insulin-like growth 
factor (IGF) and fibroblast growth factor (FGF). Like their ligands, the PDGF receptors 
are different, but highly homologous molecules, and they form homo- and hetero-dimers 
upon ligand binding (Claesson-Welsh, 1994, 1994a). The PDGFaR displays high affinity 
for all three PDGF isoforms. However, the PDGFßR preferentially binds the BB-isoform. 
As a result, αα, aß and ßß receptor dimers will be formed, depending on the PDGF 
isoform (Seifert et ai, 1989). 
The events following receptor dimerization have been extensively studied, particularly 
in relation to the PDGFßR. Nevertheless, the exact order and importancy of events have 
still not been absolutely proven. According to Claesson-Welsh (1994a), the following 
scenario is most likely: 'receptor dimerization and accompanying conformational changes 
allow a basal kinase activity to phosphorylate a critical tyrosine residue, thereby 
"unlocking" the kinase, leading to full enzymatic activity directed toward other tyrosine 
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residues in the receptor molecules as well as other substrates for the kinase' 
Phosphorylation of these tyrosine residues within the receptor molecule attracts many 
signal transduction molecules by virtue of their SH2-domain, including Src family kinases 
(Src, Fyn and Yes), phosphatidylmositol 3'-kinase (РІЗ-kinase), Nek, GTPase-activating 
protein (GAP) of Ras, Shb, protein tyrosine phosphatase ID (Syp), phosphohpase C-γ 
(PLC-7), Grt>2 and She (reviewed by Claesson-Welsh, 1994, 1994a) These signal 
transduction molecules either carry an enzymatic activity themselves or they function as 
adaptor molecules for other proteins of the signal transduction cascade 
As mentioned above, most of this information comes from studies on the PDGFßR 
Due to their structural homology, many of these events are thought to be similar for the 
PDGFaR Recently, binding of РІЗ-kinase, Syp and PLC-γ, but not GAP to the activated 
PDGFaR has been demonstrated (Bazenet and Kazlauskas, 1993, Inui et al, 1994) 
Whether there are genuine differences in the signal transduction between the α and ß 
receptor has still to be demonstrated In most cell lines tested, the reported differences in 
mitogenic sensitivity of cells to the different PDGF isoforms mainly reflects the difference 
in ratio of PDGFaR and PDGFßR numbers in these cells (Seifert et al , 1989) However, 
some observations indicate that there is a functional difference between PDGFaR and 
PDGFßR signaling in processes like actm organization of porcine aortic endothelial cells 
(Eriksson et al, 1992), Chemotaxis of human foreskin fibroblasts (Vassbotn et al, 1992), 
proliferation of vascular smooth muscle cells (Inui et al , 1994), and transformation of 
NIH 3T3 fibroblasts (Heidaran et al , 1993, Kim et al, 1994), but the molecular 
background of these differences is currently unknown 
Structure of the PDGFaR protein and gene 
As predicted from the cDNA sequence, the human PDGFaR contains 1066 amino acids 
after cleavage of the 24 amino acids signal peptide (Claesson-Welsh et al , 1989, Matsui 
et al, 1989) Several structural and functional domains can be distinguished within the a-
receptor protein The extracellular ligand binding part contains five immunoglobulin-like 
domains and eight potential N-hnked glycosylation sites Several of these glycosylation 
sites are being used, increasing the molecular mass of the receptor from 140 kDa of the 
precursor form to approximately 170 kDa of the mature PDGFaR protein (Claesson-
Welsh, 1994a) The intracellular part, which is separated from the extracellular by a 
single membrane spanning amino acid stretch, contains the catalytic tyrosine-kinase 
domain This tyrosine-kinase region consists of two parts, separated by a non-catalytic 
kinase insert 
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As already mentioned above, the PDGFaR is highly homologous to the PDGFßR. At 
the amino acid level this homology is almost 50% overall identity, and reaches almost 
90% identity for the first tyrosine kinase domain (Claesson-Welsh et al., 1989; Matsui et 
al., 1989; Do et al., 1992). Based on the sequence similarities and structural 
characteristics, the PDGFaR and PDGFßR belong to the class III subfamily of tyrosine 
kinase receptors, which also includes the colony stimulating factor-1 (CSF-1) receptor (or 
c-fms), c-kit and FLT3 (or FLK2) (Ullrich and Schlessinger, 1990; Rosnet and Birnbaum, 
1993). These subfamily members share about 60% amino acid identity in their kinase 
domains, but are less related in their transmembrane and extracellular domains. They all 
share the structural features of the characteristic five immunoglobulin-like domains and the 
split tyrosine kinase domain. The PDGFaR sequence and structure is very well conserved 
among the different species. The human PDGFaR overall amino acid sequence shows 
more than 76% identity with that of the mouse (Do et al., 1992), rat (Lee et al, 1990) 
and Xenopus (Jones et ai, 1993). 
The gene encoding the PDGFaR has been localized to human chromosomal region 
4qll-ql2 (Matsui et al., 1989; Stenman et al., 1989; Gronwald et al., 1990), and to a 
homologous region on mouse chromosome 5 (Smith et al, 1991; Stephenson et al., 1991) 
in close proximity to c-kit. Recently Spritz et al. (1994) have shown that the human 
PDGFaR gene and c-kit are juxtaposed in a tandem head-to-tail array in chromosome 
segment 4ql2. A similar orientation has been described for the PDGFßR gene and c-fms 
on human chromosome 5 (Roberts et al., 1988) and mouse chromosome 18 (Sundaresan 
and Francke, 1989), and these data strongly suggest that the class III receptor tyrosine 
kinases are derived from one ancestral gene. 
Although currently no effort has been made to characterize the complete exon-intron 
structure of the PDGFaR gene, it most likely resembles the structure of its class III family 
members. Recent genomic sequence data on parts of the PDGFaR gene (Mosselman et 
ai, 1994; Wang and Stiles, 1994; chapter 6 of this thesis) indicate that the PDGFaR gene 
is indeed structurally similar to c-fms and the PDGFßR gene (Sherr, 1990). This implies a 
non-coding exon 1, followed by a relatively large (> 10 kb) intron 1. The translational 
start codon ATG is located within exon 2, and as predicted from the homology with the 
well characterized c-fms (Hampe et al., 1989), the complete PDGFaR gene may 
encompass 22 exons. 
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Functional expression of the PDGFaR 
A prerequisite for a cell to respond to PDGF is the expression of the appropriate PDGF 
receptor at the cell surface Expression of the PDGFaR renders the cell responsive to all 
PDGF isoforms, while the ß-receptor only contributes to PDGF-B responsiveness Due to 
the widely distributed expression of both PDGF and its receptors, it has been difficult to 
discriminate between the exact contribution of either receptor subtype in the different 
biological responses to PDGF However, several observations indicate a specific role for 
the PDGFaR in embryonic development and tumongenesis 
PDGFaR in embryonic development 
Both PDGFaR and PDGF-A are present in all cells of the mouse pre-implantation embryo 
from the two-cell stage onwards, creating an autocrine PDGF loop (Rappolee et al , 1988, 
Palmieri et al , 1992) A similar observation has been made in bovine pre-implantation 
embryos (Watson et al , 1992) In addition, the presence of both PDGF-A and the 
PDGFaR has been demonstrated in early Xenopus embryos and at this stage no PDGF-B 
or ß-receptor could be detected (Mercóla et al , 1988, Jones et al , 1993, Palmieri et al , 
1993) In the mouse PDGF-A and α-receptor expression persist after implantation, but the 
expression patterns of ligand and receptor become separated PDGF-A expression becomes 
limited to the ectoderm, whereas the PDGFaR becomes restricted to the mesoderm (Orr-
Urtreger and Lonai, 1992, Palmieri et al, 1992) This lineage specific expression of 
ligand and receptor is also apparent in Xenopus embryonal development (Jones et al , 
1993) Thus, upon formation of the different germ layers a paracrine mode of interaction 
between the ectodermal produced PDGF-AA and the adjacent mesoderm can be envisaged 
Expression of the ß-receptor becomes also detectable in mouse early post-implantation 
development, but to a lesser extent and at a later time-point than the PDGFaR (Mercola et 
al , 1990) During subsequent developmental stages, PDGFaR expression remains 
characteristic for many mesoderm-denved structures (Orr-Urtreger et al , 1992, Orr-
Urtreger and Lonai, 1992, Schatteman et al , 1992) In addition, the PDGraR is 
expressed m a non-neural subset of neural crest-derived cells (Morrison-Graham et al , 
1992) This lineage-specific expression of the PDGFaR indicates a functional role for the 
α-receptor subunit in the development of these tissues This functionality is clearly 
demonstrated in studies with Patch mice, which carry a deletion of the PDGFaR gene 
(Smith et al , 1991, Stephenson et al , 1991) Mice homozygous for this mutation display 
severe developmental defects in mesoderm- and neural crest-derived structures, eventually 
resulting in death of the embryo (Morrison-Graham et al , 1992, Orr Urtreger et al , 
1992, Schatteman et al , 1992) 
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PDGFaR in tumorigenesis 
The v-sis oncogene of simian sarcoma viras (SSV) is the viral homologue of the gene 
encoding the PDGF-B chain (Doolittle et al, 1983; Waterfield et al, 1983; Devare et al., 
1983). Transformation of cells by SSV involves the v-sis product and subsequent binding 
of this protein to the cells' own PDGF receptors, thus creating an autocrine PDGF loop 
(Owen et al, 1984; Johnson et al, 1985; Leal et al, 1985; Keating and Williams, 1988; 
Fleming et al, 1989). This concept of autocrine (but also paracrine) PDGF stimulation is 
still the basis for the suggested role of PDGF in tumor development. Many human tumor 
cell lines express PDGF and several express at the same time the appropriate PDGF 
receptor (reviewed by Westermark, 1993). Gliomas are the best studied example which 
support the idea for a functional role for the PDGFaR in tumor development. Most human 
gliomas express high levels of PDGFaR together with its ligand, thus creating autocrine 
loops within these tumors (Nistér et al, 1991; Hermanson et al, 1992). In certain 
gliomas amplifications of the PDGFaR gene occur (Kumabe et al, 1992; Collins 1993; 
Hermanson et al, 1995), while in addition a glioma-specific PDGFaR gene mutation has 
been described (Kumabe et al, 1992). Even in the absence of PDGFaR gene 
amplification, a large subgroup of gliomas overexpress the PDGFaR at the mRNA level 
(Hermanson et al, 1995). These findings together with the recent observation that a 
truncated, dominant-negative PDGF receptor inhibits glioma cell proliferation (Strawn et 
al, 1994) strongly suggest a prominent role for the PDGFaR in glioma development. 
Besides glioma development, several other tumorigenic processes have been described 
in which the PDGFaR is thought to play a role. An example is the metastasizing capacity 
of 3LL Lewis lung carcinoma and T10 sarcoma cells. In these cells the PDGFaR is not 
involved in the growth of the primary tumor, but its expression is strongly correlated with 
the capacity of the cells to metastasize to the lungs. Autocrine PDGF stimulation is not 
involved in this process, but PDGF is supplied in a paracrine fashion by the lung tissue 
(Do et al, 1992; Fitzer-Attas et al, 1993). As in gliomas, the concomitant expression of 
PDGF and the α-receptor is related to the progression of ovarian tumors (Henriksen et al,. 
1993) and has been described in neuroendocrine tumors of the digestive system (Chaudry 
et al, 1992). Recently Mosselman et al. (1994, 1995) have demonstrated that PDGFaR 
gene expression serves as an excellent indicator of human testicular tumor development. 
The highly-malignant undifferentiated embryonal carcinoma cells do not express the full 
lenght 6.4 kb PDGFaR transcript, but instead they display a 1.5 kb and 5.0 kb a-receptor 
messenger, as a result of both alternative splicing and alternative transcription initiation. 
In differentiated, non-malignant embryonal carcinoma cells the 6.4 kb PDGFaR mRNA is 
expressed together with а 3.0 kb transcript, which may encode a truncated PDGFaR. 
Although no functional role for the 1.5 kb and 5.0 kb α-receptor transcripts has been 
54 CHAPTER 5 
established yet, these transcripts appear to be specific markers for early stages of testicular 
tumors, including carcinoma in situ, and both seminoma and non-seminomatous tumors. 
Regulation of PDGFaR expression 
The important question remains what mechanisms are involved in this specific regulation 
of PDGFaR expression. As already mentioned above, gene amplification may account for 
abberantly high PDGFaR expression in certain tumors, but this cannot be considered as a 
general mechanism. Both embryonic development and tumorigenesis are highly complex 
systems in which many regulatory mechanisms are involved. Thus it seems more likely 
that timing and abundancy of PDGFaR expression is regulated by a complex interaction 
between signals from both outside and inside the cells. In this respect, the observation that 
PDGFaR expression in vitro is affected by several growth factors is of particular interest. 
This mechanism by which membrane receptors are modulated by heterologous ligands is 
referred to as transmodulation (Zachary and Rozengurt, 1985). 
Transforming growth factor β 
Transforming growth factor ß (TGFß) was the first growth factor described that 
transmodulates PDGFaR expression. TGFß-treated mouse Swiss 3T3 fibroblasts display a 
reduced mitogenic response towards PDGF and show reduced PDGF-AA binding when 
compared to untreated cells (Gronwald et al., 1989). Similar observations have been made 
in human foreskin fibroblasts (Yamakage et al., 1992; Paulsson et al., 1993), human 
smooth muscle cells (Battegay et al., 1990), and human osteoblastic cells (Yeh et al., 
1993a). In addition to reduced PDGF-AA binding upon TGFß treatment, these studies also 
demonstrated a reduction in PDGFaR mRNA levels. However, downregulation of the 
PDGFaR and a parallel reduction in mitogenic response is not a general mechanism of 
TGFß. Adult human skin fibroblasts or scleroderma fibroblasts show an increase in 
PDGFaR mRNA expression in response to TGFß treatment (Ishikawa et al., 1990; 
Yamakage et al., 1992). Whether this positive or negative transmodulation of the 
PDGFaR by TGFß is regulated transcriptionally or post-transcriptionally is currently 
unknown. 
Interleukin-1 
Interleukin-1 (IL-1) is a potent modulator of PDGFaR expression in osteoblastic cells. 
Treatment of fetal rat osteoblastic cells or the mouse osteoblast-like MC3T3-E1 cells with 
IL-1 induces PDGFaR expression and stimulates in this way the chemotactic and 
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mitogenic response of these cells to PDGF (Tsukamoto et al., 1991; Centrella et al., 
1992). However, similar experiments with normal human osteoblasts and human MG63 
osteosarcoma cells showed a decrease in PDGFaR expression and a reduced migrational 
and mitogenic response to PDGF upon IL-1 treatment (Gilardetti et al., 1991; Yeh et al., 
1993a). There is not a good explanation for these contrasting results other than that it 
reflects the difference in species. Recently, Xie et al. (1994) have demonstrated by 
nuclear run-on analysis that at least the inhibitory effect of IL-1 on PDGFaR gene 
expression is regulated at the transcriptional level. 
Retinole acid 
Mouse F9 embryonal carcinoma cells provide a widely used model system for studying 
early embryonic events in vitro. Exposure of undifferentiated, pluripotent F9 cells to 
retinole acid (RA) causes these pluripotent stem cells to differentiate into cells resembling 
extraembryonic endoderm (Strickland and Mahdavi, 1978; Strickland et al., 1980; Hogan 
et ai, 1980). This differentiation is accompanied by a strong induction of PDGFaR gene 
expression, which is largely due to a RA-induced enhancement of transcription of the 
PDGFaR gene (Mercóla et al, 1990; Wang et al, 1990). The human embryonal 
carcinoma cell line Tera-2 clone 13 displays a similar induction of PDGFaR gene 
expression by RA (Mosselman et al., 1994). In addition, it has been reported that RA 
induces PDGFaR gene expression in mouse osteoblastic MC3T3-E1 cells, but it is 
currently unknown whether RA induces this effect by increased transcription as in F9 cells 
(Tsukamoto et al., 1994). 
FGF 
Four completely different cell systems have been described in which FGF specifically 
upregulates PDGFaR expression. Firstly, basic FGF (bFGF) maintains a high level of 
PDGFaR expression in rat 0-2A oligodendrocyte precursor cells, which correlates with 
the capacity of bFGF to block oligodendrocyte differentiation of these cells (McKinnon et 
al., 1990). Another cell type in which bFGF selectively increases PDGFaR expression are 
bovine and human smooth muscle cells, thereby rendering these cells responsive to PDGF 
(Schöllmann et al., 1992). Also in mouse osteoblast-like MC3T3-E1 cells the PDGFaR 
expression is increased by FGF (Tsukamoto et al., 1991), and the same observation has 
been reported for human dermal fibroblasts (Ichiki et al., 1995). There are currently no 
indications at what level this regulation takes place. 
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PDGF-BB, EGF and insulin 
Less well documented are the actions of PDGF-BB, EGF and insulin on the PDGFaR 
expression. Eriksson et al. (1991) have reported that PDGF-BB transiently increases 
PDGFaR mRNA levels in human foreskin fibroblasts through a post-transcriptional 
mechanism. Like IL-1, FGF and RA (see above), EGF upregulates α-receptor expression 
in mouse MC3T3-E1 cells (Tsukamoto et al., 1991). In addition, one observation 
describes the inhibition of PDGF-AA binding to mouse Swiss 3T3 fibroblasts by insulin, 
apparently through a downregulation of PDGFaR numbers (Gronwald et ai, 1989). 
As indicated above, the RA-induced increase and IL-1-induced decrease in PDGFaR 
expression is controlled at the level of gene transcription. Transcriptional regulation of the 
PDGFaR gene as the target for transmodulation of α-receptor expression by the other 
factors mentioned can not be excluded, although many post-transcriptional alternatives are 
possible. 
The following three chapters will deal with some aspects of the transcriptional 
regulation of the PDGFaR gene. Chapter 6 describes the first step towards a better 
understanding of this process, namely the molecular cloning and functional 
characterization of the human PDGFaR gene promoter. The functionality of the promoter 
is assessed by its capacity to drive reporter gene expression in a orientation dependent way 
and its ability to respond to RA. Chapter 7 deals in more detail with the molecular 
mechanisms that are involved in the RA-induced transcriptional activation of the PDGFaR 
gene. Finally, in chapter 8 some in vivo aspects of the PDGFaR gene promoter in relation 
to embryonic development will be addressed using a promoter//acZ reporter gene in a 
transgenic mouse model. 
CHAPTER 6 
Molecular cloning and functional characterization of the human platelet-
derived growth factor α receptor gene promoter 
ABSTRACT 
Expression of the platelet-derived growth factor α receptor (PDGFaR) is strictly regulated 
during mammalian development and tumongenesis The molecular mechanisms involved 
in the specific regulation of PDGFaR expression are unknown, but transcriptional 
regulation of the PDGFaR gene is most likely to be involved This study describes the 
molecular cloning of the non-coding exon 1 and approximately 2 kb of 5' flanking region 
of the human PDGFaR gene This 5' flanking region is a functional promoter of the 
PDGFaR gene as concluded from its capacity to drive Iuciferase reporter gene expression 
in an orientation dependent way Analysis of 5' promoter deletion mutants revealed that 
the region from -441 to +118 is sufficient to establish high level promoter activity In 
addition, the morphogen retinole acid, in combination with dibutyryl cAMP, gives a 22-
fold induction of PDGFaR gene promoter activity in human embryonal carcinoma cells 
This indicates that the cloned PDGFaR gene promoter contains the necessary elements to 
regulate PDGFaR expression in response to cell growth regulatory factors 
Published in a slightly different form in Oncogene 10, 1667-1672, 1995, by Gijs В Afink, Monica Nister, 
Bianca H G J Stassen, Paul H L J Joosten, Pascale J H Rademakers Erik Bongcam-Rudloff Everardus 
J J Van Zoelen & Sietse Mosselman 
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INTRODUCTION 
Platelet-derived growth factor (PDGF) is a potent mitogen for mesenchymal and glial cells 
and is thought to play an important role in wound-healing, atherosclerosis, neoplasia and 
embryogenesis (for reviews see Ross et al., 1990; Bowen-Pope et al., 1991; Raines et al., 
1991; Westermark & Heldin, 1993). PDGF can occur as three isoforms, AA, AB and BB, 
which bind with different affinities to the PDGFa and ß receptor. PDGF BB is the only 
high affinity ligand for the PDGFß receptor (PDGFßR), but the PDGFa receptor 
(PDGFaR) can bind all three isoforms. Both the α and β receptor belong to the family of 
tyrosine kinase receptors. Upon ligand binding PDGF receptors dimerize, which results in 
kinase activation and receptor transphosphorylation on specific tyrosine residues. The 
phosphorylated receptors subsequently attract SH2-domain containing molecules for 
downstream signaling (for review see Claesson-Welsh, 1994). 
Although the exact contribution of either receptor subtype to the different biological 
responses of PDGF is still unclear, accumulating evidence suggests a specific role for the 
α receptor subunit in early embryonic development and tumorigenesis. This notion is 
supported by the observation that both the PDGF Α-chain and the α receptor are already 
expressed in the preimplantation embryo (Mercóla et al., 1988; Rappolee et al., 1988; 
Watson et al., 1992). In addition, both PDGF Α-chain and PDGFaR mRNA are expressed 
prior to and more abundantly than PDGF B-chain and PDGFßR mRNA in early mouse 
postimplantation development (Mercóla et al., 1990). Additional information concerning 
the importance of PDGFaR expression during early embryonic development comes from 
studies on Patch mice, which lack the PDGFaR gene (Smith et al.. 1991; Stephenson et 
al., 1991). Mice carrying this mutation display severe developmental defects (Orr-Urtreger 
et al., 1992; Schatteman et al., 1992). Although the impact of PDGFaR expression in 
later development seems to decline, expression of the PDGFaR gene still correlates with 
the development of specific tissues. Glia cell specific PDGFaR expression in the 
developing central nervous system is the most extensively studied example (Yeh et al., 
1993; Pringle et al., 1992). Tumors arising from glial cells also display a specific pattern 
of PDGFaR expression (Nistér et al., 1991; Hermanson et al., 1992) or contain PDGFaR 
gene mutations (Kumabe et al., 1992). Another observation that stresses the relevance of 
the PDGFaR subunit in tumorigenesis is its specific expression in highly metastatic 
murine tumor cells (Do et al., 1992; Fitzer-Attas et al., 1993), malignant ovarian tumors 
(Henriksen et al., 1993) and neuroendocrine tumors (Chaudhry et al., 1992). 
The regulatory mechanisms underlying the specific expression of the PDGFaR gene 
in development and tumorigenesis are unknown, but they will probably reflect a 
combination of both transcriptional and posttranscriptional control. In mouse F9 
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embryonal carcinoma cells, which resemble cells from early embryonic stages, PDGFaR 
gene expression can be induced by the morphogen retinoic acid (RA) (Mercola et al., 
1990). This induction of PDGFaR gene expression is transcriptionally regulated (Wang et 
al., 1990) and occurs also in human embryonal carcinoma cells, as shown previously by 
our group (Mosselman et al., 1994). To gain more insight in the transcriptional regulation 
of the PDGFaR gene in development and tumorigenesis, we have cloned and characterized 
exon 1 and approximately 2 kb of 5' flanking sequences of the human PDGFaR gene. 
This 5' flanking region is able to drive luciferase reporter gene expression in both human 
and mouse cells. In addition, this PDGFaR gene promoter displays responsiveness to RA 
and dibutyryl cAMP (Bt2cAMP), which are important regulators of embryonal carcinoma 
cell differentiation. 
RESULTS 
Cloning and nucleotide sequence analysis of exon 1 and 5'flanking region of the human 
PDGFaR gene 
A 255 nucleotides EcoRI fragment, representing the 5' end of the human PDGFaR cDNA 
(kindly provided by Dr. L. Claesson-Welsh, Ludwig Institute, Uppsala, Sweden), was 
used to screen a human genomic DNA library. Southern blot analysis of restriction 
enzyme digested DNA from three out of thirty positively hybridizing phages indicated that 
all three phage clones contained the same region of the PDGFaR gene (data not shown). 
Subsequent subcloning of this phage DNA (from two independent phage clones) into 
pBluescript and reselecting for FxoRI probe positive clones resulted in the 1.4 kb 
pPARTlOl and 4.5 kb pPARP9 genomic subclones as outlined in figure 6.1. Additional 
Southern blot analysis (data not shown) and partial sequencing of these subclones revealed 
that both pPARTlOl and pPARP9 contained sequences corresponding to the 5' end of the 
human PDGFaR cDNA (Claesson-Welsh et al., 1989; Matsui et al., 1989). This sequence 
corresponding to the cDNA sequence does not contain the ATG initiation codon and, 
analogous to the c-fins proto-oncogene (Hampe et al., 1989), a close gene family member 
of the PDGFaR gene, reflects the non-coding exon 1 of the human PDGFaR gene. The 
sequence of exon 1 and approximately 2.1 kb of 5' flanking DNA is shown in figure 6.2. 
The exon-intron boundary sequence of exon 1 is conform to the AG-GT rule and matches 
almost perfectly to the overall boundary consensus sequence econ..AG/GTPuAG..wfro/j 
(Mount, 1982). From these sequence data it follows that the EcoRI fragment, used to 
screen the genomic library, also encompasses sequences extending at least into exon 2. 
However, Southern blot analysis of exon 1 containing phage DNA never indicated the 
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Figure 6.1 Schematic representation of the genomic subclones pPARTIOl шні pPARP9 
which together encompass approximately 5 kb of genomic sequences Both subclones contain 
sequences homologous to the 5 end of the human PDGFaR cD\A (Clacsson Welsh el al 
1989 Matsui et al 1989) indicated by the black box In addition the restriction map of the 
region used for promoter studies is shown at the bottom part of the figure Indicated are those 
restriction en/ymc sites that were used for subcloning into pSI A4 (promoter luciterase 
constructs) or pBluescript (sequence analysis) 
presence of additional exons on the same genomic clone (data not shown) 
Analysis ol the PDGFaR gene promoter sequence revealed several elements that 
might bind proteins of the transcription machinery An obvious element is the ГА ГА box­
like sequence located approximately 30 nucleotides upstream ot the sequence 
corresponding to the 5' end ol the PDGFraR cDNA (boxed sequence, figure 6 2) The 
TATA-box typically directs the transcription initiation 10 nucleotides downstream of the 
TATA motif (/awel & Reinberg 1992) To test whether the transcription initiation ol the 
PDGtcxR gene actually starts approximately 30 nucleotides downstream ot the Ι ΑΓΑ 
motil, as suggested by the 5' end ot the cDNA primer extension analysis was performed 
to identity the transcription start location As shown in figure 6 3 a major primer 
extension product was detected which size indicates a transcription initiation site at the 
position marked by the hooked arrow in tiguie 6 2 This initiation site however is located 
34 nucleotides upstream of the 5 end of the cDNA sequence This position ot 
transcription initiation makes it very unlikely that the TAT Α-motif directs the transcription 
start ot the PDGfaR gene Analysis ot the promoter sequence tor other putative 
transcription lactor binding sites (Iaisst and Me>er 1992) revealed several consensus 
motifs including those for Γ 21 GATA AP2 and ΡΓΑ3 (tiguie 6 2) It remains to be 
established however, whether these elements play a functional role in the PDGhaR gene 
tianscnption regulation 
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I 2 1 2 ° AP2 
2123 gtcgacctct cttctttgca cagtctctcc gcaaaatttt cccccaacca tttgctttct tgcgccaccc cccaccggca ctatccctgg agtcagctcc 
-2023 teaggccttt aaaccttcea gaatgtcaca catggaaacc cttagcaaat gtttgttaat gatcataaca aaggcatcac tcaaattagg caggtaatta 
192Э ccaccagaag gacaactggg tgctcgcttg ctcatccatt gctttctgct ttaaactccc gaggagtcgc tgcctgaaga cactcccgcc cggactgctt 
1 2Э ctcgggcccc actaaacggc tctgaaatga actgtgaagt taccatttgt gggcggagag cgctggggcc ctgcggacgg aagaccctgg cttgaccgga AP2 
172Э ccaacagtgt cgccgaagca aagcagcccc tctggtaggc tgtctgtctc gcctcctacc ctctgggcaa ctagcctaaa aacccggttc tcaacttaac 
1623 agcatgtggc ccagcacccg cttttgcctt Ctattccgca ctctgatttt tggggggatc gtttgttccc gctcattttc tacaaacatt acggtatcct 
1523 gttageattc cgaacaaggg gctgttcata tatttgcctt caatgatttc tgaagggaca tgtggaagta atagcgagcg gtgcagtcac ceaagctgaa 
AP2 ДР2 
-1423 gatgcacgag agcgggtcgc gtagaagaac tgcggcaatg gacccccagc gcacgcccag gcgccctgtt ttcgaggctg acatcccaag atcctgccct 
Ί323 ggttaggcac agcaccgcgc ccgttggagt acttctctgt gactctcccc tgtccaccgc actgtgtcca ccctcctggt gaaggaggag acggctgttg 
AP2 
-1223 gacatgccag tcceaacctg ccactttggc catcttcaga gtgcgtgtgt tggggtggqg ttgagggaga aggatgaagg argarrccca accccaacag 
*£2 AP2 
-1123 gagaattcaa aaateagaga gcgatgaagg tgaacgcgct cccctccccc gctgtcgctg ggaagcccca ctctgtccag gtctggttce tggagcatca 
I 944 
-1023 gcgccccctt tccctcgccg gcaggatcgt ttcctcccga cactggcctc tcgccttggg cgcagggttt ggggctcagc tgtcaatccc aaggaattcg 
AP2 PEA3 ÂP2 I 825 
923 tagggttcga cccacgcggc gggagggaac ggagggagaa tcaaaaggca tcctccccca cgaacgcgga ggcggtggta egattcccca aacgcccaag 
GATA GATA PATA 
-823 ctcgagcttt ttttgtatgc gagatagaag ccagggcaac ctcgcccaga taaccccgaa aacaaaggca cgarcagata agLgactcca agggagtaaa 
-723 ggtcgttcca tcggagaacg ctccaaacct acacagaccc tcttttcttt gtaccgtatt tcagaccacc cagtcttgta caracacaca caccacacaa 
623 aacaaaaacc catcattgtc atactggact caacagcttg cccaatccta ttaaataact agcaactata cageccttcc cctaaaagac ccrtagttca 
,441 
523 aaacggcgca accgcttgga gatttctccc gagggcccca cttctcgttg ggccgagctc gtagaaggga catttcttga ttccagactt atattccctc 
-423 tgggtattaa atgcaatttt gtatgttccc tttcttcttt tcaaagagaa tacaaaacta cagcagccta agaaaataac cccaaaatgg ggaggcaaac 
E2F | 275 AP2 
323 icattctgga aatgatgqgc tgtttgcagt rtcacaaaac ctctctcccg gcagagcacc aacacctccc ccttccacca crccccatcc catctggtct 
AP2 I 197 1-175 
-223 gctcctcccc gccccccagt tgttgccgaa gcctgggggc tgggaccgga ccccctgatt gcgtaagagc aaaaagcgaa gqrgcaatct gqaractggg 
ÂF2 I 52 
-123 aqattcggag cgcagggagt ttgagagaaa cttttatttt gaagagacca aggttgaggg ggggcctatt tcctgacagc tatttactta gagcaaatga 
, C* PEA! 
-23 ttagttttag aaggatggac jlataajcattg aatcaattac aaaacgcggt ttttgagCCC ATTACTarro OAQCTACAOO OAOAOAAACA ΟλσαλσΟΑΟΑ 
' *118| . ΕΧΟΝ 1 •*-!-)• INT RON 1 
«78 CTOCAAOAOA TCATTOOAOO CCOTOUOCAC OCTCTTTACT CCATOTOTOO (lACATTCATT CCOOAATAAC ATCW3AOOAO AAagtagggg aaaaqaaaaa 
AP2 
•17B atgatttttt gctcataagg gaagtccccg accagact 
Figure 6.2. Nucleotide sequence of exon 1 and 5' flanking region of the human PDGFaR gene 
Nucleotide sequence analysis was performed on multiple overlapping subclones from both pPARP9 and 
pPARTlOl The sequence homologous to the PDGFaR cDNA (Claesson-Welsh et al , 1989, Matsui el al , 
1989) is shown bold face, and the position of the transcription start (+1) is indicated by the hooked arrow 
The 5' and 3' ends of the promoter deletion mutants are represented by vertical lines with nucleotide 
position number Putative transcription factor binding sites for AP2, PEA3, GATA (Faisst and Meyer, 1992) 
and for E2F (Ouelette et al , 1992) are marked by a horizontal line above (indicating 5'-3' orientation) or 
below (indicating 3'-5' orientation) the nucleotide sequence The TATA-box-Iike element (see text) is boxed 
The astenx marked Τ nucleotide at +123 has been mutated to a G in PCR experiments to generate a unique 
Ncol restriction enzyme sue within exon 1 for subcloning into pSla4 (see materials and methods) 
Functional characterization of the PDGFaR gene promoter 
To perform a functional analysis of the PDGFaR gene promoter, approximately 2 kb of 
5'flanking region and part of exon 1 was cloned m front of a luciferase reporter gene (see 
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Figure 6.3. Primer extension analysis on PDGFaR RNA. 
RNA (50 μg) was reverse transcribed using an end-labeled oligonucleotide, complementary to 
nucleotides 45-70 of exon 1 (figure 6.2). The products were analysed on a 6% polyacrylamide-
ureum gel and visualized by autoradiography. T=tRNA, G=Germa II RNA, M = MA-90 
RNA. As size marker, a parallel nucleotide sequence reaction on plasmid DNA, containing 
exon 1 and 5' flanking sequences, was performed with the same oligonucleotide. Indicated is 
the nucleotide sequence from -4 to +6. 
materials and methods). In addition, a series of 5' deletion mutants were constructed and 
the promoter activity of these constructs was determined by transient transfection into 
several mammalian cell lines and monitoring luciferase activity. Figure 6.4 shows the 
results of the transfections into two PDGFaR expressing cell lines, RA-differentiated 
human Tera-2 cells (Mosselman et al., 1994) and mouse Swiss 3T3 cells (Gronwald et al., 
1989). It is clear from these data that the 5' flanking region of the human PDGFaR gene 
is able to drive luciferase gene expression from a reporter construct in both human and 
mouse cells. Thus, the 5' flanking region can act as a functional promoter. The pattern of 
promoter activity of the different 5' deletion mutants is similar in both human and mouse 
cells. The highest promoter activity was observed in the -441/ + 118 LUC construct. 
Shortening this construct to -275/+ 118 dramatically decreased luciferase expression, but 
further 5' deletions up to -175 restored much of the promoter activity. Additional 
deletions from -175 to -52 reduced the luciferase expression to a level <5% of the 
maximal expression, but well above background (pSLA4). Extending the -441/+ 118 LUC 
construct at the 5' end also results in a decrease of promoter activity. This complex 
activity pattern of the 5' deletion mutants suggests that both positive and negative 
promoter elements are involved in basal PDGFaR gene transcription. However, it can be 
concluded that the human PDGFaR gene 5' flanking region up to nucleotide -441 contains 
all the elements necessary for high level promoter activity in both human and mouse cells. 
-4 
+6 
А С G Τ 
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relative promoter activity (%) 
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Figure 6.4. Promoter activity of 5' deletion mutants. 
A series of 5' promoter deletion mutants, fused to a luciferase reporter gene, were transiently 
transfected into differentiated Tera-2 cells (black bars) or mouse Swiss 3T3 cells (open bars). 
Luciferase activity in the cell lysatc was determined 24 hrs. (Tera-2), or 48 hrs. (Swiss 3T3) 
post transfection. The luciferase activity was normalized to the ß-galactosidase activity of the 
co-transfecled pCHl 10 plasmid. Values represent mean promoter activity relative to the 
activity of -441/+118 LUC (error bars indicate sample standard deviation of triplicate 
determinations). pSLA4 represents the luciferase vector without promoter insertion and the 
activity of the -944/+ 118 LUC was not determined in Swiss 3T3 cells. 
In addition to Tera-2 and Swiss 3T3 cells, several other cell lines have been tested 
for PDGFaR gene promoter activity. When transfected with promoter-luciferase 
constructs, the human malignant glioma cell lines U-1242 MG, U-343 MGa 35L (Nistér et 
al., 1991), mouse normal osteoblast-like cells MC3T3-E1 (Tsukamoto et al., 1991) and 
NIH 3T3 cells showed to be positive for luciferase activity (data not shown). This 
indicates that the promoter constructs are active in a wide variety of PDGFaR expressing 
cells. 
An important observation that confirms the promoter activity of the cloned 5' 
flanking region of the PDGFaR gene is the orientation dependence of the promoter 
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Figure 6.5. The promoter activity is orientation dependent. 
The activity of the PDGFaR gene promoter was determined in 
both the 5'-3' (-2120/+118 LUC) and the 3'-5' ( + 118/-2120 
LUC) orientation. Values are mean + sample standard deviation 
of triplicate determinations. 
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constructs. When the -2120/+118 promoter fragment is cloned in the reverse orientation 
in front of the luciferase gene, the promoter activity is abolished, as shown in figure 6.5. 
RA and с AM Ρ strongly induce PDGFaR gene promoter activity 
Mouse F9 embryonal carcinoma stem cells can be differentiated into endoderm-like cells 
by treatment with RA or RA in combination with Bt2cAMP (Hogan et al., 1981). This 
differentiation is accompanied by an induction of PDGFaR expression, which is 
completely absent in undifferentiated F9 cells (Mercóla et al., 1990; Wang et al., 1990). 
Enhanced transcription plays a prominent role in the RA/Bt2cAMP-induced PDGFaR 
expression (Wang et al., 1990). We have recently shown that RA-induced differentiation 
of human embryonal carcinoma Tera-2 cells is also paralleled by an induction of PDGFaR 
gene expression (Mosselman et al., 1994). The data in figure 6.6 demonstrate that the 
above described effects can be explained by RA/Bt2cAMP-induced promoter activity. 
Treatment of -825/+ 118 LUC transfected Tera-2 cells with RA increased the promoter 
activity 10-fold, and the combination RA/Bt2cAMP enhanced promoter activity 22-fold 
over the unstimulated control levels. In contrast to the PDGFaR expression in mouse F9 
cells, Bt2cAMP alone has also a pronounced effect on the PDGFaR gene promoter 
activity. The RA or RA/Bt2cAMP-induced PDGFaR gene promoter activity seems to be 
specific for embryonal carcinoma cells. When applied to transfected Swiss 3T3 cells, no 
effect of RA or Bt2cAMP could be detected (data not shown). 
Figure 6.6. RA and Bt2cAMP induce PDGFaR gene promoter 
activity 
The -825/ +118 LUC construct was transfected into 
undifferentiated Tera-2 cells (3 10' cells/cm2) The cells were 
treated for 48 hrs with the indicated compounds (control = no 
treatment), after which the cells were lysed and luciferase/ß-
galactosidase activities of the lysate were determined The 
phosphodiesterase inhibitor theophylline was added in 
combination with BtcAMP, as described as standard conditions 
for PDGFaR gene expression in mouse F9 cells (Wang et al , 
1990) Values represent mean + sample standard deviation of 
duplicate determinations Final concentrations 350 μΜ 
theophylline (Th), 5 μΜ RA, 100 μΜ Bt2cAMP 
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DISCUSSION 
The PDGFaR gene belongs to a family of tyrosine kinase receptor genes which also 
includes the PDGFßR gene, c-fins and c-kit. These four genes are pairwise localised on 
human chromosomes 4 and 5, and it has become evident that they must have originated 
from the same ancestral gene (Sherr, 1990). The current data on exon 1, and our previous 
data on exon 13 to 16 (Mosselman et al., 1994), suggest that the PDGFaR gene is 
structurally similar to the PDGFßR gene and c-fins (Sherr, 1990). All three genes are 
characterized by a non-coding exon 1, which is not present in c-kit (Giebel et al.. 1992; 
Vandenbark et al., 1992). Although the size of the first intron of the PDGFaR gene has 
not been established, the lack of additional exons in exon 1 containing phage DNA 
indicates that the PDGFaR gene probably contains the typical large intron 1, like the other 
family member genes. 
The 5' flanking region of the PDGFaR gene functions as a promoter, based on three 
criteria. 1. When fused to the firefly luciferase reporter gene, the 5' flanking sequences 
are able to drive the expression of this luciferase gene. 2. Luciferase reporter gene 
expression is not accomplished when the promoter is in the reverse orientation. 3. RA and 
BticAMP greatly enhance the luciferase expression of the promoter-luciferase constructs. 
Although this promoter is able to drive luciferase expression in a variety of cell lines, it 
does not necessarily have to be the only promoter of the PDGFaR gene. The c-fins proto-
gene has two seperate promoters that confer tissue specific transcription of the gene. One 
promoter is located upstream of the non-coding exon 1, and another is present just 
upstream of exon 2 (Roberts et al., 1992). Due to the non-coding nature of exon 1, 
transcription initiation from both promoters results in identical protein products. Since the 
PDGFaR gene and c-fins arc closely related, this regulatory mechanism may also occur in 
the PDGFaR gene. Currently there are no indications for an additional PDGFaR gene 
promoter just upstream of exon 2. In all the cell lines tested so far, the 6.4 kb PDGFaR 
mRNA hybridizes with an exon 1 specific probe (unpublished observation). However, in 
addition to the 6.4 kb PDGFaR transcript, alternative transcripts are generated in 
undifferentiated human embryonal carcinoma cells (Mosselman et al., 1994). These 
transcripts initiate from a promoter within intron 12 of the PDGFaR gene. This promoter 
is also capable to drive luciferase reporter gene expression in undifferentiated cells (Kraft, 
H.J., Mosselman, S., Hohenstein, P., Overdijk, E.J. & Van Zoelen, E.J.J., manuscript in 
preparation). 
The regulation in embryonal carcinoma cells by RA and Bt2cAMP is a very 
important characteristic of the PDGFaR promoter. Although PDGFaR gene expression is 
affected by a number of growth regulating factors, including interleukin-1 (Tsukamoto et 
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al , 1991, Yeh et al , 1993a), PDGF BB (Eriksson et al , 1991), TGFß (Gronwald et al , 
1989, Battegay et al , 1990, Ishikawa et al . 1990, Yamakage et al . 1992, Paulsson et 
al , 1993), bFGF (McKinnon et al , 1990, Schollmann et al , 1992), and RA (Mercola et 
al , 1990, Wang et al , 1990, Mosselman et al , 1994), only for RA it has been shown 
that it affects the transcription of the PDGFaR gene (Wang et al , 1990) The current 
study confirms this transcriptional effect of RA on the PDGFaR gene expression and the 
synergizing effect of Bt2cAMP However, in contrast to the data of Wang et al (1990), 
Bt2cAMP itself also generates a strong induction of promoter activity The exact reason 
for this discrepancy it not known, but it may reflect the difference in the cell system used 
The molecular mechanisms by which RA and Bt2cAMP increase the PDGFaR gene 
promoter activity are unknown The promoter sequence does not contain any putative RA 
receptor or cAMP responsive elements However, the activity of many transcription 
factors can be modulated by RA and Bt2cAMP (Faisst and Meyer, 1992) In particular 
AP2, for which many putative binding sites are available in the human PDGFaR gene 
promoter, is of interest It has been shown that AP2 activity is induced upon RA 
differentiation of human embryonal carcinoma cells (Williams et al , 1988, Luscher et al , 
1989) Another transcription factor that could mediate the RA inducibility of the PDGFaR 
gene promoter is GATA This factor is involved in the transactivation by RA of the J6 
Serpin gene in mouse embryonal carcinoma cells, as recently described by Wang (1994) 
Current studies are underway to characterize the precise sequence elements involved in the 
RA- and BticAMP-induced promoter activity 
Two other putative transcription factor binding sites attract attention The sequenced 
promoter region contains two PEA3 consensus sites High PEA3 expression, like high 
PDGFaR expression, has been correlated with the metastatic potential of tumour cells (Do 
et al , 1992, Fitzer-Attas, 1993, Trimble et al , 1993) More interesting however, is the 
E2F-hke sequence element (Ouelette et al , 1992) located at nucleotide position -280/ 271 
Deletion of the region -441 to -275, which partially includes this putative F2F site, results 
in a dramatic decrease of promoter activity In addition it has been hypothesised that the 
inhibitory effect of TGFß on the L-myc promoter is mediated through E2F (Moses, 1992), 
which makes this transcription factor a potential target for the TGFß regulated inhibition 
of PDGFaR gene expression (Gronwald et al , 1989, Battegay et al , 1990 Paulsson et 
al , 1993) Future experiments will have to establish the role of E2F in both basal and 
regulated transcription of the PDGFaR gene 
In conclusion, the cloned 5' flanking region represents a functional promoter of the 
PDGFaR gene The promoter activity can be regulated by factors that play an important 
role in cell growth and differentiation Thus, the cloned PDGFaR promoter region may be 
a useful tool for studying the molecular mechanisms that are involved in PDGhaR gene 
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expression in development and in tumongenesis 
MATERIALS AND METHODS 
Cell Culture 
The human embryonal carcinoma cell line Тега 2 clone 13 was maintained m α-modification of minimal 
essential medium lacking nucleosides and deoxynucleosides, supplemented with 10% fetal calf serum (Gibco 
BRL) Mouse Swiss 3T3 cells were grown in Dulbecco's Modified Eagle Medium, supplemented with 10% 
newborn calf serum (Gibco BRL) 
Genomic DNA cloning and sequencing 
An amplified human genomic DNA library in phage XEMBL3 (kindly provided by Dr G Grasveld, 
Erasmus University, Rotterdam, The Netherlands) was screened with an EcoRI fragment containing 
nucleotide 1 255 of the human cDNA clone pSV7dl5 1+5 (Claesson-Wclsh et al , 1989) The EcoRI 
fragment was labeled using a random priming labeling kit (Amersham) and hybridization and washing was 
carried out as described previously (Mosselman et al , 1989) Using standard molecular cloning techniques 
(Sambrook et al , 1989), three out of thirty positively hybridizing plaques were analyzed in more detail 
Southern blot analysis of phage DNA with the EcoRI probe revealed that all three phages contained an 
identical region of the PDGFaR gene Phage DNA was subcloned into pBluescnpt SK (Stratagene) and DNA 
sequence analysis was performed using the Pharmacia T7 sequencing kit 
Primer extension analysis 
A 26-mcr oligonucleotide complementary to the nucleotides 1 to 26 of the human PDGFaR cDNA 
(Claesson Welsh, 1989) was end-labeled with 32P-ATP using T4 polynucleotide kinase (Boehnnger) Total 
RNA (50 /tg) from the differentiated human embryonal carcinoma cell lines Germa II (Walt and Hedinger, 
1984), MA 90 (Hamers et al , 1991) or tRNA was ethanol-precipitated together with labeled oligonucleotide 
(5 105 cpm), and the precipitate was dissolved in 50 μ\ hybridization buffer (10 mM Tris pH 8 0, 1 т М 
EDTA and 500 mM NaCl) The samples were heated at 95 °C for 15 minutes, incubated at room 
temperature overnight and ethanol-precipitated Reverse transcription was performed in a 30 μ\ reaction (50 
mM Tris pH 8 3, 75 mM KCl, 3 mM MgCl2 and 10 mM dilhiothreitol) using 200 U Superscript (Gibco 
BRL) at 37 °C for 45 minutes and subsequently at 42 °C for an additional 45 minutes After treatment with 
25 /jg RNAse at 37 °C for 30 minutes, the samples were extracted with phenol-chloroform, precipitated with 
ethanol and analyzed on a 6% Polyacrylamide ureum sequencing gel 
Construction of promoter-luciferase plasmtds 
The 2120/ + 118, -825/+118, -52/ +118 PDGFaR promoter fragments were amplified from the genomic 
subclone pPARP9 (figure 6 1), using the polymerase chain reaction (PCR) technique with primers 
introducing a unique Ncol restriction enzyme site within exon 1 (figure 6 2) PCR fragments were cloned 
into the Τ tailed pT7 Blue vector (Novagen) and subsequently cloned in front of the luciferase gene of the 
plasmid pSLA4 pSLA4 is a modification of the luciferase gene containing plasmid pSLA3 (Van Dijk et al , 
1991) in which the BamHI-Sall part of the polylinker has been replaced by the BamHI Sail part of the 
pBluescnpt SK polylinker All other promoter fragments were isolated from either 2120/+118 or -
825/+118 in pT7 Blue, using the appropriate restriction enzymes and were cloned in front of the pSLA4 
luciferase gene Correctness of the promoter-luciferase constructs was confirmed by restriction enzyme 
analysis and partial sequencing 
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Transfections 
Тега 2 cells were seeded in 0 I % gelatin coated 6-well tissue culture dishes, at a density of 5 10' cells/cm2 
The cells were treated with 5 μΜ retinole acid (Sigma) for 6 days to induce differentiation before 
transfection Swiss 3T3 cells were seeded at a density of 3 IO4 cells/cm3 in a 6 well tissue culture dish, one 
day prior to transfection Both Tera-2 and Swiss 3T3 cells were transfected using the calcium phosphate 
technique as described (Sambrook et al , 1989) Transfections were carried out using 5 /ig (Tera-2) or 10 ^g 
(Swiss 3T3) luciferase construct DNA, and a 4 hrs (Tera-2) or 24 hrs (Swiss 3T3) calcium phosphate-DNA 
incubation The cells were harvested 24 hrs (Tera-2) or 48 hrs (Swiss 3T3) post-transfection and luciferase 
activity was assayed in a LKB 1250 lummometer, using a luciferase assay kit (Promega) To assess for 
transfection efficiency, 1 /i¿g (Tera-2) or 5 μ& (Swiss 3T3) of the lacZ gene containing plasmid pCHl 10 
(Pharmacia) was cotranfected with the luciferase construct DNA ß-Galactosidase activity was determined 
using a chemiluminescent assay as described (Jain and Magrath, 1991) All transfections were performed in 
several independent experiments, with at least two different batches of DNA 
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An API-like element is involved in the retinoic acid-induced transcription 
of the human PDGFa receptor gene in embryonal carcinoma cells 
ABSTRACT 
Platelet-derived growth factor a receptor (PDGFaR) gene expression is strongly induced 
upon retinole acid and cAMP treatment of embryonal carcinoma cells as a result of an 
increased transcription rate The molecular mechanisms behind this process are currently 
not known, but it apparently does not involve a direct binding of RA receptors to the 
PDGFaR promoter region The data from the present study demonstrate that an API-like 
regulatory element is involved in the RA- and cAMP-induced PDGFaR gene transcription 
in embryonal carcinoma cells In addition, this induction can also be accomplished by 
ectopic expression of c-jun, which suggests a role for this transcription factor in this 
process 
with Marcel J Τ M van Lith, Paul H L J Joosten & Evcrardus J J van Zoelen 
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INTRODUCTION 
Platelet-derived growth factor (PDGF) is a widely expressed growth factor and is thought 
to be involved in many biological processes, including embryonic development, 
atherosclerosis, wound-healing and tumorigenesis (Ross et al., 1990; Bowen-Pope et al., 
1991; Raines et al, 1991; Raines and Ross, 1993; Westermark and Heldin, 1993). Three 
isoforms of PDGF exist (AA, AB and BB), which bind with different affinities to two 
PDGF receptors, denoted α and ß. The α-receptor (PDGFaR) binds all three isoforms, 
whereas the ß-receptor (PDGFßR) displays only high affinity for PDGF-BB. The PDGF 
receptors dimerize upon ligand binding, which results in activation of their intracellular 
tyrosine kinase domain. The subsequent phosphorylation of tyrosine residues within the 
dimerized receptors themselves initiates a cascade of signaling events, finally resulting in 
a biological response (Claesson-Welsh, 1994a). 
Expression of the PDGFaR, and thus responsiveness to all PDGF isoforms, is 
strictly regulated during embryonic development. Although present in all cells of the pre-
implantation embryo from the two-cell stage onwards (Palmieri et al., 1992), PDGFaR 
expression becomes limited to mesoderm- and certain neural crest-derived structures after 
implantation (Morrison-Graham et ai, 1992; Orr-Urtreger et al., 1992; Orr-Urtreger and 
Lonai, 1992; Schatteman et al., 1992). However, loss of this tight regulation may have 
taken place in the process of tumorigenesis. Many tumors and tumor cell lines (in 
particular gliomas) express high levels of the PDGFaR together with its ligands, resulting 
in autocrine PDGF loops (Nistér et al., 1991; Hermanson et al.. 1992; reviewed by 
Westermark, 1993). 
An important mechanism in the regulation of PDGFaR expression is the 
transcriptional control of the PDGFaR gene. The best studied example in this is the RA-
induced PDGFaR expression in embryonal carcinoma cells. Both human and mouse 
embryonal carcinoma stem cells do not display the 6.4 kb PDGFaR mRNA, but its 
expression is strongly induced upon RA treatment, as a result of increased transcription 
(Mercóla et ai, 1990; Wang et ai, 1990; Mosselman et ai, 1994). We have recently 
cloned and characterized the promoter region of the human PDGFaR gene. Although RA 
strongly induced the promoter activity, sequence analysis revealed no putative binding site 
for RA receptors (Afink et ai, 1995). A similar observation has been made for the mouse 
PDGFaR gene promoter (Wang and Stiles, 1994). Thus, the RA-induced transcription of 
the PDGFaR gene does not seem to be mediated via direct binding of a RA receptor to 
the promoter region. 
This chapter describes the possible mechanism responsible for the RA-induced 
transcription of the human PDGFaR gene in human embryonal carcinoma cells. Promoter 
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deletion studies and gel-retardation assays indicate the involvement of an API-like element 
in this process. However, the experimental data indicate that in embryonal carcinoma cells 
not the fos/jun dimer binds to this element. Another, as-yet-unidentified protein diplays 
high affinity binding for this API-like element and is a candidate transcription factor to 
mediate the RA-induced activation of PDGFaR gene transcription in embryonal carcinoma 
cells. 
RESULTS 
Mapping of RA and cAMP responsive elements 
As we have recently shown, the human PDGFaR promoter activity is strongly induced by 
RA in embryonal carcinoma cells A similar effect can be obtained with the cAMP 
analogue dibutyryl cAMP (Bt2cAMP), and together RA and Bt2cAMP display a synergism 
in activation of the promoter (Afink et al., 1995) Since the promoter region does not 
contain an obvious sequence with similarity to the known RA or cAMP responsive 
elements, a panel of progressive 5' deletion mutants of the promoter, cloned into a 
luciferase reporter gene vector (see materials and methods), was used to map the cis-
element(s) involved in the RA- and cAMP-induced promoter activity. The promoter-
Tera-2 EC Tera-2 RA 
construct 
-52/+118LUC 
-175/+118LUC 
-I97/+118LUC 
-275/+118LUC 
-441/+118LUC 
-82S/+118LUC 
RA 
9.3 ± 0.1 
7.9 ± 0.1 
6.1 ± 0.7 
9.3 ± 0.4 
9.2 ± 0.7 
6.2 ± 0.0 
RACT 
16.5 ± 0.0 
22.4 ± 1.0 
25.8 ± 0.7 
16.3 ± 0.9 
21.9 ± 1.8 
18.8 ± 2.1 
RA 
2.5 ± 0.2 
3.1 ± 0.3 
2.6 ± 0.0 
2.2 ± 0.4 
3.8 ± 0.3 
3.2 ± 0.1 
RACT 
10.7 ± 0.2 
11.8 ± 0.3 
13.6 +1.7 
18.6 ± 0.6 
8.8 ± 0.2 
11.9 ± 1.0 
table 7.1: RA- and cAMP-induced activity of PDGFaR promoter deletion mutants. 
A panel of 5' promotcr-LUC deletion mutants was transfected into Tera-2 EC or Tera-2 RA 
cells The cells were subsequently treated with 10 μΜ RA or a combination of 10 μΜ RA, 
1 mM BtjCAMP and 350 μΜ theophylline (RACT) for 48 hrs After this incubation period, 
luciferase activity in the cells was determined and corrected for transfcction efficiency (see 
materials and methods) The values represent the fold induction of luciferase activity after 
treatment, relative to the luciferase activity of unstimulated cells and the sample standard 
deviation (duplicate determinations) 
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luciferase constructs were transfected into undifferentiated Tera-2 (Tera-2 EC) cells, 
which are derived from a spontaneous human testis tumor. The cells were subsequently 
treated with either RA or a combination of RA, Bt2cAMP and theophylline (RACT). The 
resulting fold induction of promoter activity (determined as luciferase activity) of the 
different promoter mutants is shown in table 7.1. 
All the promoter deletion mutants transfected into Tera-2 EC cells display an 
approximately 9-fold and 20-fold induction in response to treatment with RA and RACT 
respectively. Although not tested in detail, Bt2cAMP alone also induces the complete panel 
of promoter deletion mutants to a similar extent as RA (data not shown). This implies that 
both RA and Bt2cAMP mediate their effect through elements within the -52/ + 118 region 
of the human PDGFaR gene. In addition, the same results were obtained when the 
transfections were performed in RA-differentiated Tera-2 (Tera-2 RA) cells. Since these 
cells already display a high basal PDGFaR promoter activity (Afink et al., 1995), RA and 
RACT enhance, rather than induce, the promoter activity. 
To characterize the transcription factors that bind to this promoter region, gel-
retardation assays were performed using the -52/+ 118 promoter fragment as a probe. As 
shown in figure 7.1, treatment of Tera-2 EC cells with RA or RACT results in a complex, 
but typical change in protein binding to the -52/ +118 promoter fragment. The RACT-
treated cells display a similar, although more pronounced change in protein binding than 
the cells treated with RA alone. This difference in potency of effect between RA and 
RACT is also apparent on promoter activity (Afink et al., 1995 and table 1). Thus, the 
gel-retardation data correlate well with the promoter activity and suggest that RA and 
cAMP use the same transcription factors to stimulate PDGFaR gene expression. 
figure 7.1: Gel retardation analysis of nuclear extracts from untreated, 
RA- and RACT-treated Tera-2 cells. 
A 32-P-labelled PDGFaR promoter fragment, encompassing nucleotide -52 
to +118 was incubated with nuclear extracts from Tera-2 EC cells treated 
24 hrs with tlje indicated compounds (see table 1 for concentrations). The 
resulting protein-DNA complexes were analyzed by Polyacrylamide 
electrophoresis and visualized on X-ray film. Six specific protein-DNA 
complexes were observed. Four of these complexes are induced upon RA 
or RACT treatment (arrows), whereas two protein-DNA complexes 
decrease in intensity after treament of Tera-2 EC cells with RA or RACT 
(asterisks). 
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rigure 7.2: A PARAP1 oligonucleotide competes with the -52/ +118 promoler fragment for 
specific protein binding. 
A similar gel retardation experiment as described in figure 7.1 was performed with the -
52/+ 118 promoter fragment as a probe and nuclear extracts from either untreated 
(CONTROL) or 24 hrs RA-treated Tera-2 EC cells. In addition, an approximately 500-fold 
excess of unlabelled competitor DNA (as indicated) was added to the reaction mixtures. The 
same specific protein-DNA complexes as in figure 7.1 are marked by arrows and asterisks. 
RA induces changes in protein binding to an API-like element 
As described previously, the PDGFaR gene promoter contains many putative binding sites 
for the RA-inducible transcription factor AP2 (Afink et al., 1995) and one of these AP2 
sites (+41GCCGTGGG'im) is located within the -52/ + 118 region. In addition, the 
sequence +bTGAATCA + [1 (denoted as PARAP1) bears a strong homology with the 
consensus binding site for the transcription factor complex API (TGASTCA; Angel et al., 
1987; Lee et al., 1987). The involvement of these sequences in the protein binding to the 
-52/+ 118 region has been further investigated and the results are shown in figure 7.2. 
Competition with the unlabelled PARAP1 oligonucleotide results in a complete loss of five 
of the six specific protein-DNA complexes bound to the -52/ +118 probe. Interestingly, a 
consensus API oligonucleotide has no effect on any protein binding to the -52/ + 118 
fragment. The AP2 oligonucleotide and an oligonucleotide containing a cAMP responsive 
element (Borrelli et al., 1992) also do not display any competition. Thus, the PARAP1 
sequence appears to be the target element involved in most of the RA-induced changes in 
74 CHAPTER 7 
control RA 
• ·* 
it II 
^ ^ À 
control 
- * • 
probe ^ PARAPI _ 
.S4 ^P ompeliloi r V 
ІІ 
/ 
ч ^ 
.-
*4 
API 
g|p я^Ш 
bFGF 
„ PARAP 
^
4 
11 
—• 
1
 fc. 
- * — 
- « — 
•j 
API 
¿ДДДДДддД 
figure 7.3: Effect of RA on protein binding to the PARAPI element. 
Gel retardation analysis was performed with the PARAPI oligonucleotide as a probe. Nuclear extracts in A) 
were derived from untreated (CONTROL) or 24 hrs RA-treated Tera-2 EC cells and in B) were derived 
from untreated Tera-2 RA cells (CONTROL) or 24 hrs bFGF-treated Tera-2 RA cells. In addition, the 
consensus API oligonucleotide was used as a probe, and approximately 300-fold excess of unlabelled 
competitor DNA was added to the reaction mixture where indicated. At least two specific protein complexes 
could be separated, indicated as A and B. 
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protein binding to the -52/+ 118 region 
From these competition data it was also concluded that although homologous in 
sequence, the PARAP1 seems to have different binding characteristics than the consensus 
API sequence This notion is further supported by the data from gel retardation 
experiments with the PARAP1 oligonucleotide as probe As shown in figure 7 ЗА, the 
PARAP1 oligonucleotide binds a protein (complex A) m Tera-2 EC cells, which can not 
be competed by an excess of unlabelled non-specific (not shown) or consensus API DNA 
Upon 24 hrs RA treatment, at least one additional specific protein complex (complex B) 
can be identified, which again shows no obvious affinity for the consensus API sequence, 
as determined by competition analysis At the same time, RA treatment reduces complex 
A Neither of these two PARAP1 binding proteins resembles API, which has a much 
slower mobility than complex A and В (data not shown, and compare with figure 7 3B) 
Tera-2 RA cells (treated for 6 days with RA), which have high level PDGFaR gene 
expression and promoter activity, display the same protein-DNA complexes as the 24 hrs 
RA-treated Tera-2 EC cells (figure 7 3B) Treatment of these Tera-2 RA cells with bFGF, 
which results in an additional 3-5 fold increase in promoter activity (unpublished 
observation), induces the binding of API protein to the consensus API oligonucleotide 
Although PARAP1 still prefers to form the complex В under these conditions, excess of 
unlabelled PARAP1 is very well able to compete with the consensus API probe for API 
protein binding 
Together these data indicate that the PARAP1 is an API-like element, but within the 
context of the PDGFaR promoter it does not bind the fos/jun dimer Instead, some other, 
as-yet-unidentified proteins bind to this regulatory element 
Expression ofc-jun induces the activity of the PDGFaR gene promoter 
The API protein is apparently not involved in binding to the PARAP1 element, but it is 
very well conceivable that an API-like protein is involved As shown in figure 7 4, co-
transfection with a c-jun expression vector indeed results in a dramatic increase of the 
PDGFaR promoter activity This result could not be obtained with either c-fos or fral 
expression vectors A similar result was observed in Tera 2 RA cells (data not shown) In 
addition, the cAMP-induuble transcriptional activators CREB and CRFMr, which also 
bind to sequences closely related to the PARAP1/AP1 sequence (Borrelli et al , 1992), do 
not increase the activity of the PDGFaR promoter From these data it appears that c-jun 
could be a limiting component of the proteins binding to the PARAP1 element and thus be 
involved in the activation of PDGFaR gene transcription 
A mutation of the Τ nucleotide in the 3' halt of the API consensus sequence results 
in a dramatic loss of fos/jun binding (Risse et al, 1989) An identical mutation in the 
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figure 7.4: c-jun activates the PDGFaR 
promoter.The -441/+118LUC promoter 
construct was transfected into Tera-2 EC cells 
together with an expression vector containing c-
jun, c-fos, frai, CREB or C R E M T . 48 hrs post-
transfection, luciferase levels within the cells 
were determined and corrected for transfection 
efficiency. Values represent the fold induction 
of promoter activity, relative to the activity of 
- 441/+118LUC cotransfected with the empty 
expression vector (pSG5, Stratagene). Error 
bars indicate sample standard deviation of 
duplicate determinations. 
PARAP1 sequence (denoted as mPARAPl) also results in a strongly decreased affinity for 
the API protein, as determined in A431 cells (figure 7.5A), but it does not compete for 
the proteins bound to the PARAP1 element (data not shown). However, when this 
mutation was introduced into a promoter-luciferase construct, no decrease of the RA-, 
RACT- (figure 7.5B) or с AMP- (data not shown) induced promoter activity could be 
observed. Thus, when c-jun is indeed a component of the proteins binding to the 
PARAP1, it displays different binding requirements than as being a component of API. 
DISCUSSION 
Transcription of the PDGFaR gene in embryonal carcinoma cells is strongly induced upon 
differentiation of the cells with RA or RACT (Wang et al., 1990; Mosselman et al., 
1994). The mechanism by which RA and cAMP induce this PDGFaR gene transcription 
in these cells is not known, but it apparently does not involve direct binding of RA 
receptors to the PDGFaR promoter region (Wang and Stiles, 1994; Afink et al. ,1995). 
The experiments in this study were designed to elucidate the molecular mechanisms 
involved in the RA- and cAMP-stimulated transcription of the PDGFaR gene in 
embryonal carcinoma cells. Deletion mapping studies showed that both the induction and 
enhancement of PDGFaR promoter activity by RA and cAMP are mediated through 
element(s) located within the -52/ +118 region of the gene. A more detailed analysis 
indicated the involvement of an API-like element (denoted as PARAP1) in this process. In 
addition, the RA- and cAMP-stimulated promoter activity can be mimicked by expression 
of c-jun. 
RA and cAMP affect PDGFaR promoter activity in both Tera-2 EC and RA-
differentiated Tera-2 RA cells, and in both cell types they mediate their effects through 
,o 
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figure 7.5: Mutation analysis of the PARAP1 element. 
A) Gel retardation analysis with the consensus API oligonucleotide as a probe and nuclear 
extracts from TPA-treated A431 cells (lane 1). An 300-fold competition with either unlabelled 
mPARAPl (lane 2) or PARAP1 (lane 3) DNA was performed where indicated. 
B) The -441/+118LUC and Ш-441/+118LUC were transfected seperately into Tera-2 EC 
cells. The cells were subsequently treated for 48 hrs with either RA or RACT, after which the 
luciferase levels within the cells was determined and corrected for transfection efficiency. The 
values represent the fold induction of promoter activity, relative to the unstimulated situation 
for either construct. Error bars indicate sample standard deviation of duplicate determinations. 
the same -52/ +118 region. This indicates that the RA- and cAMP-induced PDGFaR gene 
transcription in Tera-2 EC cells is not necessarily coupled to differentiation of the cells. 
This notion is further supported by our previous observation that elements outside the 
-52/+ 118 region are involved in the establishment of high basal promoter activity in 
PDGFaR gene expressing cells (Afink et al., 1995). 
The target regulatory element for the RA- and cAMP-induced transcriptional 
activation of the PDGFaR gene seems to be the PARAP1 sequence. This conclusion is 
based on the observation that a PARAP1 oligonucleotide competes five of the six typical 
protein-DNA complexes identified with the -52/+ 118 promoter fragment in gel retardation 
assays (figure 7.2). However, subsequent experiments showed only the appearance of two 
protein-DNA complexes with the PARAP1 oligonucleotide as a probe. Therefore, 
additional mechanisms other than exclusive protein binding to the PARAP1 element must 
occur. One interesting option is that PARAP1 facilitates the binding of several proteins to 
other parts of the -52/ +118 region. This would explain the difference in the number of 
complexes bound to, and competed by the PARAP1 oligonucleotide. However, additional 
experiments have to be performed to support this hypothesis. In addition, not all the 
« • 
i. .li 
-441/+118LUC 
,¿· Λ 
m-441/+118LUC 
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typical protein binding to the -52/+ 118 region can be competed with PARAP1 DNA. 
Thus the involvement of additional regulatory elements can not be excluded. 
Together with its surrounding nucleotides, this PARAP1 forms an 11 nucleotides 
palindromic element. Although capable of binding API, this PARAP1 element diplays a 
higher affinity for other proteins, and the important question remains, what proteins bind 
to the PARAP1 site and thus probably mediate the RA- and cAMP-induced transcription 
of the PDGFaR gene? The product of the c-jun gene is a good candidate to be involved in 
this process, as concluded from several observations. Upon RA-induced differentiation of 
F9 and P19 murine embryonal carcinoma cells, c-jun gene expression is strongly increased 
(De Groot et al., 1990a; Yang-Yen et al., 1990) as a result of an enhanced c-jun 
transcription (Yang-Yen et al., 1990; De Groot et ai, 1991; Kitabayashi et al., 1992), 
and ectopie expression of c-jun in these cells leads to differentiation independently of RA 
(De Groot et al., 1990; Yamaguchi-Iwai et al., 1990). Furthermore, c-jun can also be 
activated by the с AMP pathway (de Groot and Sassone-Corsi, 1992) and displays affinity 
for several API-like sequences, which is dependent on its partner proteins (Sassone-Corsi 
et al., 1990; Hai and Curran, 1991; Chatton et ai, 1994; De Cesare et al., 1995). 
Together with the observation that c-jun expression activates the PDGFaR promoter, these 
data strongly argue for a role for c-jun in the RA- and cAMP-induced PDGFaR gene 
transcription. However, it may also be possible that other, most likely c-jun-related 
transcription factors are involved in the activation of the PDGFaR promoter. At least in 
Tera-2 RA cells, both junB and junD can also stimulate PDGFaR promoter activity 
(unpublished observations). Current studies are underway to investigate the role of c-jun 
and possible other, c-jun-related transcription factors in this process. 
Together, the current data demonstrate the involvement of an API-like regulatory 
element within the PDGFaR gene promoter in the RA- and cAMP-induced expression of 
the PDGFaR gene in embryonal carcinoma cells. However, not the fos/jun dimer, but 
more likely a complex of jun-related proteins binds to this regulatory element and 
mediates the RA and cAMP effects. 
MATERIALS AND METHODS 
Vectors 
The construction of the promoter-luciferasc reporter gene vectors -2120/+118LUC, 
-441/+118LUC, -275/+118LUC, -197/+ 118LUC, -175/+118LUC and -52/+118LUC has been 
described previously (Afink et al., 1995). The promoter-luciferase construct M-441/+118LUC, which 
contains а Г to G mutation at position +10, was generated with the Altered Sites Mutagenesis system 
(Promega). The eukaryotic expression vectors for c-fos, c-jun, CREB, CREMT and fra-1 were kindly 
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provided by Dr R de Groot, University of Utrecht, The Netherlands 
Cell culture and transfections 
The human embryonal carcinoma cell line Tera-2 clone 13 (Thompson et al , 1984) was maintained in 
«-modification of minimal essential medium lacking nucleosides and deoxynucleosides, supplemented 
with 10% fetal calf serum (Gibco BRL) One day prior to transfections, 25 103 cells/cm2 were seeded 
in a 0 1 % gelatin-coated 6-well tissue culture dish Transfections using the calcium-phosphate 
technique (Sambrook el al , 1989) were earned out with 5 fig/well promoter-luciferase vector and 5 
jig/well of expression vector (where necessary) In addition, 2 jig/well of the facZ-expressing vector 
pCHHO (Pharmacia) was co-transfected to correct for differences in transfection efficiency After the 
appropriate incubation times, cells were lysed in reporter lysis buffer (Promega) Luciferase activity in 
the lysate was determined by a luciferase assay kit (Promega), according to the manufacturer's 
protocol ß-Galactosidase was assayed as described by Jain and Magrath (1991) using Galacton 
(Tropix) as the substrate 
Gel-retardation assays 
Nuclear extracts from Tera-2 cells were prepared as described by Schreiber et al (1989) These 
extracts (10-15 μg) were incubated with 30 103 cpm 32P-labelled DNA. 2 ^g dl-dC, and where 
necessary unlabelled competitor DNA, m a reaction buffer (20 mM Hepes, pH 7 9, 50 mM NaCl, 1 
mM EDTA, 0 15 mM EGTA, 1 mM DTT, 0 15 mM PMSF, 4% (w/v) Ficoll and 8 mM KCl) at room 
temperature for 10 minutes The resulting protein-DNA complexes were separated on a 4% 
Polyacrylamide gel using 0 5xTBE as running buffer (Sambrook et al , 1989), and visualized on X-ray 
film (Kodak X-Omat, Fuji RX) 
Oligonucleotides 
The synthetic oligonucleotides PARAP1 {5'-CTATAACATTGAATCAA1TACAA-3'),mVARAPl (5'-
CTATAACATTGAAGCAATTACAA-У),consensus CRE (5'-AGAGATTGCCTGACGTCAGAGAGCTAG-
3') and consensus API (5'-CGCTTGATGACTCAGCCGGAA-У) were obtained as single-stranded 
oligonucleotides in both the sense and anti-sense conformation Equal amounts of the sense and anti-
sense oligonucleotide were mixed in distilled water, heated to boiling temperature and slowly cooled to 
room temperature The resulting double stranded product was subsequently purified by Polyacrylamide 
gel electroforesis if necessary (Sambrook el al . 1989) The double-stranded consensus AP2 (5'-
GATCGAACTGACCGCCCGCGGCCCGT-3') oligonucleotide was obtained from Promega 
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CHAPTER 8 
Specific expression in mesoderm- and neural crest-derived tissues of a 
human PDGFa receptor promoter/tocZ gene in transgenic mice 
ABSTRACT 
Platelet-derived growth factor α receptor (PDGFaR) has previously been shown to be 
required for normal development of mesoderm and cephalic neural crest derivatives. The 
purpose of the present study was to demonstrate the in vivo promoter function of 2.2 kb 
and 0.9 kb genomic DNA fragments representing the 5'-flanking part of the human 
PDGFaR gene. The fragments, ligated to a lacZ reporter gene, were microinjected into 
fertilized mouse eggs. Several transgenic mouse lines were established and nearly half of 
those which had incorporated the construct, expressed the LacZ gene. With the exception 
of the central nervous system, the expression patterns were basically similar in these lines 
and overlapped grossly the PDGFaR gene expression pattern. The results demonstrate that 
2.2 kb and most likely even 0.9 kb upstream regulatory sequences are sufficient to drive 
the activity of the PDGFaR gene properly in most tissues in vivo. The transgenic line with 
the highest expression level was shown to express LacZ in paraxial mesoderm and 
branchial arches from embryonic day 8.5. The gene continued to be expressed during the 
remaining embryonic period, when IxicZ expression was mainly confined to tissues of 
mesodermal and neural crest origin. These data are consistent with previously reported 
PDGFaR mRNA expression patterns. The gene was also expressed however, in specific 
areas of the developing neural tube. In addition, lacZ expression in brain was seen after 
birth and was strong in cerebellum and in some restricted areas of cerebral cortex, 
thalamus, hypothalamus and hippocampus. The location and morphology of the lacZ-
expressing cells in brain and spinal cord indicate that they are mostly neuronal, while 
PDGFaR mRNA in postnatal central nervous system has been described as confined 
mainly to glial derivatives. In conclusion, the isolated human PDGFaR promoter contains 
most of the necessary regulatory elements to establish tissue specific reporter gene 
expression in transgenic mice. The resulting lac/ expression pattern during development 
points to an important role of the PDGFaR in the formation of skeletal, central and 
peripheral nervous system, lung and facial structures. 
with: Xiao Qun Zhang. Krisiian Svcnsson. Erik Bongcam-Riidlol'f, Inga Hansson. Karin Forsbcrg-Nilsson. 
Kvcrardus J.J. van Zoden. Bcngl Wcslermark and Monica Nislér 
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INTRODUCTION 
Platelet-derived growth factor (PDGF) is produced by a wide variety of both normal and 
tumor cells (reviewed by Raines et al, 1991; Westermark, 1993). The PDGF molecule is 
a dimer composed of two different, but highly homologous PDGF chains, denoted A and 
B. The A and В chains can either form homo- or hetero-dimers by disulfide bonds, which 
results in three PDGF isoforms: AA, AB and BB. Although PDGF is the best known for 
its mitogenic effect on mesenchymal cells, it is able to elicit many different effects ranging 
from vasoconstriction to Chemotaxis (see Ross et al., 1990; Raines et al., 1991). As a 
result of this widely distributed expression and pleiotropy of effects, PDGF has been 
postulated to play an important role in many different biological processes, including 
embryogenesis, wound-healing, atherosclerosis and neoplasia (Ross et al., 1986; Bowen-
Pope et ai, 1991; Raines et al, 1991; Raines and Ross, 1993). 
Two different PDGF receptors have been characterized, denoted α (PDGFaR) and ß 
(PDGFßR), which belong to the superfamily of tyrosine kinase receptors. Like their 
ligands, the PDGF receptors are highly homologous molecules, and they form homo- and 
hetero-dimers upon ligand binding. The PDGFaR displays high affinity for all three 
PDGF isoforms, whereas the PDGFßR binds only the BB-isoform with high affinity. As a 
result, aa, aß and ßß receptor dimers will be formed depending on the PDGF isoform 
(Claesson-Welsh, 1994a). 
Although it is difficult to discriminate between the contribution of either receptor 
subunit in the different biological responses to PDGF, several studies have indicated a 
specific role for PDGF-A/PDGFaR in embryonic development. Most of this information 
is derived from expression studies in mouse and Xenopus embryos. In the mouse pre-
implantation embryo, both PDGF-A and the PDGFaR are co-expressed in all cells from 
the two-cell stage onwards (Rappolee et al, 1988; Palmieri et al, 1992). Following 
implantation however, the expression patterns of PDGF-A and the PDGFaR become 
separated. Expression of PDGF-A becomes limited to the ectoderm, whereas PDGFaR 
expression becomes restricted to the mesoderm (Orr-Urtreger and Lonai, 1992; Palmieri 
et al, 1992). A similar observation has been made in Xenopus embryos, where mesoderm 
induction establishes this lineage-specific pattern of ligand and receptor gene expression 
(Jones et al, 1993). Expression of PDGF-B and the PDGFßR have not been detected in 
pre-implantation embryos. However, the ß-receptor subunit is expressed shortly after 
implantation, but to a lesser extent than the PDGFaR (Mercóla et al, 1990). During later 
development PDGFaR expression remains characteristic for many mesoderm-derived 
structures, including mesenchyme and connective tissue, intervertebral discs and dermis 
(Orr-Urtreger et al, 1992; Orr-Urtreger and Lonai, 1992; Schatteman et al, 1992). In 
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addition, the PDGFaR is expressed in a non-neural subset of neural crest-derived cells 
(Morrison-Graham et al., 1992; Ho et ai, 1994). The functionality of this PDGFaR 
expression in the formation of these tissues is clearly demonstrated in Patch mice, which 
carry a naturally occuring deletion of the PDGFaR gene. Mice homozygous for this 
mutation display severe developmental defects in mesoderm- and neural crest-derived 
structures, eventually resulting in the death of the embryo (Orr-Urtreger et al., 1992; 
Morrison-Graham et al., 1992; Schatteman et al., 1992). 
The mechanisms that control this tissue specific expression of the PDGFaR are 
currently unknown. Several growth modulating factors, which are also expressed in the 
developing embryo, transmodulate PDGFaR expression in vitro. This includes 
transforming growth factor ß (Gronwald et al., 1989; Battegay et al., 1990; Yamakage et 
al., 1992; Paulsson et al., 1993; Yeh et al., 1993a), fibroblast growth factor (McKinnon 
et al., 1990; Tsukamoto et al., 1991; Schöllmann et ai, 1992) and retinole acid (Mercóla 
et al., 1990; Wang et al., 1990; Mosselman et al, 1994; Tsukamoto et al., 1994). With 
respect to embryonic development, the retinole acid-induced expression of the PDGFaR 
gene in embryonal carcinoma cells is of particular interest (Mercóla et al., 1990; Wang et 
al., 1990; Mosselman et al., 1994). These embryonal carcinoma stem cells resemble in 
many aspects the pluripotent inner mass cells of the early embryo. Thus, the regulatory 
mechanisms that control the PDGFaR gene expression in these cells may also occur in the 
developing embryo. 
We have recently cloned and characterized the promoter region of the human 
PDGFaR gene and shown that retinole acid strongly induces the promoter activity in 
human embryonal carcinoma cells (Afink et al., 1995). A similar observation has been 
made for the mouse PDGFaR promoter (Wang and Stiles, 1994). Although these studies 
have established a role for the PDGFaR promoter in some regulatory aspects of PDGFaR 
expression in vitro, it is still unclear whether it contributes to the in vivo regulation. 
In this paper we assess the functionality of the isolated human PDGFaR promoter in 
vivo, using a transgenic mouse model. A 2.2 kb human PDGFaR promoter fragment 
cloned in front of a lacZ reporter gene drives the tissue specific ß-galactosidase expression 
in the developing mouse. Virtually similar results can be obtained with a shorter 0.9 kb 
promoter fragment. These results indicate that approximately 0.9 kb upstream regulatory 
sequences of the human PDGFaR gene contain most of the cis-acting elements necessary 
to establish tissue specific expression of the PDGFaR. 
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RESULTS 
Generation of transgenic mouse lines 
A total of ten founders of 2.2 kb and 0.9 kb PDGFaR-/acZ transgenic mouse lines were 
established (see materials and methods). The expression of lacZ was investigated in brains 
at 5-10 days postnatal stage (P), and in embryonic day (E) 9 to E15 embryos using X-gal 
staining of whole mount tissues or embryos (table 1). The expression patterns differ 
somewhat from line to line but are mainly overlapping irrespective which of the two 
different constructs was used. Two 2.2 kb lines and three 0.9 kb lines showed similar 
expression patterns in mesoderm-derived and facial structures of the developing embryo, 
i.e. expression in sclerotome, limb buds and branchial arches. Only two lines, however, 
the 2.2-07 and 0.9-04 expressed lacZ in postnatal cerebellum, and the 2.2-0.7 line also in 
specific structures of the cerebrum. The levels of expression varied considerably between 
lines, and the strongest expression was found in the 2.2-07 line which therefore was 
chosen for a more detailed analysis. 
table 1 : Transgenic lines generated for both promoter 
constructs 
Ten independent transgenic founder lines were 
established and lacZ gene expression in bram of P5 to 
PIO mice and/or in whole mount E9 to El5 embryos 
was determined (+ expression, -: no expression) The 
different transgenic lines are identified by promoter 
construct used (either 2.2 or 0 9) and a number. 
2.2-19 
0.9-02 
0.9-04 +* + 
0.9-10 + + 
0.9-14 + 
" LacZ expression in cerebellum 
"" LacZ expression in somites and branchial arches 
Expression of LacZ in the developing 2.2-07 transgenic mouse 
The lacZ expression was examined between E7.5 and E15.5 by whole mount X-gal 
staining. The stained E7.5, E9.5, E12.5 and E15.5 embryos were also paraffin embedded 
and sectioned. Sagittal or/and transverse sections were analysed. There were no lacZ 
positive cells at E7.5, neither in embryonic nor in extraembryonic parts. During mouse 
transgenic LacZ LacZ 
line brain embryo 
2.2-03 
2.2-07 + · + " 
2.2-11 
2.2-12 
2.2-14 - + " 
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development, the first somite arises in the cervical region at E8 after which pairs of new 
somites appear in craniocaudal direction. The lacZ expression was found to start in 
somites and the first branchial arch of E8.5 embryos, and subsequently followed the 
somite formation pattern, starting from the cervical region and spreading craniocaudally. 
In sagittal and transverse sections of E9.5 embryo, strong lacZ expression was thus 
detected in developing somites, first, second and third branchial arches (figure 8.1 A, C). 
Around E12.5, the somite-derived segmentally arranged sclerotome, dermatome and 
myotome appear. LacZ expression in this stage was mainly seen in the sclerotome and in 
the mesenchyme of the developing dermis (figure 8. IB, D, E). 
Whole mount X-gal staining also revealed lacZ activity in developing limb buds 
(figure 8. IB), and was found in the developing chondrocytes of the primordia of vertebral 
bodies, ribs, and skeleton of limbs. Expression was especially strong in the condensed 
perichondrial mesenchyme during formation of these structures at E12.5 and E15.5 (figure 
8. IB, E, figure 2A, B). There was no expression in the ossified areas, however. Figure 
8.2C and D shows the lacZ expression in the cartilagineous skeleton of a P8 transgenic 
mouse. LacZ was expressed in the cartilaginous epiphyseal areas of the long bones, carpal 
and metacarpal bones, but was absent from the diaphyseal regions that had already 
ossified. Likewise, expression was absent in the ossified centers of the vertebrae but 
present in the cartilaginous laminae. The centers of the intervertebral discs, which are 
supposed to develop from the notochord, were negative. The cartilage of ribs and sternum 
continuously expressed lacZ during adulthood. 
In mouse development, the mesenchymal tissue of the first and second branchial 
arches are of neural crest origin and later differentiate into facial and neck muscles and 
cartilages. LacZ was expressed in mesenchymal tissue of the first branchial arch at E8.5 
and in the maxillary and the mandibular processes, with Meckel's cartilage, at E12.5 
(figure 8.1 А, С ). Strong expression was found in well demarcated areas of the 
mesenchymal tissue of the developing upper and lower lips (figure 8.ЗА), eyelids and 
nostrils (not shown) at El5.5. The mesenchymal tissue of the future dermal hair papilla 
(figure 8.3C) also stained blue during the formation of the hair follicle, as seen at E15.5. 
The epithelial structures of the otic vesicle, and the lateral and posterior semicircular 
canal, had strong lacZ expression at E9.5 and E12.5 respectively (figure 8.3B, figure 
8.4A). Although previous in situ studies have shown PDGFaR expressed in the retina, 
lens and optic nerve (Schatteman, et al. 1992, Mudhar, et al. 1993), we did not find lacZ 
expressed in the eye, nor in the optic nerves atE12.5, E15.5 and postnatal stages of the 
2.2-07 line (not shown). 
Mesenchymal tissue of lung, gut, kidney, pancreatic primordium and urogenital 
sinus expressed lacZ during organogenesis stage of E9.5 to E15.5 as exemplified in the 
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lung (figure 8.3D, figure 8.4B). Mesenchymal tissue of trachea and lung buds had 
detectable lacZ expression at E9.5 and E12.5. At E15.5, an abundance of lacZ positive 
cells were found in the interstitial mesenchymal tissue surrounding epithelium of the 
bronchioli (figure 8.3D, E). LacZ expression in lung mesenchymal tissue declined after 
one postnatal week and expression had disappeared around P20 (data not shown). Tracheal 
cartilage expressed lacZ for a longer period than lung mesenchymal tissue and the blue 
staining appeared in whole mounts of this tissue during more than 200 days postnatally. 
Gut and kidney have endogeneous ß-galactosidase, therefore it is difficult to evaluate the 
lacZ expression in these tissues in the postnatal period. Urinary bladder mesenchyme had 
strong lacZ expression from embryonic stage until adulthood in the 2.2-07 line but not in 
non-transgenic mice (data not shown). Uterus, ovary and testis did not show lacZ 
expression in postnatal stage. 
LacZ expression in the central nervous system (CNS) 
At E12.5 lacZ expression was found in areas of the developing neural tube (figure 8.4A, 
B, C, D, figure 8. IB, D), i.e. the neuroepithelial cells at the dorsal aspect of the central 
canal, as well as in small well demarcated ventro-lateral regions of the spinal cord, in the 
roof of the third ventricle, in the epithalamus, hypothalamus, and rhombencephalon. 
Strong expression was seen in the rhombic lip of the fourth ventricle which is the future 
cerebellum. The thin roof of the fourth ventricle, which develops the choroid plexus, 
however, was not stained with blue color, neither was staining found in the choroid plexus 
of the fourth ventricle at embryonic and postnatal stages. The lacZ positive cells in the 
spinal cord were large and closely packed in small groups which array along the 
longitudinal axis in a dorsal as well as a ventro-lateral portion of the spinal cord at E12.5. 
The location and morphology of these cells indicate that they are neuronal cells. LacZ 
expression in the posterior aspect of the spinal cord was transient and disappeared at 
E15.5. LacZ stained cells were found at the ventral hom of the spinal cord, but were no 
longer detectable in the lateral portion at E15.5 and postnatally. Facial ganglion cells, 
which are of neural crest origin, expressed lacZ at E15.5 and in P2 mice (figure 8.4E). 
Strong lacZ expression in the brain of line 2.2-0.7 mice starts at the end of the 
embryonic stage and is maintained for about two weeks postnatally. Thereafter the blue 
color becomes faint when compared to newborn mice, but still continues into adulthood. A 
sheet and/or dot shaped blue color appeared in several specific areas of the brain, e.g. 
cerebral parietal cortex, olfactory bulb, hypothalamus, thalamus, pontine nuclei and 
hippocampus (figure 8.4F, G). The shape and the size of the lacZ positive cells of the 
cerebral cortex suggest that they are neuronal cells. The strongest expression was found in 
the cerebellum where abundant lacZ positive cells covered the molecular and granular 
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layers but were absent from the white matter (figure 8.4 F, G and not shown). This 
localization indicates that the lacZ positive cells in the cerebellum are probably not glial 
cells since glial cells are known to be abundant in the white matter. 
The same result was noticed from the combined lacZ and immunohistochemistry 
staining with the glial fibrillary acidic protein (GFAP) antibody. The Purkinje cells as well 
as probably the granular neurons themselves were, however, lacZ negative. Microtubule 
associated protein (MAP) 2 and GFAP immunohistochemistry staining combined with 
whole mount brain lacZ staining was followed by paraffin embedding and 
immunostaining. The coronal sections of both the cerebral cortex and cerebellum 
contained different cell populations which were immuno-reactive with the anti-MAP2 and 
the anti-GFAP antibodies respectively. MAP2 has been proven to be a useful dendritic 
marker and is present in most dendrites of neurons in the grey matter. GFAP is an 
astrocyte specific marker. As expected, it was found that MAP2 antibodies stained the 
neurons in cerebral cortex. The lacZ positive cells co-localized with the MAP2 staining 
(Figure 8.5), but not with GFAP staining (not shown). This result clearly demonstrated 
that the lacZ positive cells in the cerebral cortex are neurons. In cerebellum, MAP2 
stained mainly cells in the granular layer. Here it was difficult to identify single 
double-labeled cells because of overlapping cell bodies. The blue cells in the molecular 
layer were, however, negative for MAP2, and GFAP positive cells were located in the 
white matter of cerebellum (not shown) where lacZ expression was never detected. This 
clearly different expression pattern of lacZ and GFAP proved that the lacZ cells in 
cerebellum are non-astrocytic cells. Possibly, the lacZ positive cells represent a subset of 
cerebellar intemeurons, but this remains to be proven. 
PDGFaR in situ hybridization 
In order to compare the expression pattern of lacZ and PDGFaR mRNA, we examined 
E12.5 sagittal sections of normal mice with a digoxigenin-labelled PDGFaR probe. A 
similar expression pattern as lacZ was found at E12.5 in that the PDGFaR signals were 
strongly detected in the sclerotome and the branchial arches (figure 8.6A). A different 
expression pattern was, however, found in cerebellum and cerebral cortex of P5 
transgenic mice (figure 8.6B-D). In cerebellum most of the PDGFaR positive cells were 
located in the white matter and in meninges, and only scattered signals were found in the 
molecular and granular layers. Abundant signals also covered the brain stem. None of 
these structures expressed lacZ. In the cerebral cortex the PDGFaR positive cells were 
negative for lacZ expression, and were found scattered throughout the whole of the brain 
tissue. The mRNA positive cells had small round cell bodies indicating that they probably 
are glial cells or their precursors but not neurons. 
88 CHAPTER 8 
DISCUSSION 
The aim of the present study was to demonstrate the functionality of the human PDGFaR 
promoter in vivo. For this purpose, transgenic mice were generated containing either 2.2 
kb or 0.9 kb of human PDGFaR promoter sequences fused to the E.coli lacZ reporter 
gene. The resulting lacZ expression pattern, as determined by whole mount X-gal staining, 
grossly overlapped the PDGFaR expression pattern. Although not analyzed in detail, both 
the 2.2 kb and 0.9 kb promoter-/acZ constructs display a similar pattern of expression. 
These data demonstrate that 2.2 kb, and probably even 0.9 kb, of promoter sequence is 
sufficient to realize most of the tissue specific expression characteristics of the PDGFaR 
gene. 
A more detailed analysis of transgenic line 2.2-07 showed that the first lacZ 
expression in the post-implantation embryos could be detected in the developing somites 
and branchial arches. Upon further differentiation, lacZ expression becomes localized to 
the subsequently derived axial skeleton and dermis. This pattern of expression correlates 
very well with the PDGFaR in situ hybridization signals reported for these structures by 
others (Orr-Urtreger et al., 1992; Orr-Urtreger and Lonai, 1992; Palmieri el al., 1992), 
and that was confirmed in this study. In addition to the paraxial mesoderm and its 
derivatives, lacZ expression overlaps rather well with the PDGFaR expression pattern in 
most other mesoderm- and neural crest-derived structures, i.e. cartilage primordia, 
mesenchymal tissues of developing internal organs, branchial arch and facial neural 
crest-derived mesenchyme (Morrison-Graham et al., 1992; Orr- Urtreger et al., 1992; 
Orr-Urtreger and Lonai, 1992; Schatteman et al., 1992). Very strong lacZ expression was 
detected in the cartilagineous parts of the skeleton and this expression even continues after 
birth, but decreases upon ossification. It has been shown previously that the PDGFaR is 
expressed in the perichondrium/periosteum of the developing bones (Schatteman et 
al., 1992). This expression appears to be important for at least the formation of the axial 
skeleton, since Patch embryos have severe vertebral defects (Grüneberg and Truslove, 
1960). The current data therefore indicate that the PDGFaR expression correlates very 
well with the development of all skeletal elements in both embryonic and adult stages and 
therefore may play an important role in bone (re)modeling in general. 
Our results also support the theory that the PDGFaR is involved in facial 
development probably by controlling differentiation, migration and proliferation of the 
neural-crest derived cells. The homozygous Patch mutant mice also have a deformed, split 
face, which provides more evidence for the role of PDGFaR during facial formation. It is 
notable that heavy lacZ expression is found in condensed mesenchyme immediately 
adjacent to epithelium of newly formed facial structures. Likewise, the presence of 
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Legend of figures page 90 & 91 
figure 8.1: Expression of lacZ in somites, branchial arches and limb buds. 
LacZ staining of whole mount embryos cleared in BABB to reveal internal staining A) Lateral view of a 
whole mount embryo of ЕЮ 5 shows lacZ mainly expressed in somites (S) and branchial arches (BA) В) A 
dorsal view at E12 5 LacZ was expressed m the neural tube, particularly in the rhombencephalon and 
rhombic lip in the area of the fourth ventricle (FV), in pnmodium of ribs (Ri) and in developing limbs (L). 
C) Transverse section of an E9.5 embryo double stained with X-Gal and H&E LacZ was expressed in the 
sclerotome (ST). D) Parasagittal section of an E12 5 embryo with X-Gal staining shows LacZ expressed in 
the neuroepithehum of the fourth ventricle (FV), lung buds (LB), urogenital sinus (US), maxillary (MX) and 
mandibular components (MO E) A parasagittal section shows lacZ expressed in sclerotome (ST) and dermis 
(D) of an E12 5 embryo Root ganglion (RG) is negative. 
figure 8.2: Expression of lacZ in chondroid tissue. 
A) Parasagittal section of E12 5 embryo shows heavily stained condensed mesenchyme of developing ribs 
(Ri) В) Section of palm of a E12 5 embryo shows lacZ expression in cartilage pnmordium of phalangeal 
bones (P) and surrounding mesenchyme (M) C-D) LacZ expressed in the cartilagineous skeleton in a P8 
mouse Notice that the costo-chondral junction and the epiphysis (Ep) of the long bones are heavily stained, 
while ossified areas are negative (V) vertebra, (ID) intervertebral disc 
figure 8.3: Expression of lacZ in newly formed tissues 
A) Sagittal section of lips and tongue (T) of an E15.5 embryo shows strong blue colour m an area of the 
mesenchymal tissue (M) adjacent to newly forming epithelial structures of the lower lip (LP) B) Parasagittal 
section of an E12 5 embryo shows lacZ expressed in neuroepithehum of otic vesicle (OV) C) High 
magnification of the skin of the Up with the pnmordium of a hairfollicle of an E15.5 embryo shows lacZ 
only expressed in the condensed mesenchyme (M) apposing the epithelial bud (E) D) Sagittal section of an 
E15 5 embryo shows that abundant lacZ positive cells are present m the lung mesenchymal tissue (M), while 
the epithelium (E) is negative E) LacZ expressed in whole lung lobes (LL) and in cartilage of trachea (7) 
and bronchi in whole mount staining of a P8 mouse 
PDGFaR promoter activity in the interstitial mesenchyme of internal organs, like the 
lung, indicates that PDGF paracrine stimulatory mechanisms might play an important role 
during the proper development of these organs. 
The lacZ expression pattern in the postnatal CNS, however, deviates from that of the 
PDGFaR in situ hybridization signal PDGFaR mRNA in situ hybridization data reported 
by others (Pringle et ai, 1992; Yeh et al ,1993) and in this study clearly demonstrate that 
PDGFaR expression in the postnatal CNS is restricted to glial cells and their precursors 
Although the exact nature of the lacZ expressing cells in the 2.2-0.7 line has not been 
determined, they appear to be neurons This is indicated by cell morphology and MAP2 
staining, but also by their spatial expression pattern. The lacZ expression is confined to 
well demarcated, sometimes lamellated, structures. Likewise, the expression is highest 
before and around birth and starts to decline shortly thereafter, whereas the majority of 
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PDGFaR-expressing oligodendrocyte-astrocyte precursors develop postnatally. Another 
discrepancy is the lack of lacZ expression in the developing eye and optic nerve, where 
oligodendrocyte-astrocyte precursors, which contain the PDGFaR messenger, have been 
described extensively (Schatteman et ai, 1992; Mudhar et al., 1993). The cause of these 
discrepancies in lacZ and PDGFaR mRNA expression is currently not known. It may 
reflect a positional effect of integration of the transgene, since the lacZ expression pattern 
in the CNS differs among the lines. However, the dominant lacZ expression in the 
cerebellum has been found in two independent transgenic lines with two different 
promoter constructs, which indicates that the ectopic expression of lacZ is also partly a 
result of some regulatory element that is missing within the transgene. 
LacZ was heavily expressed in neuroepithelial cells of the rhombencephalon and of 
the rhombic lip. These areas constitute the presursors of cephalic neural crest and 
cerebellar cells respectively. Both cell populations contain multipotent stem cells that can 
give rise to multiple differentiated cell types. Such E13 mouse neuroepithelial cells of the 
cerebellar external granular layer that forms from the rhombic lip have the capacity to 
differentiate into both neuronal and glial cell types (Gao and Hatten, 1994). Human 
medulloblastoma cells, which are tumor cells supposed to represent multipotent 
neuroepithelial stem cells of the cerebellum, constantly express PDGFaR (Smits et al., 
1995). Also in other experimental systems the existence of a common neuron and 
oligodendrocyte precursor cell has been indicated (Williams et al. 1991). It can therefore 
be postulated that components which specify the receptor down-regulation in developing 
neuronal cell types and upregulation or persistence in oligodendrocytes, are missing in the 
transgene. In addition, there may be other regulatory mechanisms involved than 
transcription regulation, like alternative promoter use or posttranscriptional mechanisms, 
with the consequence that levels of mRNA and levels of transcriptional activity do not 
directly parallel each other. However, the current experimental approach does not allow to 
discriminate between all these various possibilities. The use of a heterologous system may 
also have contributed to the observed differences in lacZ and PDGFaR gene expression. 
Although the mouse and human PDGFaR gene and promoter share many characteristics in 
embryonal carcinoma cells (Wang et al., 1990; Mosselman et ai, 1994; Wang and Stiles, 
1994; Afink et al., 1995), it cannot be ruled out that important differences exist between 
the regulation of PDGFaR gene expression in humans and mice. Additional experiments 
are currently undertaken to investigate the details of the PDGFaR promoter activity in the 
CNS. 
The data presented in this paper clearly demonstrate the in vivo functionality of the 
isolated human PDGFaR gene promoter to establish the spatio-temporal correct reporter 
gene expression in most mesoderm- and neural crest-derived structures. The results also 
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Legend of figures page 94 & 95 
Figure 8.4: Expression of lacZ in the CNS. 
A) Transverse section of an E12 5 embryo through the fourth (FV) and third (TV) ventricles shows lacZ 
expressed in the rhombic lip (RL) of the fourth ventricle and the top wall of the third ventricle (WTV) В) A 
transverse section shows spotted lacZ staining along the posterior and lateral aspect of the developing spinal 
cord (SC), and heavy staining in the sclerotome (ST) and the mesenchyme at the ventral aspect of trachea 
(TQ C) A longitudinal section through the spinal cord of an E12 5 embryo Notice that lacZ is expressed in 
longitudinally arranged spots of the dorsal and ventral parts of the spinal cord D) Lateral view of a whole 
mount E12 5 embryo shows the same linear array of blue dots in the cervical part of the spinal cord E) 
LacZ positivity in the facial ganglion cells of a P2 mouse F) Whole brain and G) coronal section of 
forebrain of a P8 mouse shows lacZ expressed in olfactory bulb (OB), cerebral parietal cone\(CPQ, 
thalamus (TM), hypothalamus (HTM) and pontine nuclei (PN) 
figure 8.5: Immunohistochemistry staining of brain with MAP2 antibody using paraffin 
embedded sections of lacZ stained whole mounts. 
LacZ and MAP2 double stained neuronal cells are shown in an area of parietal cerebral cortex in postnatal 
mouse brain. 
figure 8.6: PDGFaR tn situ hybridization 
A), B) Combined lacZ and PDGFcrR in situ hybridization of a coronal section of the cerebral cortex shows 
that lacZ positive cells (blue-green) are PDGFaR negative PDGFOÌR positive cells (dark brown-blue) are 
found scattered over the brain substance while lacZ positive cells are confined to a laminar region C) 
Coronal section of cerebellum (CB) and brain stem (BS) of a P5 mouse The PDGFaR positive cells (dark 
brown-blue colour) were scattered over the whole brain stem and in the cerebellum mainly located in the 
white matter and sparsely scatteredin the granular and molecular layers D) A high magnification of the 
cerebellum of C. (WM) white matter,(EGZ.) external granular layer; (ML) molecular layer 
indicate that transcriptional control is the important mechanism in both induction and 
repression of PDGFaR gene expression during embryonic development. However, the 
isolated promoter does not confer specific reporter gene expression to all tissues, in 
particular not in the CNS. Despite some discrepancies with the PDGFaR gene expression 
pattern, these PDGFaR promoter-/acZ transgenic mice provide a powerful tool to study 
the regulation and function of PDGFaR gene expression under normal and pathological 
conditions. Since expression of the PDGFaR gene is indispensible for the formation of 
many mesoderm- and neural crest- derived structures (Morrison-Graham et al., 1992; 
Orr-Urtreger et al., 1992; Schatteman et al , 1992), elucidation of the gene expression 
control mechanisms will provide relevant information about the molecular mechanisms 
involved in the formation of these embryonic structures. 
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MATERIALS AND METHODS 
Design of transgenic mice 
An approximately 2 2 kb and a 0 9 kb genomic DNA fragment encompassing nucleotides -2120 to +129 
(2 2 kb) and -825 to +129 (0 9 kb) of the human PDGFaR gene 5'-flanking part (Afink et al , 1995) were 
cloned into the Hindlll restriction site of the lacZ reporter vector pCHl 10 (Pharmacia) using standard 
molecular biological techniques (Sambrook et al , 1989) Before injection, the PDGFaR gene-tocZ fragments 
were released from the rest of the pCHl 10 vector by digestion with Avril and BamHI (Promega) and 
purified by gel electrophoresis The resulting 6kb (2 2-lacZ) and 5kb (0 9-lacZ) DNA fragments, at a 
concentration of 2 mg/ml, were microinjected into pronuclei of fertilized eggs Injected eggs were cultured 
to two cell stage and transferred into the oviduct of pseudo-pregnant female mice Tail DNA of P20 pups 
was isolated with proteinase К digestion in a buffer containing 50 mM Tns-HCl (pH 8 0), 100 mM EDTA, 
100 mM NaCl and 1 % SDS at 37 °C overnight followed by phenol and chloroform isoamylalcohol (24 1) 
extractions Transgenic founder mice were identified by PCR using one primer 
(S'-TAAGCCGTAGATAAACAGGC-V) corresponding to a sequence in the lacZ gene, and the second primer 
(5'-CACCCAGTCTTGTACACACA-y) corresponding to a sequence in the PDGFaR promoter Positive 
results were confirmed by Southern blot analysis using a ,2P-labelled lacZ DNA probe A total of ten 
transgenic founders were established (listed in table 1) LacZ expression was determined by whole mount 
X-Gal staining of postnatal brains or/and of embryos There were no obvious differences detected between 
the growth of transgenic and normal mice 
ß-Galactosidase assay of whole mount embryos or tissues 
The methods used for the analysis of ß-galactosidase activity in whole mount tissues and embryos have been 
described previously (Jegalian et al , 1992) Embryos were dissected out free of extracellular membranes 
and fixed in 2% paraformaldehyde in PBS (phosphate buffered saline) for Ihr Embryos and tissues were 
then rinsed three times in PBS and permeabilized in 2 mM MgCl2, 0 02% NP40, 0 01 % Na-deoxycholate in 
PBS three times 20 min at room temperature The ß-galactosidase was detected with 
5-bromo-4 chloro-3-indolyl-
ß-D-galactopyranosidase (X-Gal, Promega) as a substrate X-Gal staining was performed wuh a substrate 
concentration of 1 mg/ml in a buffer containing 2 mM MgCl2, 0 02% NP40, 0 01% Na-deoxycholate, 5 
mM K4Fe(N)6, 5 mM K3Fe(N)6 in PBS at 37 °C overnight in the dark The embryos and tissues were 
subsequently washed three times in PBS, and could either be dehydrated in methanol and cleared in BABB 
(benzyl alcohol benzyl benzoate 1 2) for photos of whole mounts or embedded in paraffin for histological 
studies 
Histology 
Tissues and embryos were dissected and fixed in freshly prepared 2% paraformaldehyde in PBS for one 
hour For dissected tissues, the animal was first fixed by whole body perfusion with 2% paraformaldehyde 
Paraffine embedding was performed either directly after fixation or after X Gal staining with the method 
described above For paraffin embedded embryos and tissues, five to ten micron sections were cut and 
mounted on gelatin-coated or Superfrost Plus (Fisher) slides Sections were air dried for 24 hours After 
deparaffiliation, part of the sections were counterstained with hematoxylin and eosin (H&E) 
In situ hybridization 
Embedding, cryosectioning, postfixation, hybridization and washing was as previously described by Pringle 
et al (1989, 1992) The PDGFaR sense and antisense RNA probe were m vitro transcribed from a 0 7 kb 
Hindlll fragment corresponding to the mouse PDGFaR cDNA, encoding most of the extracellular domain 
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(obtained from M Mercola, Boston, USA and В Richardson, London, UK) The probes were labelled 
either with digoxigemn or with 35S 
¡mmunohistochemistry 
Tissue dissection, fixation, paraffin embedding and sectioning was as described for the histological analysis 
The immunohistochemistry protocol was based on that of Li et al (1995) Monoclonal anti-microtubule 
associated protein (MAP2) antibody (Amersham) was used at a 1 1000 dilution in blocking solution (1 % 
BSA in PBS) and the monoclonal anti-ghal fibrillary acidic protein (GFAP) antibody (Labsystems Oy, 
Helsinki, Finland) at a 1 200 dilution The secondary antibody, biotinylated anti-mouse IgG (Vector 
laboratories), was used at a 1 200 dilution 
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Discussion & references 
Expression of the PDGFaR gene is strictly regulated during embryonic development and 
appears to be deregulated under certain pathological conditions. The mechanisms behind 
this specific expression are not known, but several external stimuli have been shown to 
affect PDGFaR gene expression in vitro. In order to investigate these regulatory 
mechanisms, the promoter region of the human PDGFaR gene was cloned and its 
functionality was demonstrated both in vitro and in vivo. Although most aspects of this 
work has already been discussed in the individual chapters, some points deserve some 
additional attention. 
Interspecies conservation of PDGFaR gene regulation 
Several observations have indicated that regulation of PDGFaR gene expression is a rather 
conserved process among the different species studied. Both in mouse and Xenopus, 
induction of PDGFaR gene expression appears to be tightly correlated with the induction 
of mesoderm (Orr-Urtreger and Lonai,1992; Orr-Urtreger et al., 1992; Palmieri et al., 
1992; Schatteman et al., 1992; Jones et al., 1992), and with the migration of neural crest 
cells (Morrison-Graham et ai, 1992; Ho et al., 1992). In addition, RA induces expression 
of the PDGFaR gene in a similar fashion in both human and mouse embryonal carcinoma 
cells (Mercóla et al., 1990; Wang et al., 1990; Mosselman et al., 1994). 
This conservation of PDGFaR gene regulation is also rather obvious in the described 
promoter studies. Both the human (chapter 6) and the mouse (Wang and Stiles, 1994) 
promoter activity are strongly increased upon RA and cAMP treatment of embryonal 
carcinoma cells. In both cases, this effect is apparently not mediated via a direct binding 
of RA receptors to the PDGFaR promoter. As shown in chapter 7, this RA- and cAMP-
stimulated human promoter activity appears to be mediated through an API-like regulatory 
element. Whether a similar mechanism occurs in the mouse is currently unknown. 
Although a RACT-responsive element in the mouse promoter has been confined to an 
approximately 450 bp fragment (which is located at least 500 bp upstream of the 
transcription initiation site), no additional information concerning this regulatory element 
has been reported yet. Since the nucleotide sequence of the mouse promoter region has not 
been disclosed, it is not possible to align the mouse and human promoter sequences and 
search for conserved elements within the two promoters. Almost upon completion of this 
thesis, the sequence of the rat PDGFaR promoter was published (Kitami et al., 1995). 
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Interestingly, the rat promoter sequence shares a high degree of homology with the human 
promoter sequence, including the -52/+ 118 region, and the PARAP1 element is 
completely conserved in both species The elements involved in the basal transcription 
seem also to be conserved As shown m chapter 6, the activity pattern of the promoter 
deletion mutants is the same m both human and mouse cells However, the best example 
of the conserved regulation of PDGFaR gene expression is described in chapter 8 The 
human PDGFaR promoter is capable to drive tissue-specific reporter gene expression m 
transgenic mice The expression pattern of the reporter gene overlaps the endogeneous 
mouse PDGFaR pattern in most tissues 
From these data it seems appropriate to conclude that both the in vitro and in vivo 
regulation of the PDGFaR gene expression in human and mouse share many 
characteristics This conclusion has certainly an important impact on the experimental 
approach that can be undertaken to investigate the mechanisms behind this regulation of 
gene expression The combined use of human, mouse and even Xenopus systems may 
provide the relevant information about the molecular mechanisms behind the regulation of 
PDGFaR gene expression in normal and disease conditions In addition, the described 
transgenic mouse model will allow a rather simple detection of PDGFaR promoter 
activity, and thus PDGFaR gene expression, during most stages of embryonic 
development and m adult life Therefore, these mice may serve as a powerful tool to 
investigate the possible role of PDGFaR expression in the development and maintenance 
of certain tissues 
Molecular mechanisms involved in the regulation of the PDGFaR promoter 
The data presented in chapter 8 strongly indicate that transcription regulation is the most 
important determinant of the correct spatio-temporal PDGFaR gene expression in vivo In 
addition, in vitro studies have clearly demonstrated that transmodulation ot PDGFaR 
expression by RA in embryonal carcinoma cells (Wang et al , 1990, Wang and Stiles, 
1994, chapter 6), and Il-l in osteosarcoma cells (Xie et al , 1994) is also controlled at the 
level of transcriptional regulation Therefore, identification of the transcription factors that 
affect PDGFaR promoter activity is an important step in the understanding of the 
molecular mechanisms behind this regulation of PDGFaR expression 
A first attempt to establish the identity of these transcription factors has been 
described in chapter 7 and has resulted in the identification of API-like transcription 
factors as candidates to mediate the RA- and cAMP-induced transcription ot the PDGFaR 
gene in embryonal carcinoma cells It should be stressed however, that this is a 
preliminary conclusion The work described in chapter 7 is not completely finished and 
additional experiments have to be performed to sustain the conclusions In particular the 
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role of the PARAP1 element should be confirmed by extended mutational analysis and the 
possible involvement of c-jun in PARAP1 binding should be analyzed with specific 
antibodies. Preliminary data from in vivo footprint analysis on the -52/+ 118 region did so 
far not provide additional support for the involvement of the PARAFI element in the RA-
induced PDGFaR promoter activity (HJ Kraft et al., unpublished). In addition, the 
described RA and cAMP effects are specific for embryonal carcinoma cells. In other cell 
types, for instance mouse Swiss 3T3 fibroblasts, RA appears to affect PDGFaR promoter 
activity through inhibitory elements, while cAMP is without any effect in these cells (in 
collaboration with В Stassen and E Lammerts, unpublished). 
As already mentioned in the prologue, the TGFß-mediated downregulation of 
PDGFaR expression in fibroblasts and the resulting decrease in mitogenic response to 
PDGF (Gronwald et al., 1989; Paulsson et al., 1993) was the initiative for the current 
work on the transcriptional regulation of the PDGFaR gene. However, preliminary studies 
in mouse Swiss 3T3 and human AG1523 fibroblasts never indicated a decrease in 
PDGFaR promoter activity upon TGFß treatment (in collaboration with E. Lammerts, В 
Stassen, unpublished). Therefore, it had to be concluded that this downregulation process 
in these cells was not controlled at the transcriptional level or was mediated through 
regulatory elements outside the investigated -2120/+ 118 promoter region. In MG63 
osteosarcoma cells, both TGFß and 11-1 have been shown to decrease PDGFaR mRNA 
levels, which resulted in an attenuated biological response to PDGF (Yeh et ai, 1993a). 
Subsequent studies have demonstrated that at least the IL-1 effect is mediated at the level 
of gene transcription (Xie et al., 1994), but these studies do not provide information about 
the working mechanism of TGFß. However, recent experiments indicate that both IL-Iß 
and TGFß are indeed inhibitors of PDGFaR promoter activity (in collaboration with E 
Lammerts, unpublished). This effect is confined to the -441/+118 region of the human 
promoter and additional experiments are being performed to exactly locate the regulatory 
elements and transcription factors involved in this inhibitory process. Together these data 
indicate however, that inhibition of PDGFaR numbers by TGFß is mediated through 
different, cell type specific mechanisms. 
Another topic of interest, which is currently being investigated, is the elucidation of 
the molecular mechanisms that regulate the tissue-specific expression of the PDGFaR gene 
in embryonic development. The embryonic expression pattern of many transcription 
factors has been described in detail, and some of these patterns display a striking overlap 
with that of the PDGFaR gene. One important candidate transcription factor to regulate 
the PDGFaR gene expression is GLI. The GLI gene was originally identified by its 
amplified copy number in a human glioma (Kinzler et al., 1987), a tumor type which also 
frequently displays high PDGFaR levels (Hermanson et al., 1995). The GLI protein is 
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presumably a transcription factor which binds to the DNA sequence 5'-GACCACCCA-3' 
(Kinzler and Vogelstem, 1990) This sequence motif is also present within the PDGFaR 
promoter (nucleotide -660 to -651, figure 2, chapter 6) In addition, GLI expression in the 
developing embryo overlaps that of the PDGFaR m many tissues, including limbs, 
vertebra, lung, bones and facial structures (Walterhouse et al , 1993, Hui et al , 1994) 
The final observation that supports a possible role for GLI in regulation of PDGFaR gene 
expression is the recent demonstration that transfection of a GLI expression vector, 
together with a promoter-luciferase construct, into glioma cells results in an increase of 
PDGFaR promoter activity (in collaboration with J Jacobs, unpublished) Another 
candidate transcription factor is PAX1 PAX1 expression (Balling et al , 1988, Wallin et 
al , 1994) correrates well with the PDGFaR expression in the developing axial skeleton, 
and recently Helwig et al (1995) reported an functional interaction between PAX1 and 
the PDGFaR in the correct formation of this structure In addition, expression of PAX1 
together with a promoter-luciferase construct also leads to an increase in PDGFaR 
promoter activity m several cell lines tested (in collaboration with J Jacobs, unpublished) 
Thus, at least in the somites and its derivatives PAX1 could be a determinant of correct 
PDGFaR gene expression 
There are of course many other candidate transcription factors that may play a role 
in regulation of tissue specific PDGFaR promoter activity Ho et al (1994) already 
indicated the possible involvement of distall-less, twist and snail in PDGFaR expression 
during the migration of Xenopus cephalic neural crest Future research may reveal the 
possible involvement of these and other transcription factors in the regulation of PDGFaR 
gene expression during embryonic development 
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SUMMARY 
Growth factors play a prominent role in the intercellular communication between cells in 
multicellular organisms. In this way they participate in the coordinated growth and 
maintenance of the organism. Growth factors are released from cells and achieve their 
effects on the same (autocrine stimulation), on nearby (paracrine stimulation) or distantly 
located (endocrine stimulation) cells. This effect on cells is mediated through specific 
receptors, which are located within the cells' plasmamembrane. Upon binding of a growth 
factor to its cognate receptor, the receptor becomes "activated", and transduces a signal to 
the inside of the cell. This last process is a highly complex system of biochemical 
reactions, which finally results in a "growth response". In this thesis, two studies have 
been carried out which deal with this growth factor signal transduction process. 
In part A, the signal transduction mechanisms of growth factors that affect NRK cell 
proliferation were investigated. NRK cells are a model system for a process called 
density-dependent growth arrest or contact-inhibition. This process restricts cell growth of 
most normal cells when they reach a critical cell density. However, tumor cell have lost 
this inhibitory mechanism, and as a result they can grow without limitation. In NRK cells, 
several growth factors (e.g. TGFß) are able to overcome this density-dependent growth 
arrest and thus phenotypically transform these cells to a "tumor-like" cell type. From the 
data in chapter 2 it has become clear that the induction of a receptor for another growth 
factor (EGF) is the crucial signal transduction step by which TGFß, but also the vitamin A 
derivative retinoic acid exert their action. On the other hand, the lipid LPA does not seem 
to transform NRK cells through this indirect mechanism, but by an as-yet unknown 
mechanism. In addition, the small peptide bradykinin inhibits the transformation process 
elicited by TGFß, retinoic acid and LPA. This inhibitory effect is presumably mediated 
through the production of a growth inhibitory prostaglandin as described in chapter 3. The 
exact nature of this prostaglandin and its intracellular targets are currently being 
investigated. 
In part В the regulation of the human PDGFa receptor (PDGFaR) expression has been 
studied. The first requirement for a cell to respond to a growth factor is obviously the 
expression of its cognate receptor. One receptor for PDGF is the PDGFaR. The 
expression of this receptor is strictly regulated during embryonic development. Only 
certain cell types at very specific time points express the PDGFaR and hence are 
responsive to PDGF. Also in adult life, the PDGFaR expression is restricted to specific 
cell types. Disregulation of this tightly regulated expression can result to severe embryonic 
defects and diseases such as cancer. To investigate the mechanisms involved in this 
112 
specific regulation of PDGFaR expression, the regulatory elements of the gene encoding 
the human PDGFaR were characterized. As described in chapter 6, the region that 
controls the expression of the PDGFaR gene (PDGFaR promoter) was cloned and its 
functionality was assessed. In addition, the mechanism by which retinole acid, a potent 
inducer of PDGFaR expression, increases the activity of the promoter and thereby the 
expression of the PDGFaR gene was analysed. This work has been extended in more 
detail in chapter 7. From these data it was concluded that a small, but specific sequence of 
DNA within the human PDGFaR promoter mediates the activating effect of retinole acid. 
In addition, in chapter 8 the functionality of the cloned promoter was examined in vivo, 
using a transgenic mouse model. For this purpose, the human PDGFaR promoter was 
attached to a reporter gene and incorporated into the mouse genome. The activity of the 
promoter in these transgenic mice can be easily detected by means of the attached reporter 
gene. The reporter gene produces a typical blue color in cells where the promoter is 
active. In this way, the activity of the promoter, and the regulation of this activity could 
be monitored during embryonic development. This approach has lead to more insight in 
both the function of the PDGFaR in embryonic development, and the in vivo functionality 
of the PDGFaR promoter. 
SAMENVATTING 
Groeifactoren spelen een belangrijke rol in de onderlinge communicatie tussen 
verschillende cellen in een multicellular organisme. Op deze wijze dragen zij bij aan de 
gecoördineerde groei van het organisme. Groeifactoren worden geproduceerd door cellen 
en hebben vervolgens effect op diezelfde cellen (autocriene stimulatie), naburige cellen 
(paracriene stimulatie) of cellen in andere weefsels binnen het lichaam (endocriene 
stimulatie). Dit effect van een groeifactor op een cel wordt gemediëerd door specifieke 
receptoren, die aanwezig zijn in de plasmamembraan van de cel. Nadat binding van de 
groeifactor aan zijn bijbehorende receptor heeft plaatsgevonden, wordt deze "geactiveerd" 
en geeft een signaal door aan de binnenkant van de cel. Dit laatste proces is een zeer 
complex systeem van verschillende biochemische reacties, die uiteindelijk uitmonden in 
een "groeirespons". In dit proefschrift worden twee onderzoeken beschreven die 
betrekking hebben op deze groeifactor signaalgeleiding. 
In deel A worden de signaalgeleidingmechanismen onderzocht van groeifactoren die 
een rol spelen in de proliferatie van NRK cellen. NRK cellen vormen een modelsysteem 
voor contact-inhibitie. Contact-inhibitie is een proces dat normaliter cellen remt in hun 
groei als ze een bepaalde kritische dichtheid bereiken. Tumorcellen hebben echter deze 
groeiremmende eigenschap verloren en als gevolg daarvan kunnen ze dan ook ongehinderd 
door blijven groeien. Verschillende groeifactoren (b.v. TGFß) zijn echter in staat om deze 
contact-inhibitie in NRK cellen op te heffen en op die manier deze cellen fenotypisch te 
transformeren naar een "tumor-achtig" cel type. Uit de gegevens beschreven in hoofdstuk 
2 is daarbij duidelijk geworden dat in geval van fenotypische transformatie de inductie van 
een receptor voor een andere groeifactor (EGF) de essentiële stap is in de signaalgeleiding 
van TGFß, maar ook in die van het vitamine A derivaat retinoic acid (RA). Het vetzuur 
LPA daarentegen lijkt echter een andere manier van signaalgeleiding te gebruiken in zijn 
transformerend effect, maar het is op dit moment nog onduidelijk welke. Het eiwit 
bradykinine is echter in staat om zowel de TGFß-, RA- als LP A-geïnduceerde 
transformatie te remmen. Deze remming vindt waarschijnlijk plaats door een specifieke 
inductie van een groeiremmend Prostaglandine, zoals beschreven staat in hoofdstuk 3. 
Verder onderzoek naar de precíese karakterisering van dit Prostaglandine en zijn 
remmende werking is op dit moment gaande. 
Deel В beschrijft het onderzoek naar de regulatie van de humane PDGFa receptor 
(PDGFaR) expressie. De eerste vereiste voor een cel om te kunnen reageren op een 
groeifactor is natuurlijk de expressie van de bijbehorende receptor. Een van de receptoren 
voor PDGF is de PDGFaR. De expressie van deze receptor wordt zeer nauwgezet 
gereguleerd tijdens de embryonale ontwikkeling. Expressie van de PDGFaR, en dus ook 
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gevoeligheid voor PDGF, vindt alleen plaats in bepaalde celtypen en op specifieke 
tijdstippen. Ook in het volwassen organisme is de PDGFaR expressie beperkt tot 
specifieke celtypes. Verstoringen in deze zeer nauwgezet gereguleerde expressie kan 
ernstige embryonale afwijkingen of ziekten zoals kanker tot gevolg hebben. Voor de 
bestudering van de mechanismen die betrokken zijn bij deze specifieke regulatie van 
PDGFaR expressie zijn de regulatoire elementen van het humane PDGFaR gen 
gekarakteriseerd. Hiertoe werd de genregio verantwoordelijk voor de controle van de 
expressie van het PDGFaR gen (PDGFaR promoter) gekloneerd en werd de 
functionaliteit van deze promoter bepaald, zoals beschreven in hoofdstuk 6. Tevens werd 
het mechanisme waardoor RA, een krachtige stimulus voor PDGFaR expressie, de 
PDGFaR promoter activeerd en op die manier de PDGFaR expressie stimuleert. Dit werk 
wordt vervolgens in meer detail voortgezet en de resultaten van dit onderzoek staan in 
hoofdstuk 7. Als conclusie van dit werk kon worden vastgesteld dat een klein specifiek 
stuk DNA binnen de humane PDGFaR promoter regio de RA activatie medièerd. 
Tenslotte in hoofdstuk 8 werd de in vivo functionaliteit van de promoter aangetoond door 
gebruik te maken van een transgene muis systeem. Hiertoe werd de humane PDGFaR 
promoter gekoppeld aan een reportergen en vervolgens geïncorporeerd binnen het genoom 
van de muis. Op die wijze kon de activiteit van de promoter in de transgene muis relatief 
gemakkelijk worden vastgesteld, doordat het gekoppelde reportergen een blauwkleuring 
geeft in die cellen waar de promoter actief is. Deze opzet heeft ertoe geleidt dat er meer 
inzicht werd verkregen in zowel de functie van de PDGFaR in embryonale ontwikkeling, 
alsook de in vivo functionaliteit van de PDGFaR promoter. 
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